


**CUMULATIVE
SUPPLEMENT 10
October 2006**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

Cumulative Supplement 10

October 2006

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes.....	v
1.4 Availability of the Edition	vi
1.5 Report of Counts for the Prescription Drug Product List	vii
1.6 Zocor (simvastatin) patent relisting	viii
1.7 Levothyroxine Sodium.....	viii
1.8 Cumulative Supplement Legend	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

**CUMULATIVE SUPPLEMENT 10
October 2006**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the

day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
AMERICAN PHARMACEUTICAL PARTNERS INC (AM PHARM PARTNERS)	ABRAXIS PHARMACEUTICAL PRODUCTS (ABRAXIS PHARM)
AMERICAN PHARMACEUTICAL CO INC SUB BURR CORP (AM PHARM)	ABRAXIS PHARMACEUTICAL PRODUCTS (ABRAXIS PHARM)
AMIDE PHARMACEUTICAL INC (AMIDE PHARM)	ACTAVIS TOTOWA LLC (ACTAVIS TOTOWA)
APOTEX CORP (APOTEX)	APOTEX INC ETOBICOKE SITE (APOTEX INC)
APOTEX CORP (APOTEX)	APOTEX INC RICHMOND HILL (APOTEX INC)
APOTEX INC (APOTEX)	APOTEX INC ETOBICOKE SITE (APOTEX INC)
APOTEX INC (APOTEX)	APOTEX INC RICHMOND HILL (APOTEX INC)
APOTEX INC (APOTEX INC)	APOTEX INC ETOBICOKE SITE (APOTEX INC)
APOTEX INC (APOTEX INC)	APOTEX INC RICHMOND HILL (APOTEX INC)
AVENTIS PHARMACEUTICALS INC (AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
AVENTIS PHARMACEUTICAL PRODUCTS INC (AVENTIS PHARMS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
CLAY PARK LABORATORIES INC	PERRIGO NEW YORK INC

(CLAY PARK)	(PERRIGO NEW YORK)
CLAY PARK LABS INC	PERRIGO NEW YORK INC
(CLAY PARK)	(PERRIGO NEW YORK)
DERMIK LABORATORIES INC	SANOFI AVENTIS US LLC
(DERMIK LABS)	(SANOFI AVENTIS US)
DERMIK LABORATORIES INC SUB RORER	SANOFI AVENTIS US LLC
(DERMIK LABS)	(SANOFI AVENTIS US)
FIRST HORIZON PHARMACEUTICAL COMPANY	SCIELE PHARMA INC
(FIRST HORIZON)	(SCIELE PHARMA INC)
LOREX PHARMACEUTICALS	SANOFI AVENTIS US LLC
(LOREX)	(SANOFI AVENTIS US)
MARTEC PHARMACEUTICALS	MARTEC USA LLC
(MARTEC)	(MARTEC USA LLC)
MARTEC SCIENTIFIC INC	MARTEC USA LLC
(MARTEC)	(MARTEC USA LLC)
MCNEIL CONSUMER AND SPECIALTY	MCNEIL PEDIATRICS
PHARMACEUTICALS DIV MCNEIL PCC IN	
(MCNEIL CONS SPECLT)	
ORPHAN MEDICAL INC	(MCNEIL PED)
(ORPHAN MEDCL)	JAZZ PHARMACEUTICALS
PHARMACEUTICAL FORMULATIONS INC	(JAZZ)
(PHARM FORM)	LEINER HEALTH PRODUCTS INC
PHARMA TEK INC	(LEINER HLTH PRODS)
(PHARMA TEK)	X GEN PHARMACEUTICALS INC
PRIVATE FORMULATIONS INC	(X GEN)
(PRIVATE FMLTNS)	LEINER HEALTH PRODUCTS INC
SANKYO PHARMA INC	(LEINER HLTH PRODS)
(SANKYO)	DAIICHI SANKYO INC
SANOFI AVENTIS US INC	(DAIICHI SANKYO)
(SANOFI AVENTIS US)	SANOFI AVENTIS US LLC
SANOFI-AVENTIS US INC	(SANOFI AVENTIS US)
(SANOFI AVENTIS)	SANOFI AVENTIS US LLC
SANOFI INC	(SANOFI AVENTIS US)
(SANOFI)	SANOFI AVENTIS US LLC
SANOFI SYNTHELABO INC	(SANOFI AVENTIS US)
(SANOFI SYNTHELABO)	SANOFI AVENTIS US LLC
SANOFI SYNTHELABO RESEARCH DIV SANOFI	(SANOFI AVENTIS US)
SYNTHELABO INC	SANOFI AVENTIS US LLC
(SANOFI SYN RES)	(SANOFI AVENTIS US)
STERIS LABORATORIES INC	WATSON LABORATORIES INC
(STERIS)	(WATSON)
TRIGEN LABORATORIES INC	JUBILANT PHARMACEUTICALS INC
(TRIGEN)	(JUBILANT PHARMS)
UCB PHARMA INC	UCB INC
(UCB PHARMA)	(UCB INC)

1.4 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly

Since 1997, the Electronic Orange Book (EOB)
<http://www.fda.gov/cder/ob/default.htm>, has been available on the internet
and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at
<http://www.fda.gov/cder/ob/default.htm>. The Query provides searching of

the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use

in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2005	MAR 2006	JUN 2006	SEPT 2006
DRUG PRODUCTS LISTED	11368	11487	11636	11741
SINGLE SOURCE	2428	2461	2447	2456
	(21.4%)	(21.4%)	(21.0%)	(20.9%)
MULTISOURCE	8851	8937	9000	9196
	(77.9%)	(77.8%)	(78.2%)	(78.3%)
THERAPEUTICALLY EQUIVALENT	8642	8730	8900	8997
	(76.04%)	(76.0%)	(76.5%)	(76.6%)
NOT THERAPEUTICALLY EQUIVALENT EXCEPTIONS ¹	209 (1.8%)	207	200	199
		(1.8%)	(1.7%)	(1.7%)
NUMBER OF APPLICANTS	89 (0.8%)	89 (0.8%)	89 (0.8%)	89 (0.8%)
NEW MOLECULAR ENTITIES APPROVED	11	6	8	1
	628	629	642	649

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 ZOCOR (SIMVASTATIN) PATENT RELISTING

U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in *Ranbaxy Labs. v. Leavitt*, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

1.7 LEVOTHYROXINE SODIUM

The Description of Special Situations, Levothyroxine Sodium, published in the 26th Annual Edition of the Orange Book, has been modified in the Cumulative Supplement to include information on a supplemental approval for Genpharm ANDA 76752 approved in 2006. The full discussion as published in the 26th Annual Edition is repeated in the Cumulative Supplement and includes recent approval information on Levothyroxine Sodium.

Because there are multiple reference listed drugs of Levothyroxine Sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for Levothyroxine Sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Genpharm ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187) and Levothyroxine Sodium (Genpharm ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other Levothyroxine Sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other Levothyroxine Sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other Levothyroxine Sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	GENPHARM	0.025MG	AB2	76752	001
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	GENPHARM	0.025MG	AB3	76752	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.8 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 26TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 10 - October 2006

1-1

ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

@ PRAECIS

100MG/VIAL

N21320 001 Nov 25, 2003 Sep DISC

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

SECTRAL

AB DR REDDYS LABS INC EQ 200MG BASE
AB + EQ 400MG BASEN18917 001 Dec 28, 1984 May CAHN
N18917 003 Dec 28, 1984 May CAHNACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

AB + MIKART 650MG;50MG
SEDAPAP
@ MAYRAND 650MG;50MGN89988 001 Oct 26, 1992 Jan CRLD
N88944 001 Oct 17, 1985 Jan DISCACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AB + MIKART 712.8MG;60MG;32MG
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITATRATE
AB WEST WARD 712.8MG;60MG;32MGN40316 001 Apr 28, 1999 Sep CFTG
N40637 001 Sep 22, 2006 Sep NEWAACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA + ACTAVIS MID ATLANTIC 120MG/5ML;12MG/5ML
@ CLONMEL 120MG/5ML;12MG/5MLN85861 001 Jul CAHN
N40098 001 Sep 20, 1996 Jan DISC

SUSPENSION; ORAL

CAPITAL AND CODEINE

AA ACTAVIS MID ATLANTIC 120MG/5ML;12MG/5ML

N85883 001 Jul CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA + TEVA 300MG;60MG
ACETAMINOPHEN W/ CODEINE NO. 3
@ ROXANE 300MG;30MGN88629 001 Mar 06, 1985 Apr CRLD
N84656 001 Jul DISCACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ENDO PHARMS 500MG;7.5MG
@ 650MG;7.5MG
@ 650MG;10MG
@ 750MG;7.5MG
AA INTERPHARM 325MG;5MG
AA 325MG;10MG
AA 500MG;5MG
AA 500MG;7.5MG
AA 650MG;7.5MG
AA 650MG;10MG
AA 750MG;7.5MGN40280 001 Sep 30, 1998 Feb DISC
N40280 002 Sep 30, 1998 Feb DISC
N40280 003 Sep 30, 1998 Feb DISC
N40281 002 Sep 30, 1998 Feb DISC
N40736 001 Aug 25, 2006 Aug NEWA
N40746 001 Aug 25, 2006 Aug NEWA
N40729 001 Aug 25, 2006 Aug NEWA
N40748 001 Aug 25, 2006 Aug NEWA
N40754 001 Aug 25, 2006 Aug NEWA
N40757 001 Aug 25, 2006 Aug NEWA
N40769 001 Aug 28, 2006 Aug NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	MIKART	300MG;5MG	N40658	001	Jan 19,	2006	Jan	NEWA
+		300MG;7.5MG	N40556	002	Mar 24,	2006	Mar	NEWA
AA	VINTAGE PHARMS	325MG;5MG	N40655	001	Jan 19,	2006	Jan	NEWA
AA		325MG;7.5MG	N40656	001	Jan 19,	2006	Jan	NEWA
	HY-PHEN							
@	ASCHER	500MG;5MG	N87677	001	May 03,	1982	Mar	DISC
	ZYDONE							
+	ENDO PHARMS	400MG;5MG	N40288	001	Nov 27,	1998	May	CTNA
+		400MG;7.5MG	N40288	002	Nov 27,	1998	May	CTNA
+		400MG;10MG	N40288	003	Nov 27,	1998	May	CTNA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	MALLINCKRODT	325MG/5ML;5MG/5ML	N40680	001	Sep 29,	2006	Sep	NEWA
AA	+ ROXANE	325MG/5ML;5MG/5ML	N89351	001	Dec 03,	1986	Sep	CFTG

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

+	MIKART	400MG;2.5MG	N40679	001	May 16,	2006	May	NEWA
+		400MG;5MG	N40687	001	Apr 27,	2006	Apr	NEWA
+		400MG;7.5MG	N40698	001	Apr 27,	2006	Apr	NEWA
+		400MG;10MG	N40692	001	Apr 27,	2006	Apr	NEWA
		500MG;10MG	N40676	001	Apr 19,	2006	Apr	NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	ACTAVIS ELIZABETH	650MG;100MG	N70910	001	Jan 02,	1987	Jun	CAHN
	CORNERSTONE	325MG;100MG	N76743	001	May 07,	2004	Jul	CAHN
AB		500MG;100MG	N76750	001	Jun 28,	2004	Jul	CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	BARR	325MG;37.5MG	N76914	001	Jul 26,	2006	Jul	NEWA
----	------	--------------	--------	-----	---------	------	-----	------

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

AB	+ TARO	250MG	N40195	002	May 28,	1997	Mar	CRLD
	DIAMOX							
@	DURAMED PHARMS BARR	125MG	N08943	001			Mar	DISC
@		250MG	N08943	002			Mar	DISC

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

AT	ACTAVIS MID ATLANTIC	2%	N87146	001			Jul	CAHN
----	----------------------	----	--------	-----	--	--	-----	------

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC ACETASOL HC		
AT ACTAVIS MID ATLANTIC 2%;1%	N87143 001	Jan 13, 1982 Jul CAHN
HYDROCORTISONE AND ACETIC ACID		
AT VINTAGE 2%;1%	N40609 001	Feb 06, 2006 Jan NEWA

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC MIOCHOL		
@ NOVARTIS	20MG/VIAL	N16211 001
		Sep DISC

ACYCLOVIR

CAPSULE; ORAL ACYCLOVIR		
AB ACTAVIS ELIZABETH 200MG	N74906 001	Aug 26, 1997 Jun CAHN
AB CLONMEL HLTHCARE 200MG	N74833 001	Apr 22, 1997 May CAHN
SUSPENSION; ORAL ACYCLOVIR		
AB ACTAVIS MID ATLANTIC 200MG/5ML	N74738 001	Apr 28, 1997 Jul CAHN
TABLET; ORAL ACYCLOVIR		
AB ACTAVIS ELIZABETH 400MG	N74870 001	Jun 05, 1997 Jun CAHN
AB 800MG	N74870 002	Jun 05, 1997 Jun CAHN
AB CLONMEL HLTHCARE 400MG	N74946 001	Nov 19, 1997 May CAHN
AB 800MG	N74946 002	Nov 19, 1997 May CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION ACYCLOVIR SODIUM		
@ HOSPIRA	EQ 500MG BASE/VIAL	N74663 001
@	EQ 1GM BASE/VIAL	Apr 22, 1997 Jun DISC
		N74663 002 Apr 22, 1997 Jun DISC

ALBUTEROL

AEROSOL, METERED; INHALATION ALBUTEROL		
@ GENPHARM	0.09MG/INH	N73045 001 Aug 19, 1997 Feb DISC
@ PLIVA	0.09MG/INH	N74072 001 Aug 01, 1996 Feb DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION ALBUTEROL SULFATE		
AN ACTAVIS MID ATLANTIC EQ 0.083% BASE	N73533 001	Sep 26, 1995 Jul CAHN
AN RXELITE EQ 0.083% BASE	N77569 001	Apr 04, 2006 Mar NEWA
SYRUP; ORAL ALBUTEROL SULFATE		
AA ACTAVIS MID ATLANTIC EQ 2MG BASE/5ML	N74454 001	Sep 25, 1995 Jul CAHN
AA EQ 2MG BASE/5ML	N75262 001	Mar 30, 1999 Jul CAHN
TABLET, EXTENDED RELEASE; ORAL VOSPIRE ER		
DAVA PHARMS INC EQ 4MG BASE	N76130 002	Sep 26, 2002 Sep CAHN
+ EQ 8MG BASE	N76130 003	Sep 26, 2002 Sep CAHN

ALITRETIINOIN

GEL; TOPICAL

PANRETIN

>A>	+ EISAI MEDCL RES	EQ 0.1% BASE	N20886 001 Feb 02, 1999 Oct CAHN
>D>	+ LIGAND	EQ 0.1% BASE	N20886 001 Feb 02, 1999 Oct CAHN

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;0.03MG/ML	N21163 001 May 18, 2000 Jan CAHN
----------	--	----------------------------------

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+ SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;30UGM/ML	N21559 001 Jun 16, 2003 Jan CAHN
----------	---	----------------------------------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB ACTAVIS ELIZABETH	0.25MG	N74342 001 Oct 31, 1993 Jun CAHN
AB	0.5MG	N74342 002 Oct 31, 1993 Jun CAHN
AB	1MG	N74342 003 Oct 31, 1993 Jun CAHN
AB	2MG	N74342 004 Oct 31, 1993 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB BARR	0.5MG	N77725 001 Jul 31, 2006 Jul NEWA
AB	1MG	N77725 002 Jul 31, 2006 Jul NEWA
AB	2MG	N77725 004 Jul 31, 2006 Aug NEWA
AB	3MG	N77725 003 Jul 31, 2006 Jul NEWA
AB MYLAN	0.5MG	N77391 002 Jan 26, 2006 Jan NEWA
AB	1MG	N77391 003 Jan 26, 2006 Jan NEWA
AB	2MG	N77391 004 Jan 26, 2006 Jan NEWA
AB	3MG	N77391 001 Jan 26, 2006 Jan NEWA
AB SANDOZ	0.5MG	N77777 001 Jun 30, 2006 Jun NEWA
AB	1MG	N77777 002 Jun 30, 2006 Jun NEWA
AB	2MG	N77777 003 Jun 30, 2006 Jun NEWA
AB	3MG	N77777 004 Jun 30, 2006 Jun NEWA

XANAX XR

AB PHARMACIA AND UPJOHN	0.5MG	N21434 001 Jan 17, 2003 Jan CFTG
AB	1MG	N21434 002 Jan 17, 2003 Jan CFTG
AB	2MG	N21434 003 Jan 17, 2003 Jan CFTG
AB +	3MG	N21434 004 Jan 17, 2003 Jan CFTG

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB AMIDE PHARM	100MG	N77659 001 Feb 23, 2006 Feb NEWA
----------------	-------	----------------------------------

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

AA + ACTAVIS MID ATLANTIC	50MG/5ML	N72655 001 Oct 30, 1990 Jul CAHN
---------------------------	----------	----------------------------------

AMCINONIDE

CREAM; TOPICAL
AMCINONIDE

AB	+	ALTANA	0.1%	N76065 001 May 15, 2003 Sep CRLD
		CYCLOCORT		
	@	ASTELLAS	0.1%	N18116 002 Sep DISC
		LOTION; TOPICAL		
		AMCINONIDE		
	+	ALTANA	0.1%	N76329 001 Nov 06, 2002 Sep CRLD
		CYCLOCORT		
	@	ASTELLAS	0.1%	N19729 001 Jun 13, 1988 Sep DISC
		OINTMENT; TOPICAL		
		AMCINONIDE		
AB	+	ALTANA	0.1%	N76096 001 Nov 19, 2002 Sep CRLD
		CYCLOCORT		
	@	ASTELLAS	0.1%	N18498 001 Sep DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL
AMILORIDE HYDROCHLORIDE

+	PAR PHARM	5MG	N70346 001 Jan 22, 1986 Jun CRLD
MIDAMOR			
@	MERCK	5MG	N18200 001 Jun DISC

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	+	MYLAN	EQ 5MG ANHYDROUS;50MG	N73209 001 Oct 31, 1991 Jun CRLD
		MODURETIC 5-50		
	@	MERCK	EQ 5MG ANHYDROUS;50MG	N18201 001 Jun DISC

AMINOPHYLLINE

SOLUTION; ORAL
AMINOPHYLLINE DYE FREE

AA	+	ACTAVIS MID ATLANTIC	105MG/5ML	N87727 001 Apr 16, 1982 Jul CAHN
----	---	----------------------	-----------	----------------------------------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

AP	+	AKORN	50MG/ML	N76232 001 Jul 05, 2006 Jun NEWA
----	---	-------	---------	----------------------------------

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

>D>	AB	MYLAN	10MG;2MG	N70336 001 Nov 10, 1988 Oct CTEC
>A>			10MG;2MG	N70336 001 Nov 10, 1988 Oct CTEC
>D>	AB		10MG;4MG	N71442 001 Nov 10, 1988 Oct CTEC
>A>			10MG;4MG	N71442 001 Nov 10, 1988 Oct CTEC
>D>	AB		25MG;2MG	N70337 001 Nov 10, 1988 Oct CTEC
>A>			25MG;2MG	N70337 001 Nov 10, 1988 Oct CTEC
>D>	AB	+	25MG;4MG	N70338 001 Nov 10, 1988 Oct CTEC
>A>		+	25MG;4MG	N70338 001 Nov 10, 1988 Oct CTEC
>D>	AB	+	50MG;4MG	N71443 001 Nov 10, 1988 Oct CTEC
>A>		+	50MG;4MG	N71443 001 Nov 10, 1988 Oct CTEC

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

>D>	AB	SANDOZ	10MG;2MG	N71062	001	Nov 27,	1987	Oct	DISC
>A>		@	10MG;2MG	N71062	001	Nov 27,	1987	Oct	DISC
>D>	AB		10MG;4MG	N71862	001	Dec 21,	1987	Oct	DISC
>A>		@	10MG;4MG	N71862	001	Dec 21,	1987	Oct	DISC
>D>	AB		25MG;2MG	N71063	001	Nov 27,	1987	Oct	DISC
>A>		@	25MG;2MG	N71063	001	Nov 27,	1987	Oct	DISC
>D>	AB		25MG;4MG	N71064	001	Nov 27,	1987	Oct	DISC
>A>		@	25MG;4MG	N71064	001	Nov 27,	1987	Oct	DISC
>D>	AB		50MG;4MG	N71863	001	Dec 21,	1987	Oct	DISC
>A>		@	50MG;4MG	N71863	001	Dec 21,	1987	Oct	DISC
>D>	AB	WATSON LABS	10MG;2MG	N73007	001	Oct 17,	1991	Oct	DISC
>A>		@	10MG;2MG	N73007	001	Oct 17,	1991	Oct	DISC
>D>	AB		10MG;4MG	N73009	001	Oct 17,	1991	Oct	DISC
>A>		@	10MG;4MG	N73009	001	Oct 17,	1991	Oct	DISC
>D>	AB		25MG;2MG	N73008	001	Oct 17,	1991	Oct	DISC
>A>		@	25MG;2MG	N73008	001	Oct 17,	1991	Oct	DISC
>D>	AB		25MG;4MG	N73010	001	Oct 17,	1991	Oct	DISC
>A>		@	25MG;4MG	N73010	001	Oct 17,	1991	Oct	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

NOVARTIS	EQ 5MG BASE;40MG	N20364	007	Apr 11,	2006	Apr	NEWA
	EQ 10MG BASE;20MG	N20364	005	Jun 20,	2002	Apr	CRLD
+	EQ 10MG BASE;40MG	N20364	006	Apr 11,	2006	Apr	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	PADDOK	EQ 12% BASE	N76829	001	Feb 07,	2006	Jan	NEWA
----	--------	-------------	--------	-----	---------	------	-----	------

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	N62058	001			Jan	CAHN
AB		500MG	N62058	002			Jan	CAHN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	125MG/5ML	N62059	001			Jan	CAHN
AB		250MG/5ML	N62059	002			Jan	CAHN
AB	HIKMA	125MG/5ML	N65322	002	Jun 19,	2006	Jun	NEWA
AB		200MG/5ML	N65325	002	Jun 19,	2006	Jun	NEWA
AB		250MG/5ML	N65322	001	Jun 19,	2006	Jun	NEWA
AB		400MG/5ML	N65325	001	Jun 19,	2006	Jun	NEWA

TABLET; ORAL

AMOXICILLIN

AB	HIKMA	875MG	N65255	001	Mar 29,	2006	Mar	NEWA
----	-------	-------	--------	-----	---------	------	-----	------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	N40472	001	Sep 30,	2003	May	CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40472	002	Sep 30,	2003	May	CAHN

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	TEVA PHARMS	5MG;5MG;5MG;5MG 7.5MG;7.5MG;7.5MG;7.5MG	N40472 003	Sep 30, 2003	May CAHN
AB			N40472 004	Sep 30, 2003	May CAHN

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

AP	X GEN PHARMS	50MG/VIAL	N63206 001	Apr 29, 1992	Jun CAHN
----	--------------	-----------	------------	--------------	----------

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	SANDOZ	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65241 001	Jul 25, 2006	Jul NEWA
AP		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65310 001	Jul 25, 2006	Jul NEWA
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65241 002	Jul 25, 2006	Jul NEWA
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65310 002	Jul 25, 2006	Jul NEWA
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65240 001	Jul 25, 2006	Jul NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS	EQ 250MG BASE	N61602 001
@	EQ 500MG BASE	N61602 002

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

@ AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61601 001
@	EQ 250MG BASE/5ML	N61601 002

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

AB	ALPHAPHARM	EQ 0.5MG BASE	N77613 001	Jun 27, 2006	Jun NEWA
AB		EQ 1MG BASE	N77613 002	Jun 27, 2006	Jun NEWA

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+ VICURON	50MG/VIAL	N21632 001
-----------	-----------	------------

Feb 17, 2006 Feb NEWA

ANISINDIONE

TABLET; ORAL

MIRADON

@ SCHERING	50MG	N10909 003
------------	------	------------

Jan DISC

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

>D>	VERNALIS	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Oct DISC
>A>	@	20MG/2ML (10MG/ML)	N21264 001	Apr 20, 2004	Oct DISC

APREPITANT

CAPSULE; ORAL
EMEND
MERCK 40MG N21549 003 Jun 30, 2006 Jun NEWA

>A> ARFORMOTEROL TARTRATE

SOLUTION; INHALATION
BROVANA
+ SEPRACOR EQ 0.015MG BASE/2ML N21912 001 Oct 06, 2006 Oct NEWA

ARIPIPRAZOLE

INJECTABLE; INTRAMUSCULAR
ABILIFY
+ OTSUKA 9.75MG/1.3ML (7.5MG/ML) N21866 001 Sep 20, 2006 Sep NEWA
TABLET; ORAL
ABILIFY
OTSUKA 2MG N21436 006 Nov 15, 2002 Jul CMFD
+ 10MG N21436 001 Nov 15, 2002 Sep CRLD
TABLET, ORALLY DISINTEGRATING; ORAL
ABILIFY
OTSUKA 10MG N21729 002 Jun 07, 2006 Jun NEWA
15MG N21729 003 Jun 07, 2006 Jun NEWA
20MG N21729 004 Jun 07, 2006 Jun NEWA
+ 30MG N21729 005 Jun 07, 2006 Jun NEWA

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION
SEPTOCAIN
DEPROCO 4%;EQ 0.005MG BASE/ML N22010 001 Mar 30, 2006 Mar NEWA
+ 4%; EQ 0.017MG BASE/1.7ML (4%;
EQ 0.01MG BASE/ML) N20971 001 Apr 03, 2000 Mar CPOT

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
SEPTOCAIN
+ DEPROCO 4%;EQ 0.0085MG BASE/1.7ML(4%; EQ 0.005MG BASE/ML) N22010 001 Mar 30, 2006 Apr CAIN
+ 4%; EQ 0.017MG BASE/1.7ML (4%;
EQ 0.01MG BASE/ML) N20971 001 Apr 03, 2000 Apr CAIN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)
INFUVITE PEDIATRIC
+ SANDOZ 80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1
4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG
/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL N21265 001 Feb 21, 2001 Jan CAHN
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)
+ SANDOZ 80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1
4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG
/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL N21646 001 Jan 29, 2004 Jan CAHN

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+ NORGINE B V	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	N21881 001 Aug 02, 2006 Aug NEWA
+ SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	N21881 001 Aug 02, 2006 Sep CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

ASPIRIN AND CAFFEINE W/ BUTALBITAL

AB ACTAVIS ELIZABETH	325MG;50MG;40MG	N86710 002 Aug 23, 1983 Jun CAHN
----------------------	-----------------	----------------------------------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ ENDO PHARMS	325MG;50MG;40MG;30MG	N75351 001 Mar 05, 1999 Feb DISC
---------------	----------------------	----------------------------------

AB + WATSON PHARMS	325MG;50MG;40MG;30MG	N19429 003 Oct 26, 1990 Apr CTNA
--------------------	----------------------	----------------------------------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

ASPIRIN AND OXYCODONE

+ ENDO PHARMS	325MG;4.8355MG	N07337 007 Aug 05, 2005 Jun NEWA
---------------	----------------	----------------------------------

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

PERCODAN-DEMI

@ ENDO PHARMS	325MG;2.25MG;0.19MG	N07337 005 Feb DISC
---------------	---------------------	---------------------

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

>D> + BRISTOL MYERS SQUIBB	EQ 200MG BASE	N21567 003 Jun 20, 2003 Oct CRLD
>A>	EQ 200MG BASE	N21567 003 Jun 20, 2003 Oct CRLD
>A> +	EQ 300MG BASE	N21567 004 Oct 16, 2006 Oct NEWA

ATENOLOL

TABLET; ORAL

ATENOLOL

AB UNIQUE PHARM LABS	25MG	N77443 001 Sep 13, 2006 Aug NEWA
AB	50MG	N77443 002 Sep 13, 2006 Aug NEWA
AB	100MG	N77443 003 Sep 13, 2006 Aug NEWA

ATOVAQUONE

TABLET; ORAL

MEPRON

@ GLAXOSMITHKLINE	250MG	N20259 001 Nov 25, 1992 May DISC
-------------------	-------	----------------------------------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+ MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML	N21983 001 Sep 28, 2006 Sep NEWA
------------------	-----------------------	----------------------------------

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

AB	PLIVA	EQ 100MG BASE/5ML	N65246 002 Jul 05, 2006 Jun NEWA
AB		EQ 200MG BASE/5ML	N65246 001 Jul 05, 2006 Jun NEWA
AB	SANDOZ	EQ 100MG BASE/5ML	N65297 001 Sep 18, 2006 Sep NEWA
AB		EQ 200MG BASE/5ML	N65297 002 Sep 18, 2006 Sep NEWA
	ZITHROMAX		
AB	PFIZER	EQ 100MG BASE/5ML	N50710 001 Oct 19, 1995 Jun CFTG
AB	+	EQ 200MG BASE/5ML	N50710 002 Oct 19, 1995 Jun CFTG

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

@ PFIZER

125MG/5ML

N50556 001 Mar 23, 1982 Feb DISC

TABLET; ORAL

SPECTROBID

@ PFIZER

400MG

N50520 001

Feb DISC

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	CARACO	10MG	N77984 001 Aug 14, 2006 Aug NEWA
AB		20MG	N77862 002 Aug 14, 2006 Aug NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	5MG	N77128 001 Mar 08, 2006 Feb NEWA
AB		10MG	N77128 002 Mar 08, 2006 Feb NEWA
AB		20MG	N77128 003 Mar 08, 2006 Feb NEWA
AB		40MG	N77128 004 Mar 08, 2006 Feb NEWA
AB	BIOKEY	5MG	N76820 001 Feb 03, 2006 Jan NEWA
AB		10MG	N76820 002 Feb 03, 2006 Jan NEWA
AB		20MG	N76820 003 Feb 03, 2006 Jan NEWA
AB		40MG	N76820 004 Feb 03, 2006 Jan NEWA

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-5

@ APOTHECON

5MG

N12164 002

Jun DISC

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	PADDOCK	50MG	N40578 001 Apr 17, 2006 Apr NEWA
AA	DIDREX		

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

@ PFIZER

EQ 50MG BASE/VIAL

N16820 001

Mar DISC

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL
CYSTADANE

+ JAZZ 1GM/SCOOPFUL

N20576 001 Oct 25, 1996 Feb CAHN

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

@ SAVAGE LABS EQ 0.05% BASE

N19138 001 Jun 26, 1984 Jun DISC

BETAMETHASONE DIPROPIONATE

AB ACTAVIS MID ATLANTIC EQ 0.05% BASE

N70885 001 Feb 03, 1987 Jun CAHN

AB + FOUGERA EQ 0.05% BASE

N19137 001 Jun 26, 1984 Jun CRLD

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB + ALTANA EQ 0.05% BASE

N75276 001 May 13, 2003 Aug CRLD

DIPROLENE

@ SCHERING EQ 0.05% BASE

N19408 002 Nov 22, 1991 Aug DISC

LOTION; TOPICAL

ALPHATREX

@ SAVAGE LABS EQ 0.05% BASE

N70273 001 Aug 12, 1985 Jun DISC

BETAMETHASONE DIPROPIONATE

AB ACTAVIS MID ATLANTIC EQ 0.05% BASE

N70281 001 Jul 31, 1985 Jul CAHN

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ACTAVIS MID ATLANTIC EQ 0.05% BASE

N71012 001 Feb 03, 1987 Jun CAHN

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB ACTAVIS MID ATLANTIC EQ 0.05% BASE

N74304 001 Aug 31, 1995 Jun CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

TACLONEX

+ LEO PHARM PRODS 0.064%;0.005%

N21852 001 Jan 09, 2006 Jan NEWA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB ACTAVIS MID ATLANTIC EQ 0.05% BASE;1%

N76002 001 Aug 02, 2002 Jun CAHN

BETAMETHASONE VALERATE

CREAM; TOPICAL

VALNAC

AB ACTAVIS MID ATLANTIC EQ 0.1% BASE

N70050 001 Oct 10, 1984 Jun CAHN

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB ACTAVIS MID ATLANTIC EQ 0.1% BASE

N70052 001 Jul 31, 1985 Jul CAHN

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB ACTAVIS MID ATLANTIC EQ 0.1% BASE

N70051 001 Oct 10, 1984 Jun CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

>A> AA IMPAX LABS 5MG

N40739 001 Nov 01, 2006 Oct NEWA

TABLET; ORAL

BETHANECHOL CHLORIDE

>A>	AA	IMPAX LABS	10MG	N40741	001	Nov 01, 2006	Oct	NEWA
>A>	AA		25MG	N40740	001	Nov 01, 2006	Oct	NEWA
>A>	AA		50MG	N40721	004	Nov 01, 2006	Oct	NEWA

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

>A>	+	EISAI MEDCL RES	75MG	N21055	001	Dec 29, 1999	Oct	CAHN
>D>	+	LIGAND	75MG	N21055	001	Dec 29, 1999	Oct	CAHN
GEL; TOPICAL								
TARGRETIN								
>A>	+	EISAI MEDCL RES	1%	N21056	001	Jun 28, 2000	Oct	CAHN
>D>	+	LIGAND	1%	N21056	001	Jun 28, 2000	Oct	CAHN

BISKALCITRATE; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+	AXCAN SCANDIPHARM	140MG;125MG;125MG	N50786	001	Sep 28, 2006	Sep	NEWA
---	-------------------	-------------------	--------	-----	--------------	-----	------

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	ACTAVIS ELIZABETH	2.5MG;6.25MG	N75672	001	Sep 25, 2000	Jun	CAHN
AB		5MG;6.25MG	N75672	002	Sep 25, 2000	Jun	CAHN
AB		10MG;6.25MG	N75672	003	Sep 25, 2000	Jun	CAHN

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

@	SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N64084	001	Jun 01, 1996	Jun	DISC
@		EQ 30 UNITS BASE/VIAL	N64084	002	Jun 01, 1996	Jun	DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

AT	+	ALLERGAN	0.15%	N21262	001	Mar 16, 2001	May	CTEC
BRIMONIDINE TARTRATE								
AT		AKORN	0.2%	N76439	001	Mar 14, 2006	Feb	NEWA
AT		ALCON RES	0.15%	N21764	001	May 22, 2006	May	NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

AZOPT

+	ALCON	1%	N20816	001	Apr 01, 1998	Feb	CAHN
---	-------	----	--------	-----	--------------	-----	------

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

@	FOREST LABS	12.5MG/5ML;10MG/5ML	N09319	006	Jan 10, 1984	Aug	DISC
---	-------------	---------------------	--------	-----	--------------	-----	------

MYBANIL

+	MORTON GROVE	12.5MG/5ML;10MG/5ML	N88626	001	Oct 12, 1984	Aug	CRLD
---	--------------	---------------------	--------	-----	--------------	-----	------

BUDESONIDE

POWDER, METERED; INHALATION
 BUDESONIDE

ASTRAZENECA	0.08MG/INH	N21949 001 Jul 12, 2006 Jul NEWA
+	0.16MG/INH	N21949 002 Jul 12, 2006 Jul NEWA
SPRAY, METERED; NASAL		
RHINOCORT		
+ ASTRAZENECA	0.032MG/INH	N20746 001 Oct 01, 1999 Mar CRLD
@	0.064MG/INH	N20746 002 Oct 01, 1999 Mar DISC

BUDESONIDE; FORMOTEROL FUMARATE

SPRAY, METERED; INHALATION
 SYMBICORT

ASTRAZENECA	0.08MG/INH;EQ 0.045MG BASE	N21929 001 Jul 21, 2006 Jul NEWA
+	0.016MG/INH;EQ 0.045MG BASE	N21929 002 Jul 21, 2006 Jul NEWA

BUMETANIDE

INJECTABLE; INJECTION
 BUMETANIDE

AP + BEDFORD	0.25MG/ML	N74441 001 Jan 27, 1995 Feb CRLD
BUMEX		
@ ROCHE	0.25MG/ML	N18226 001 Feb 28, 1983 Feb DISC

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
 BUPIVACAINE HYDROCHLORIDE

+ HOSPIRA	0.5%;EQ 0.009MG BASE/ML	N22046 001 Jul 13, 1983 Aug CTNA
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE		
AP SEPTODONT	0.5%;0.0091MG/ML	N77250 001 Sep 27, 2006 Sep NEWA
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE		
>D> + HOSPIRA	0.5%;0.0091MG/ML	N22046 001 Jul 13, 1983 Oct CTEC
>A> AP +	0.5%;0.0091MG/ML	N22046 001 Jul 13, 1983 Oct CTEC
+	0.5%;EQ 0.009MG BASE/ML	N22046 001 Jul 13, 1983 Apr NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL
 BUPROPION HYDROCHLORIDE

AB APOTEX INC	75MG	N76143 001 Jan 17, 2006 Jan NEWA
AB	100MG	N76143 002 Jan 17, 2006 Jan NEWA

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
 BUSPIRONE HYDROCHLORIDE

AB ACTAVIS TOTOWA	5MG	N75388 001 May 09, 2002 Aug CAHN
AB	10MG	N75388 002 May 09, 2002 Aug CAHN
AB	15MG	N75388 003 May 09, 2002 Aug CAHN

BUSULFAN

INJECTABLE; INJECTION
 BUSULFEX

+ PDL BIOPHARMA INC	6MG/ML	N20954 001 Feb 04, 1999 Jan CAHN
---------------------	--------	----------------------------------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS CAF'CIT			
AP + MEAD JOHNSON	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N20793 001	Sep 21, 1999 Sep CFTG
CAFFEINE CITRATE PHARMAFORCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77233 001	Sep 21, 2006 Sep NEWA
SOLUTION; ORAL CAF'CIT			
AA + MEAD JOHNSON	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N20793 002	Apr 12, 2000 Sep CFTG
CAFFEINE CITRATE PHARMAFORCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77304 001	Sep 21, 2006 Sep NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL CAF'RGOT			
@ NOVARTIS	100MG;2MG	N09000 002	Feb DISC
MIGERGOT			
+ G AND W LABS	100MG;2MG	N86557 001	Oct 04, 1983 Feb CRLD

CALCIPOTRIENE

CREAM; TOPICAL DOVONEX			
+ LEO PHARM	0.005%	N20554 001	Jul 22, 1996 Feb CAHN
OINTMENT; TOPICAL DOVONEX			
+ LEO PHARM	0.005%	N20273 001	Dec 29, 1993 Feb CAHN
SOLUTION; TOPICAL DOVONEX			
+ LEO PHARM	0.005%	N20611 001	Mar 03, 1997 Feb CAHN

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL FORTICAL			
+ UPSHER SMITH	200 IU/SPRAY	N21406 001	Aug 12, 2005 Jun CAHN

CALCITONIN, SALMON

INJECTABLE; INJECTION MIACALCIN			
+ NOVARTIS	200 IU/ML	N17808 002	Mar 29, 1991 Jan CTEC

CALCITRIOL

CAPSULE; ORAL CALCITRIOL			
AB ROXANE	0.25UGM	N76917 001	Mar 27, 2006 Mar NEWA
INJECTABLE; INJECTION CALCITRIOL			
AP GENIX THERAP	0.001MG/ML	N77102 001	Feb 08, 2006 Jan NEWA

CALCIUM ACETATE

TABLET; ORAL PHOSLO			
@ NABI	EQ 169MG CALCIUM	N19976 001	Dec 10, 1990 Jun DISC

>A> CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

>A> INJECTABLE; INJECTION

>A> PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

>A> + GAMBRO RENAL PRODS 3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML N21703 006 Oct 25, 2006 Oct NEWA

>A> PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

>A> + GAMBRO RENAL PRODS N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML N21703 002 Oct 25, 2006 Oct NEWA

>A> PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

>A> + GAMBRO RENAL PRODS 5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML N21703 003 Oct 25, 2006 Oct NEWA

>A> PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

>A> + GAMBRO RENAL PRODS N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML N21703 005 Oct 25, 2006 Oct NEWA

>A> PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

>A> + GAMBRO RENAL PRODS 3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML N21703 004 Oct 25, 2006 Oct NEWA

>A> PRISMASOL BK 0/0 IN PLASTIC CONTAINER

>A> + GAMBRO RENAL PRODS N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML N21703 007 Oct 25, 2006 Oct NEWA

>A> PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

>A> + GAMBRO RENAL PRODS 5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML N21703 001 Oct 25, 2006 Oct NEWA

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT SOLUTION

AT AKORN 0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML N75503 001 Sep 27, 2006 Sep NEWA

AT BSS 0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML N20742 001 Dec 10, 1997 Sep CFTG

AT + ALCON 0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML N20742 001 Dec 10, 1997 Sep CFTG

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

ASTRAZENECA

8MG

N20838 002 Jun 04, 1998 May CRLD

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ CLONMEL HLTHCARE	12.5MG	N74423 001 Feb 13, 1996 Jan DISC
@	25MG	N74423 002 Feb 13, 1996 Jan DISC
@	50MG	N74423 003 Feb 13, 1996 Jan DISC
@	100MG	N74423 004 Feb 13, 1996 Jan DISC
@ ENDO LABS	12.5MG	N74418 001 Feb 13, 1996 Feb DISC
@	25MG	N74418 002 Feb 13, 1996 Feb DISC
@	50MG	N74418 003 Feb 13, 1996 Feb DISC
@	100MG	N74418 004 Feb 13, 1996 Feb DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

Captopril And Hydrochlorothiazide

@ ENDO LABS	25MG;15MG	N74788 001	Dec 29, 1997	Feb	DISC
@	25MG;25MG	N74788 002	Dec 29, 1997	Feb	DISC
@	50MG;15MG	N74788 004	Dec 29, 1997	Feb	DISC
@	50MG;25MG	N74788 003	Dec 29, 1997	Feb	DISC

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

Carbamazepine

AB	JUBILANT PHARMS	100MG	N71940 001	Feb 01, 1988	Jul	CAHN
----	-----------------	-------	------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

Carbidopa And Levodopa

AB	ACTAVIS ELIZABETH	10MG;100MG	N74260 001	Sep 03, 1993	Jun	CAHN
AB		25MG;100MG	N74260 002	Sep 03, 1993	Jun	CAHN
AB		25MG;250MG	N74260 003	Sep 03, 1993	Jun	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

Carboplatin

AP	WATSON LABS	50MG/VIAL	N77383 001	Jan 27, 2006	Jan	NEWA
AP		150MG/VIAL	N77383 002	Jan 27, 2006	Jan	NEWA
AP		450MG/VIAL	N77383 003	Jan 27, 2006	Jan	NEWA

INJECTABLE; IV (INFUSION)

Carboplatin

AP	@ AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Feb	DISC
AP		EQ 50MG/5ML (10MG/ML)	N77266 001	Feb 15, 2006	Jan	NEWA
AP	@	EQ 150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Feb	DISC
AP		EQ 150MG/15ML (10MG/ML)	N77266 002	Feb 15, 2006	Jan	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77266 003	Feb 15, 2006	Jan	NEWA
AP		EQ 600MG/60ML (10MG/ML)	N77266 004	Feb 15, 2006	Jan	NEWA
AP	BEDFORD LABS	EQ 600MG/60ML (10MG/ML)	N77244 004	Jan 20, 2006	Jan	NEWA
AP	DABUR ONCOLOGY PLC	EQ 50MG/5ML (10MG/ML)	N77432 001	Sep 29, 2006	Sep	NEWA
AP		EQ 150MG/15ML (10MG/ML)	N77432 002	Sep 29, 2006	Sep	NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77432 003	Sep 29, 2006	Sep	NEWA

>A> CARVEDILOL PHOSPHATE

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> COREG CR

>A>	SB PHARMCO	10MG	N22012 001	Oct 20, 2006	Oct	NEWA
>A>		20MG	N22012 002	Oct 20, 2006	Oct	NEWA
>A>		40MG	N22012 003	Oct 20, 2006	Oct	NEWA
>A>	+	80MG	N22012 004	Oct 20, 2006	Oct	NEWA

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

Cancidas

+	MERCK	50MG/VIAL	N21227 001	Jan 26, 2001	May	CAHN
+		70MG/VIAL	N21227 002	Jan 26, 2001	May	CAHN

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CEFACLOR

AB + PAR PHARM EQ 500MG BASE N65057 001 Jan 05, 2001 May CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB + IVAX PHARMS EQ 500MG BASE N62766 001 Mar 03, 1987 Mar CRLD

AB ORCHID HLTHCARE EQ 500MG BASE N65309 001 Sep 18, 2006 Sep NEWA

AB SANDOZ EQ 500MG BASE N62291 001 Aug CAHN

AB TEVA PHARMS EQ 500MG BASE N65282 001 Jan 20, 2006 Jan NEWA

AB WESTWARD EQ 500MG BASE N65311 001 Feb 07, 2006 Jan NEWA

DURICEF

@ WARNER CHILCOTT

EQ 500MG BASE

N50512 001 Jan DISC

FOR SUSPENSION; ORAL

CEFADROXIL

>A> AB ORCHID HLTHCARE EQ 250MG BASE/5ML N65307 002 Oct 16, 2006 Oct NEWA

>A> AB EQ 500MG BASE/5ML N65307 003 Oct 16, 2006 Oct NEWA

+ RANBAXY

EQ 125MG BASE/5ML

N65115 001 Mar 26, 2003 Jul CRLD

AB TEVA PHARMS EQ 250MG BASE/5ML N65278 001 Jan 20, 2006 Jan NEWA

AB EQ 500MG BASE/5ML N65278 002 Jan 20, 2006 Jan NEWA

DURICEF

@ WARNER CHILCOTT

EQ 125MG BASE/5ML

N50527 002 Feb DISC

TABLET; ORAL

CEFADROXIL

AB HIKMA EQ 1GM BASE N65260 001 Mar 30, 2006 Mar NEWA

AB + IVAX PHARMS EQ 1GM BASE N62774 001 Apr 08, 1987 Feb CRLD

AB ORCHID HLTHCARE EQ 1GM BASE N65301 001 Sep 18, 2006 Sep NEWA

DURICEF

@ WARNER CHILCOTT

EQ 1GM BASE

N50528 001 Jan DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

@ B BRAUN

EQ 500MG BASE/VIAL

N50779 001 Jul 27, 2000 May DISC

CEFDINIR

CAPSULE; ORAL

CEFDINIR

AB LUPIN 300MG N65264 001 May 19, 2006 May NEWA

OMNICEF

AB + ABBOTT 300MG N50739 001 Dec 04, 1997 May CFTG

FOR SUSPENSION; ORAL

CEFDINIR

AB LUPIN 125MG/5ML N65259 001 May 31, 2006 Jul CAHN

AB LUPIN (USA) 125MG/5ML N65259 001 May 31, 2006 May NEWA

OMNICEF

AB ABBOTT 125MG/5ML N50749 001 Dec 04, 1997 May CFTG

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

AP	WOCKHARDT	EQ 1GM BASE/VIAL	N65197 001 Aug 29, 2006 Aug NEWA
	CEFOTAXIME AND DEXTROSE	2.4% IN PLASTIC CONTAINER	
@ B BRAUN		EQ 2GM BASE	N50792 001 Jul 29, 2004 May DISC
	CEFOTAXIME AND DEXTROSE	3.9% IN PLASTIC CONTAINER	
@ B BRAUN		EQ 1GM BASE	N50792 002 Jul 29, 2004 May DISC
	CEFOTAXIME SODIUM		
AP	ORCHID HLTHCARE	EQ 500MG BASE/VIAL	N65290 001 Aug 11, 2006 Aug NEWA
AP		EQ 1GM BASE/VIAL	N65290 002 Aug 11, 2006 Aug NEWA
AP		EQ 1GM BASE/VIAL	N65293 001 Aug 10, 2006 Aug NEWA
AP		EQ 2GM BASE/VIAL	N65290 003 Aug 11, 2006 Aug NEWA
AP		EQ 2GM BASE/VIAL	N65293 002 Aug 10, 2006 Aug NEWA
AP		EQ 10GM BASE/VIAL	N65292 001 Aug 10, 2006 Aug NEWA

>D> CEFOTETAN DISODIUM

>D> INJECTABLE; INJECTION

CEFOTAN

>D>	+ ASTRAZENECA	EQ 1GM BASE/VIAL	N50588 001 Dec 27, 1985 Oct DISC
>A>	@	EQ 1GM BASE/VIAL	N50588 001 Dec 27, 1985 Oct DISC
	@	EQ 1GM BASE/VIAL	N63293 001 Apr 29, 1993 Jun DISC
>D>	+	EQ 2GM BASE/VIAL	N50588 002 Dec 27, 1985 Oct DISC
>A>	@	EQ 2GM BASE/VIAL	N50588 002 Dec 27, 1985 Oct DISC
	@	EQ 2GM BASE/VIAL	N63293 002 Apr 29, 1993 Jun DISC
>D>	+	EQ 10GM BASE/VIAL	N50588 003 Apr 25, 1988 Oct DISC
>A>	@	EQ 10GM BASE/VIAL	N50588 003 Apr 25, 1988 Oct DISC
>D>	CEFOTAN IN PLASTIC CONTAINER		
>D>	+ ASTRAZENECA	EQ 20MG BASE/ML	N50694 002 Jul 30, 1993 Oct DISC
>A>	@	EQ 20MG BASE/ML	N50694 002 Jul 30, 1993 Oct DISC
>D>	+	EQ 40MG BASE/ML	N50694 001 Jul 30, 1993 Oct DISC
>A>	@	EQ 40MG BASE/ML	N50694 001 Jul 30, 1993 Oct DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65313 001 Jan 23, 2006 Jan NEWA
AP		EQ 2GM BASE/VIAL	N65313 002 Jan 23, 2006 Jan NEWA
AP		EQ 10GM BASE/VIAL	N65312 001 Feb 13, 2006 Jan NEWA
	CEFOXITIN AND DEXTROSE	IN DUPLEX CONTAINER	
AP	B BRAUN	EQ 1GM BASE/VIAL	N65214 001 Mar 10, 2006 Feb NEWA
AP		EQ 2GM BASE/VIAL	N65214 002 Mar 10, 2006 Feb NEWA

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB	RANBAXY	125MG/5ML	N65202 001 Jun 30, 2006 Jun NEWA
AB		250MG/5ML	N65202 002 Jun 30, 2006 Jun NEWA

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

CEPTAZ

@ GLAXOSMITHKLINE

1GM/VIAL

@

2GM/VIAL

N50646 002	Sep 27, 1990	May	DISC
N50646 003	Sep 27, 1990	May	DISC

INJECTABLE; INJECTION

CEPTAZ
 @ GLAXOSMITHKLINE 10GM/VIAL N50646 004 Sep 27, 1990 May DISC

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER
 @ BAXTER HLTHCARE EQ 10MG BASE/ML N63221 001 Apr 29, 1993 Aug DISC
 @ EQ 20MG BASE/ML N63221 002 Apr 29, 1993 Aug DISC
 @ EQ 40MG BASE/ML N63221 003 Apr 29, 1993 Aug DISC
 FORTAZ IN PLASTIC CONTAINER
 + GLAXOSMITHKLINE EQ 20MG BASE/ML N50634 002 Apr 28, 1989 Aug CTEC
 + EQ 40MG BASE/ML N50634 003 Apr 28, 1989 Aug CTEC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP AM PHARM PARTNERS EQ 250MG BASE/VIAL N65245 001 Feb 15, 2006 Jan NEWA
 AP EQ 500MG BASE/VIAL N65245 002 Feb 15, 2006 Jan NEWA
 AP EQ 1GM BASE/VIAL N65245 003 Feb 15, 2006 Jan NEWA
 AP EQ 2GM BASE/VIAL N65245 004 Feb 15, 2006 Jan NEWA
 CEFTRIAXONE SODIUM
 AP TEVA EQ 1GM BASE/VIAL N65262 001 Jun 29, 2006 Jun NEWA
 AP EQ 2GM BASE/VIAL N65262 002 Jun 29, 2006 Jun NEWA

INJECTABLE; INJECTION

CEFTRIAXONE

AP AM PHARM EQ 10GM BASE/VIAL N65252 001 Feb 15, 2006 Jan NEWA
 AP LUPIN EQ 10GM BASE/VIAL N65263 001 Sep 12, 2006 Aug NEWA
 AP WOCKHARDT EQ 1GM BASE/VIAL N65180 001 May 12, 2006 May NEWA
 CEFTRIAXONE SODIUM
 AP TEVA EQ 10GM BASE/VIAL N65274 001 May 01, 2006 Apr NEWA

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB AUROBINDO PHARMA LTD EQ 125MG BASE N65308 001 Mar 29, 2006 Mar NEWA
 AB EQ 250MG BASE N65308 002 Mar 29, 2006 Mar NEWA
 AB EQ 500MG BASE N65308 003 Mar 29, 2006 Mar NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

AB HIKMA EQ 250MG BASE N65215 001 Jan 24, 2006 Jan NEWA
 AB EQ 500MG BASE N65215 002 Jan 24, 2006 Jan NEWA
 KEFLEX
 AB ADVANCIS PHARM EQ 333MG BASE N50405 004 May 12, 2006 May NEWA
 AB EQ 500MG BASE N50405 003 May CRLD
 + EQ 750MG BASE N50405 005 May 12, 2006 May NEWA

FOR SUSPENSION; ORAL

CEPHALEXIN

AB ORCHID HLTHCARE EQ 125MG BASE/5ML N65326 001 Jul 10, 2006 Jun NEWA
 AB EQ 250MG BASE/5ML N65326 002 Jul 10, 2006 Jun NEWA

CEPHRADINE

CAPSULE; ORAL ANSPOR			
@ GLAXOSMITHKLINE	250MG	N61859 001	Mar DISC
@	500MG	N61859 002	Mar DISC

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL EXOSURF NEONATAL			
@ GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N20044 001	Aug 02, 1990 May DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL CHLORHEXIDINE GLUCONATE			
AT ACTAVIS MID ATLANTIC	0.12%	N74291 001	Dec 28, 1995 Jul CAHN

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION NESACAIN			
+ ABRAXIS BIOSCIENCE	1%	N09435 001	Jul CAHN
AP	2%	N09435 002	Jul CAHN
NESACAIN-MPF			
AP + ABRAXIS BIOSCIENCE	2%	N09435 006	May 02, 1996 Jul CAHN
@	2%	N09435 003	Jul CAHN
AP +	3%	N09435 007	May 02, 1996 Jul CAHN
@	3%	N09435 004	Jul CAHN

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL DIUPRES-250			
@ MERCK	250MG;0.125MG	N11635 003	Aug 26, 1987 Jun DISC
DIUPRES-500			
@ MERCK	500MG;0.125MG	N11635 006	Aug 26, 1987 Jun DISC

CHLORPROMAZINE

SUPPOSITORY; RECTAL THORAZINE			
@ GLAXOSMITHKLINE	25MG	N09149 024	May DISC
@	100MG	N09149 033	May DISC

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL THORAZINE			
@ GLAXOSMITHKLINE	200MG	N11120 019	May DISC
@	300MG	N11120 020	May DISC
CONCENTRATE; ORAL CHLORPROMAZINE HYDROCHLORIDE			
AA ACTAVIS MID ATLANTIC	100MG/ML	N86863 001	Jul CAHN

>A> CICLESONIDE

>A> SPRAY, METERED; NASAL OMNARIS			
>A> + ALTANA PHARMA	0.05MG/INH	N22004 001	Oct 20, 2006 Oct NEWA

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX

AB	PERRIGO	0.77%	N77364 001 Mar 03, 2006 Mar CAHN
AB	PERRIGO NEW YORK	0.77%	N77364 001 Mar 03, 2006 Feb NEWA

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION
PRIMAXIN
@ MERCK

	EQ 750MG BASE/VIAL;750MG/VIAL	N50630 002 Dec 14, 1990 Jun DISC
--	-------------------------------	----------------------------------

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL

AB	MUTUAL PHARM	50MG	N77208 002 Mar 29, 2006 Mar NEWA
AB		100MG	N77208 001 Mar 29, 2006 Mar NEWA
AB	MYLAN	50MG	N77323 002 Apr 20, 2006 Apr NEWA
AB		100MG	N77323 001 Apr 20, 2006 Apr NEWA

CIMETIDINE

TABLET; ORAL
CIMETIDINE
@ ENDO PHARMS

	200MG	N74281 001 May 17, 1994 Feb DISC
@	300MG	N74281 002 May 17, 1994 Feb DISC
@	400MG	N74281 003 May 17, 1994 Feb DISC
@	800MG	N74329 001 May 17, 1994 Feb DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HYDROCHLORIDE
@ ENDO PHARMS

	EQ 300MG BASE/2ML	N74005 001 Aug 31, 1994 Feb DISC
--	-------------------	----------------------------------

SOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE

AA	+ ACTAVIS MID ATLANTIC	EQ 300MG BASE/5ML	N74176 001 Jun 01, 1994 Jul CAHN
	@ ENDO PHARMS	EQ 300MG BASE/5ML	N74251 001 Dec 22, 1994 Feb DISC

CIPROFLOXACIN

INJECTABLE; INJECTION
CIPRO
AP + BAYER PHARMS

	400MG/40ML (10MG/ML)	N19847 001 Dec 26, 1990 Aug CFTG	
AP	+	200MG/20ML (10MG/ML)	N19847 002 Dec 26, 1990 Aug CFTG
	@	1200MG/120ML (10MG/ML)	N19847 003 Dec 26, 1990 Aug DISC

CIPROFLOXACIN

AP	ABRAXIS PHARM	200MG/20ML (10MG/ML)	N76484 001 Aug 28, 2006 Aug NEWA
AP		400MG/40ML (10MG/ML)	N76484 002 Aug 28, 2006 Aug NEWA
AP	BEDFORD LABS	200MG/20ML (10MG/ML)	N76992 001 Aug 28, 2006 Aug NEWA
AP		400MG/40ML (10MG/ML)	N76992 002 Aug 28, 2006 Aug NEWA
		1200MG/120ML (10MG/ML)	N76993 001 Aug 28, 2006 Aug NEWA
AP	HOSPIRA	400MG/40ML (10MG/ML)	N77245 002 Aug 28, 2006 Aug NEWA
AP		200MG/20ML (10MG/ML)	N77245 001 Aug 28, 2006 Aug NEWA
AP	SICOR PHARMS	200MG/20ML (10MG/ML)	N77782 001 Aug 28, 2006 Aug NEWA
AP		400MG/40ML (10MG/ML)	N77782 002 Aug 28, 2006 Aug NEWA

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CITALOPRAM HYDROBROMIDE

AA	AUROBINDO PHARMA LTD	EQ 10MG BASE/5ML	N77812 001 Aug 28, 2006 Aug NEWA
AA	SILARX	EQ 10MG BASE/5ML	N77629 001 Jun 15, 2006 May NEWA

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	ACTAVIS ELIZABETH	EQ 10MG BASE	N77033 001 Oct 28, 2004 Jun CAHN
AB		EQ 20MG BASE	N77033 002 Oct 28, 2004 Jun CAHN
AB		EQ 40MG BASE	N77033 003 Oct 28, 2004 Jun CAHN
AB	INVAGEN PHARMS	EQ 10MG BASE	N77534 001 Oct 03, 2006 Sep NEWA
AB		EQ 20MG BASE	N77534 002 Oct 03, 2006 Sep NEWA
AB		EQ 40MG BASE	N77534 003 Oct 03, 2006 Sep NEWA
AB	MUTUAL PHARM	EQ 10MG BASE	N77052 001 Jul 03, 2006 Jun NEWA
AB		EQ 20MG BASE	N77052 002 Jul 03, 2006 Jun NEWA
AB		EQ 40MG BASE	N77052 003 Jul 03, 2006 Jun NEWA
AB	TARO	EQ 10MG BASE	N77278 001 Mar 22, 2006 Mar NEWA
AB		EQ 20MG BASE	N77278 002 Mar 22, 2006 Mar NEWA
AB		EQ 40MG BASE	N77278 003 Mar 22, 2006 Mar NEWA
AB	TEVA PHARMS	EQ 10MG BASE	N77213 001 Mar 31, 2006 Mar NEWA
AB		EQ 20MG BASE	N77213 002 Mar 31, 2006 Mar NEWA
AB		EQ 40MG BASE	N77213 003 Mar 31, 2006 Mar NEWA

>D> TABLET, ORALLY DISINTEGRATING; ORAL

>D> CITALOPRAM HYDROBROMIDE

>D>	BIOVAIL LABS INTL	EQ 10MG BASE	N21763 001 Dec 20, 2005 Oct DISC
>A>	@	EQ 10MG BASE	N21763 001 Dec 20, 2005 Oct DISC
>D>		EQ 20MG BASE	N21763 002 Dec 20, 2005 Oct DISC
>A>	@	EQ 20MG BASE	N21763 002 Dec 20, 2005 Oct DISC
>D>	+	EQ 40MG BASE	N21763 003 Dec 20, 2005 Oct DISC
>A>	@	EQ 40MG BASE	N21763 003 Dec 20, 2005 Oct DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N18519 001 Jun 22, 1982 Jun DISC
-------------------	--------------------------------------	----------------------------------

UROLOGIC G IN PLASTIC CONTAINER

+ HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N18904 001 May 27, 1983 Jun CTEC
-----------	--------------------------------------	----------------------------------

CITRIC ACID; UREA, C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

@ BREATHID 2006	N/A,4GM;75MG,N/A	N21314 001 Dec 17, 2002 Sep CAHN
-----------------	------------------	----------------------------------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	WOCKHARDT	250MG	N65266 001 May 31, 2006 May NEWA
AB		500MG	N65266 002 May 31, 2006 May NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

+ RANBAXY	1GM	N65210 001 Jan 26, 2005 Apr CRLD
-----------	-----	----------------------------------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

AA ACTAVIS MID ATLANTIC EQ 0.5MG BASE/5ML N74075 001 Oct 31, 1993 Jul CAHN

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT ACTAVIS MID ATLANTIC EQ 1% BASE N62811 001 Sep 01, 1988 Jul CAHN
AT ALTANA EQ 1% BASE N65254 001 Feb 14, 2006 Jan NEWACLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1 ACTAVIS MID ATLANTIC 0.05% N74139 001 Aug 03, 1994 Jun CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB ACTAVIS MID ATLANTIC 0.05% N74128 001 Aug 03, 1994 Jun CAHN

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT ACTAVIS MID ATLANTIC 0.05% N74331 001 Dec 15, 1995 Jul CAHN
@ ALTANA 0.05% N75391 001 Feb 08, 1999 May DISC

SPRAY; TOPICAL

CLOBEX

+ GALDERMA LABS LP 0.05%

N21835 001 Oct 27, 2005 Feb CAHN

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

+ NOVARTIS 50MG

N19500 002 Dec 15, 1986 Jun CMFD

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB ACTAVIS ELIZABETH 0.5MG N74869 001 Oct 31, 1996 Jun CAHN
AB 1MG N74869 002 Oct 31, 1996 Jun CAHN
AB 2MG N74869 003 Oct 31, 1996 Jun CAHN
AB VINTAGE PHARMS 0.5MG N77856 001 Jun 28, 2006 Jun NEWA
AB 1MG N77856 002 Jun 28, 2006 Jun NEWA
AB 2MG N77856 003 Jun 28, 2006 Jun NEWACLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB ACTAVIS ELIZABETH 0.1MG N70974 001 Dec 16, 1986 Jun CAHN
AB 0.2MG N70975 001 Dec 16, 1986 Jun CAHN
AB 0.3MG N70976 001 Dec 16, 1986 Jun CAHNCLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB APOTEX EQ 75MG BASE N76274 001 Jan 20, 2006 Jan NEWA
PLAVIX
AB + SANOFI SYNTHELABO EQ 75MG BASE N20839 001 Nov 17, 1997 Jan CFTG

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
 FAZACLO ODT

AVANIR PHARMS	25MG	N21590 001	Feb 10, 2004	Jul	CAHN
	50MG	N21590 003	Jun 03, 2005	Jul	CAHN
+	100MG	N21590 002	Feb 10, 2004	Jul	CAHN

COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A
 RUBRATOPE-57 KIT
 @ BRACCO N/A;N/A;N/A;N/A N16089 001 Jun DISC

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
 PROMETH VC W/ CODEINE

+ ACTAVIS MID ATLANTIC	10MG/5ML;5MG/5ML;6.25MG/5ML	N88764 001	Oct 31, 1984	Jul	CAHN
+ ALPHARMA US PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	N88764 001	Oct 31, 1984	Jan	CTEC
PROMETHAZINE VC W/ CODEINE					
@ MORTON GROVE	10MG/5ML;5MG/5ML;6.25MG/5ML	N88896 001	Jan 04, 1985	Jan	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
 PROMETH W/ CODEINE

AA + ACTAVIS MID ATLANTIC	10MG/5ML;6.25MG/5ML	N88763 001	Oct 31, 1984	Jul	CAHN
PROMETHAZINE WITH CODEINE SYRUP					
AA VINTAGE	10MG/5ML;6.25MG/5ML	N40650 001	Jan 31, 2006	Jan	NEWA

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
 TRIACIN-C

AA ACTAVIS MID ATLANTIC	10MG/5ML;30MG/5ML;1.25MG/5ML	N88704 001	Mar 22, 1985	Jul	CAHN
-------------------------	------------------------------	------------	--------------	-----	------

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL
 COlestid

AB + PHARMACIA AND UPJOHN	5GM/PACKET	N17563 004	Sep 22, 1995	Apr	CFTG
	5GM/SCOOPFUL	N17563 003	Sep 22, 1995	Apr	CFTG
COLESTIPOL HYDROCHLORIDE					
AB IMPAX LABS	5GM/SCOOPFUL	N77277 001	May 02, 2006	Apr	NEWA
	5GM/PACKET	N77277 002	May 02, 2006	Apr	NEWA
FLAVORED COlestid					
PHARMACIA AND UPJOHN	5GM/PACKET	N17563 001		Apr	CFTG
TABLET; ORAL					
COlestid					
>D> + PHARMACIA AND UPJOHN	1GM	N20222 001	Jul 19, 1994	Oct	CFTG
>A> AB +	1GM	N20222 001	Jul 19, 1994	Oct	CFTG
COLESTIPOL HYDROCHLORIDE					
>A> AB IMPAX LABS	1GM	N77510 001	Oct 24, 2006	Oct	NEWA

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
 COPPER T MODEL TCU 380A

>D> + DURAMED PHARMS BARR	309MG/COPPER	N18680 001	Nov 15, 1984	Oct	CTNA
---------------------------	--------------	------------	--------------	-----	------

INTRAUTERINE DEVICE; INTRAUTERINE

>A> PARAGARD T 380A
 >A> + DURAMED PHARMS BARR 309MG/COPPER N18680 001 Nov 15, 1984 Oct CTNA

CROMOLYN SODIUM

CONCENTRATE; ORAL
 GASTROCROM
 + AZUR PHARMA 100MG/5ML N20479 001 Feb 29, 1996 May CDFR
 SOLUTION; INHALATION
 CROMOLYN SODIUM
 AN ACTAVIS MID ATLANTIC 10MG/ML N75067 001 Jul 19, 1999 Jul CAHN
 SOLUTION, CONCENTRATE; ORAL
 GASTROCROM
 + AZUR PHARMA 100MG/5ML N20479 001 Feb 29, 1996 Feb CAHN

CYANOCOBALAMIN

GEL, METERED; NASAL
 NASCOBAL
 @ QOL MEDCL 0.5MG/INH N19722 001 Nov 05, 1996 Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
 CYCLOBENZAPRINE HYDROCHLORIDE
 AB JUBILANT PHARMS 5MG N77563 001 Apr 19, 2006 Apr NEWA
 AB 10MG N77563 002 Apr 19, 2006 Apr NEWA
 CYCLOBENZAPRINE HYDROCHLORIDE
 AB AMIDE PHARM 5MG N77291 001 Feb 03, 2006 Jan NEWA
 AB MUTUAL PHARM 5MG N73541 002 Apr 06, 2006 Mar NEWA
 AB MYLAN 5MG N73144 002 Feb 03, 2006 Jan NEWA
 AB SANDOZ 5MG N72854 002 Feb 03, 2006 Jan NEWA
 AB WATSON LABS 5MG N71611 002 Feb 03, 2006 Jan NEWA
 7.5MG N71611 003 Feb 03, 2006 Jan NEWA
 FLEXERIL
 AB MCNEIL CONS SPECLT 5MG N17821 001 Jan CFTG

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
 CYPROHEPTADINE HYDROCHLORIDE
 AA + ACTAVIS MID ATLANTIC 2MG/5ML N86833 001 Jul CAHN
 AA + ALPHARMA US PHARMS 2MG/5ML N86833 001 Jun CTEC
 AA LYNE 2MG/5ML N40668 001 Jun 28, 2006 Jun NEWA
 TABLET; ORAL
 CYPROHEPTADINE HYDROCHLORIDE
 @ TG UNITED LABS 4MG N88212 001 May 26, 1983 May CAHN
 CYPROHEPTADINE HYDROCHLORIDE
 AA STASON PHARMS 4MG N40644 001 May 30, 2006 May NEWA

DAPTOMYCIN

INJECTABLE; IV (INFUSION)
 CUBICIN
 @ CUBIST 250MG/VIAL N21572 001 Sep 12, 2003 Jun DISC

DARUNAVIR ETHANOLATE

TABLET; ORAL
 PREZISTA
 + TIBOTEC EQ 300MG BASE N21976 001 Jun 23, 2006 Jun NEWA

DASATINIB

TABLET; ORAL
 SPRYCEL
 BRISTOL MYERS SQUIBB 20MG N21986 001 Jun 28, 2006 Jun NEWA
 50MG N21986 002 Jun 28, 2006 Jun NEWA
 + 70MG N21986 003 Jun 28, 2006 Jun NEWA

DECITABINE

INJECTABLE; INTRAVENOUS
 DACOGEN
 + MGI PHARMA INC 50MG/VIAL N21790 001 May 02, 2006 May NEWA

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
 DEFEROXAMINE MESYLATE
 AP SICOR PHARMS 500MG/VIAL N76806 001 Mar 31, 2006 Mar NEWA
 AP 2GM/VIAL N76806 002 Mar 31, 2006 Mar NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
 DECLOMYCIN
 @ GLADES PHARMS LLC 75MG N50261 001 Mar CAHN
 AB 150MG N50261 002 Mar CAHN
 AB + 300MG N50261 003 Mar CAHN
 @ PROTEIN DESIGN LABS 75MG N50261 001 Feb CAHN
 AB 150MG N50261 002 Feb CAHN
 AB + 300MG N50261 003 Feb CAHN

DESLOTRADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
 CLARINEX-D 12 HOUR
 + SCHERING 2.5MG;120MG N21313 001 Feb 01, 2006 Feb NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
 DESMOPRESSIN ACETATE
 @ BEDFORD 0.004MG/ML N74575 001 Feb 18, 2000 Jan DISC
 DESMOPRESSIN ACETATE PRESERVATIVE FREE
 @ BEDFORD 0.004MG/ML N74574 001 Feb 18, 2000 Jan DISC

TABLET; ORAL

DESMOPRESSIN ACETATE
 AB APOTEX 0.1MG N77414 001 Mar 07, 2006 Feb NEWA
 AB 0.2MG N77414 002 Mar 07, 2006 Feb NEWA
 AB TEVA PHARMS 0.1MG N77122 001 Jan 25, 2006 Jan NEWA
 AB 0.2MG N77122 002 Jan 25, 2006 Jan NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

AB	+	DURAMED	0.15MG,N/A;0.02MG,0.01MG	N20713 001 Apr 22, 1998 Feb CAHN
AB	+		0.15MG,N/A;0.02MG,0.01MG	N20713 001 Apr 22, 1998 Feb CAHN

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

+ CONNETICS 0.05%

N21978 001 Sep 19, 2006 Sep NEWA

>A> GEL; TOPICAL

>A> DESONATE

>A> + SKINMEDICA 0.05%

N21844 001 Oct 20, 2006 Oct NEWA

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	+	ACTAVIS MID ATLANTIC	0.5MG/5ML	N84754 001 Jul CAHN
AA	+	ALPHARMA US PHARMS	0.5MG/5ML	N84754 001 Jun CRLD

HEXDROL

@ ORGANON USA INC

0.5MG/5ML

N12674 001 Jun DISC

MYMETHASONE

AA	+	MORTON GROVE	0.5MG/5ML	N88254 001 Jul 27, 1983 Jun CRLD
----	---	--------------	-----------	----------------------------------

TABLET; ORAL

DECADRON

@ MERCK 0.5MG

@ 0.75MG

N11664 001 Aug DISC

N11664 002 Aug DISC

DEXAMETHASONE

BP	ROXANE	0.5MG	N84611 001 Aug CTEC
BP		0.75MG	N84613 001 Aug CTEC

HEXDROL

@ ORGANON USA INC

4MG

N12675 010 Jun DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE

>D>	AP	BAXTER HLTHCARE	EQ 10MG PHOSPHATE/ML	N87702 001 Sep 07, 1982 Oct CRLD
>A>	AP	+	EQ 10MG PHOSPHATE/ML	N87702 001 Sep 07, 1982 Oct CRLD
	AP		EQ 10MG PHOSPHATE/ML	N87702 001 Sep 07, 1982 Mar CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

NOVARTIS 15MG

N21802 004 Aug 01, 2006 Aug NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

@ ENDO PHARMS 5MG

N40299 001 May 13, 1999 Feb DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

AA	+	ACTAVIS MID ATLANTIC	15MG/5ML;6.25MG/5ML	N88762 001 Oct 31, 1984 Jul CAHN
----	---	----------------------	---------------------	----------------------------------

SYRUP; ORAL

PROMETHAZINE DM

AA VINTAGE 15MG/5ML; 6.25MG/5ML N40649 001 Feb 14, 2006 Jan NEWA

DIAZEPAM

TABLET; ORAL

DIAZEPAM

AB	ACTAVIS ELIZABETH	2MG	N70781 001 Mar 19, 1986 Jun CAHN
AB		5MG	N70706 001 Mar 19, 1986 Jun CAHN
AB		10MG	N70707 001 Mar 19, 1986 Jun CAHN
AB	VINTAGE PHARMS	2MG	N77749 001 Mar 31, 2006 Mar NEWA
AB		5MG	N77749 002 Mar 31, 2006 Mar NEWA
AB		10MG	N77749 003 Mar 31, 2006 Mar NEWA

DIAZOXIDE

>D> INJECTABLE; INJECTION

>D> HYPERSTAT

>D> + SCHERING 15MG/ML

>A> @ 15MG/ML N16996 001 Oct DISC

N16996 001 Oct DISC

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	ACTAVIS ELIZABETH	50MG	N74514 001 Mar 26, 1996 Jun CAHN
AB		75MG	N74514 002 Mar 26, 1996 Jun CAHN
AB	SANDOZ	75MG	N74394 001 Nov 30, 1995 May CRLD
VOLTAREN			
AB	+ NOVARTIS	75MG	N19201 003 Jul 28, 1988 May CMFD
TABLET, EXTENDED RELEASE; ORAL			
DICLOFENAC SODIUM			
AB	ACTAVIS ELIZABETH	100MG	N75910 001 Jan 07, 2002 Jun CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

@ TG UNITED LABS 25MG N88267 001 Aug 25, 1983 May CAHN
@ 25MG N88268 001 Aug 25, 1983 May CAHNDIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+ ALTANA	0.05%	N76263 001 Dec 20, 2002 Jan CRLD
FLORONE			
	@ PHARMACIA AND UPJOHN	0.05%	N17741 001 Jan DISC
FLORONE E			
	@ PHARMACIA AND UPJOHN	0.05%	N19259 001 Aug 28, 1985 Jan DISC
OINTMENT; TOPICAL			
DIFLORASONE DIACETATE			
AB	+ TARO	0.05%	N75331 001 May 14, 1999 Jan CRLD
FLORONE			
	@ PHARMACIA AND UPJOHN	0.05%	N17994 001 Jan DISC
PSORCON			
	@ PHARMACIA AND UPJOHN	0.05%	N19260 001 Aug 28, 1985 Jan DISC

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB	+	TEVA	500MG	N73673	001	Jul 31, 1992	Jun	CRLD
		DOLOBID						
	@	MERCK	250MG	N18445	001	Apr 19, 1982	Jun	DISC
	@		500MG	N18445	002	Apr 19, 1982	Jun	DISC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP		SANDOZ	0.25MG/ML	N40481	001	Aug 21, 2003	Jan	CAHN
----	--	--------	-----------	--------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB3		ACTAVIS ELIZABETH	120MG	N74984	001	Dec 20, 1999	Jun	CAHN
AB3			180MG	N74984	002	Dec 20, 1999	Jun	CAHN
AB3			240MG	N74984	003	Dec 20, 1999	Jun	CAHN
AB3			300MG	N74984	004	Dec 20, 1999	Jun	CAHN
AB4		KV PHARM	120MG	N76563	002	Sep 12, 2006	Aug	NEWA
AB4			180MG	N76563	003	Sep 12, 2006	Aug	NEWA
AB4			240MG	N76563	004	Sep 12, 2006	Aug	NEWA
AB4			300MG	N76563	005	Sep 12, 2006	Aug	NEWA
AB4			360MG	N76563	006	Sep 12, 2006	Aug	NEWA
AB4			420MG	N76563	001	Sep 12, 2006	Aug	NEWA
		DILTZAC						
AB4		APOTEX INC	120MG	N76395	001	Feb 01, 2006	Jan	NEWA
AB4			180MG	N76395	002	Feb 01, 2006	Jan	NEWA
AB4			240MG	N76395	003	Feb 01, 2006	Jan	NEWA
AB4			300MG	N76395	004	Feb 01, 2006	Jan	NEWA
AB4			360MG	N76395	005	Feb 01, 2006	Jan	NEWA
		TIAZAC						
AB4	+	BIOVAIL	420MG	N20401	006	Oct 16, 1998	Aug	CFTG

>D> DILTIAZEM MALATE; ENALAPRIL MALEATE

>D> TABLET, EXTENDED RELEASE; ORAL

>D> TECZEM

>D> + BIOVAIL EQ 180MG HCL;5MG

>A> @ EQ 180MG HCL;5MG

N20507 001 Oct 04, 1996 Oct DISC

N20507 001 Oct 04, 1996 Oct DISC

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

RIMSO-50

AT	+	BIONICHE PHARMA	50%	N17788	001		Jul	CAHN
----	---	-----------------	-----	--------	-----	--	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB		AMIDE PHARM	25MG	N40542	001	Apr 21, 2006	Apr	NEWA
AB			50MG	N40542	002	Apr 21, 2006	Apr	NEWA
AB			75MG	N40542	003	Apr 21, 2006	Apr	NEWA
>D>		@ GLENMARK PHARMA	25MG	N88999	001	Feb 05, 1991	Oct	CMFD
>A>	AB		25MG	N88999	001	Feb 05, 1991	Oct	CMFD

TABLET; ORAL

DIPYRIDAMOLE

AB	@ GLENMARK PHARMA	25MG	N88999 001 Feb 05, 1991 Jul CAHN
		50MG	N89000 001 Feb 05, 1991 Jul CAHN
>D>	@	75MG	N89001 001 Feb 05, 1991 Oct CMFD
>A>	AB	75MG	N89001 001 Feb 05, 1991 Oct CMFD
	@	75MG	N89001 001 Feb 05, 1991 Jul CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@ IVAX PHARMS	EQ 100MG BASE	N70186 001 Nov 18, 1985 Jan DISC
@	EQ 150MG BASE	N70187 001 Nov 18, 1985 Jan DISC
@ SANDOZ	EQ 100MG BASE	N70470 001 Dec 10, 1985 Jan DISC
@	EQ 150MG BASE	N70471 001 Dec 10, 1985 Jan DISC

DISULFIRAM

TABLET; ORAL

ANTABUSE

>D>	+	ODYSSEY PHARMS	250MG	N88482 001 Dec 08, 1983 Oct CRLD
>A>			250MG	N88482 001 Dec 08, 1983 Oct CRLD
>D>	@		500MG	N88483 001 Dec 08, 1983 Oct CMFD
>A>	+		500MG	N88483 001 Dec 08, 1983 Oct CMFD

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+	SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)	N20624 002 Sep 11, 1997 Mar CAIN
+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624 001 Sep 11, 1997 Mar CAIN
+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624 003 Dec 11, 2001 Mar CAIN

TABLET; ORAL

ANZEMET

SANOFI AVENTIS US	EQ 50MG BASE	N20623 001 Sep 11, 1997 Mar CAIN
+	EQ 100MG BASE	N20623 002 Sep 11, 1997 Mar CAIN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

@ HOSPIRA	40MG/ML	N74403 001 May 23, 1996 Apr DISC
@ INTL MEDICATION	40MG/ML	N18014 001 Apr DISC
@ SICOR PHARMS	40MG/ML	N72999 001 Oct 23, 1991 Apr DISC
@	80MG/ML	N73000 001 Oct 23, 1991 Apr DISC

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	ACTAVIS ELIZABETH	EQ 1MG BASE	N75574 001 Oct 18, 2000 Jun CAHN
AB		EQ 2MG BASE	N75574 002 Oct 18, 2000 Jun CAHN
AB		EQ 4MG BASE	N75574 003 Oct 18, 2000 Jun CAHN
AB		EQ 8MG BASE	N75574 004 Oct 18, 2000 Jun CAHN

DOXYCYCLINE

CAPSULE; ORAL						
DOXYCYCLINE						
@ PAR PHARM	EQ 75MG BASE	N65055	004	Apr 18, 2005	Mar	DISC
@	EQ 150MG BASE	N65055	003	Jul 15, 2005	Mar	DISC
RANBAXY	EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC
CAPSULE, DELAYED RELEASE; ORAL						
ORACEA						
+ COLLAGENEX PHARMS	40MG	N50805	001	May 26, 2006	May	NEWA
TABLET; ORAL						
DOXYCYCLINE						
>A> AB MYLAN	EQ 50MG BASE	N65377	001	Nov 07, 2006	Oct	NEWA
>A> AB	EQ 75MG BASE	N65377	002	Nov 07, 2006	Oct	NEWA
>A> AB	EQ 100MG BASE	N65377	003	Nov 07, 2006	Oct	NEWA
AB PAR PHARM	EQ 75MG BASE	N65070	003	Dec 30, 2002	May	CPTG
	EQ 75MG BASE	N65070	003	Dec 30, 2002	Mar	CMFD
AB RANBAXY	EQ 50MG BASE	N65356	001	May 31, 2006	May	NEWA
AB	EQ 75MG BASE	N65356	002	May 31, 2006	May	NEWA
AB	EQ 100MG BASE	N65356	003	May 31, 2006	May	NEWA

DOXYCYCLINE HYCLATE

CAPSULE, DELAYED RELEASE; ORAL						
DORYX						
@ FH FAULDING CO LTD	EQ 75MG BASE	N50582	002	Aug 13, 2001	Apr	DISC
@	EQ 100MG BASE	N50582	001	Jul 22, 1985	Apr	DISC
@ MAYNE PHARMA INTL	EQ 75MG BASE	N50582	002	Aug 13, 2001	Sep	CAHN
@	EQ 100MG BASE	N50582	001	Jul 22, 1985	Sep	CAHN
@ WARNER CHILCOTT	EQ 100MG BASE	N62653	001	Oct 30, 1985	Apr	DISC
DOXYCYCLINE HYCLATE						
SANDOZ	EQ 75MG BASE	N65281	001	Dec 21, 2005	Apr	CTEC
+	EQ 100MG BASE	N65281	002	Dec 21, 2005	Apr	CRLD
INJECTABLE; INJECTION						
DOXY 100						
>D> + ABRAXIS PHARM	EQ 100MG BASE/VIAL	N62475	001	Dec 09, 1983	Oct	CTEC
>A> AP +	EQ 100MG BASE/VIAL	N62475	001	Dec 09, 1983	Oct	CTEC
DOXYCYCLINE						
>D> @ BEDFORD	EQ 100MG BASE/VIAL	N62569	001	Mar 09, 1988	Oct	CMFD
>A> AP +	EQ 100MG BASE/VIAL	N62569	001	Mar 09, 1988	Oct	CMFD
TABLET; ORAL						
DOXYCYCLINE HYCLATE						
AB PAR PHARM	EQ 20MG BASE	N65287	001	Feb 28, 2006	Feb	NEWA
TABLET, DELAYED RELEASE; ORAL						
DORYX						
>D> FAULDING	EQ 75MG BASE	N50795	001	May 06, 2005	Oct	CAHN
>D> +	EQ 100MG BASE	N50795	002	May 06, 2005	Oct	CAHN
>A> MAYNE PHARMA INTL	EQ 75MG BASE	N50795	001	May 06, 2005	Oct	CAHN
>A> +	EQ 100MG BASE	N50795	002	May 06, 2005	Oct	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL						
YAZ						
+ BERLEX	3MG;0.02MG	N21676	001	Mar 16, 2006	Jun	CAHN
+ BERLEX LABS	3MG;0.02MG	N21676	001	Mar 16, 2006	Mar	NEWA

DYPHYLLINE

TABLET; ORAL				
DILOL				
@ SAVAGE LABS	200MG	N84514 001	Jun	DISC
DILOL-400				
@ SAVAGE LABS	400MG	N84751 001	Jun	DISC
LUFYLLIN				
MEDPOINTE PHARM HLC	200MG	N84566 001	Jun	CTEC
+ 400MG		N84566 002	Jun	CRLD

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL				
ATRIPLA				
+ GILEAD	600MG;200MG;300MG	N21937 001	Jul 12, 2006	Jul NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
XYLOCAINE W/ EPINEPHRINE				
AP + ABRAXIS BIOSCIENCE	0.005MG/ML;0.5%	N06488 012	Jul	CAHN
AP +	0.005MG/ML;1%	N06488 018	Nov 13, 1986	Jul CAHN
AP +	0.005MG/ML;1.5%	N06488 017		Jul CAHN
AP +	0.005MG/ML;2%	N06488 019	Nov 13, 1986	Jul CAHN
AP +	0.01MG/ML;1%	N06488 004		Jul CAHN
@	0.01MG/ML;2%	N06488 003		Jul CAHN
@	0.02MG/ML;2%	N06488 005		Jul CAHN
+ DENTSPLY PHARM	0.02MG/ML;2%	N21381 002		Mar CRLD
PATCH; IONTOPHORESIS, TOPICAL				
LIDOSITE TOPICAL SYSTEM KIT				
+ VYTERIS	1.05MG/PATCH;100MG/PATCH	N21504 001	May 06, 2004	May CDFR
SOLUTION; IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
+ EMPI	0.01MG/ML;2%	N21486 001	Oct 26, 2004	May CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)				
EPIRUBICIN HYDROCHLORIDE				
+ MAYNE PHARMA USA	50MG/VIAL	N50807 001	Sep 15, 2006	Sep NEWA
+	200MG/VIAL	N50807 002	Sep 15, 2006	Sep NEWA

ERYTHROMYCIN

SOLUTION; TOPICAL				
A/T/S				
AT TARO PHARMS NORTH	2%	N62405 001	Nov 18, 1982	Feb CAHN
SWAB; TOPICAL				
ERYTHROMYCIN				
AT ALTANA	2%	N65320 001	Jul 25, 2006	Jul NEWA

ERYTHROMYCIN ETHYLSUCCINATE

TABLET, CHEWABLE; ORAL				
E.E.S.				
@ ABBOTT	EQ 200MG BASE	N50297 002	Aug	DISC
ERYPED				
@ ABBOTT	EQ 200MG BASE	N50297 003	Jul 05, 1988	Aug DISC

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

>D>	AB	IVAX PHARMS	5MG	N76765	001	May 22,	2006	Oct	CPOT
>A>	AB		EQ 5MG BASE	N76765	001	May 22,	2006	Oct	CPOT
	AB		5MG	N76765	001	May 22,	2006	May	NEWA
>D>	AB		10MG	N76765	002	May 22,	2006	Oct	CPOT
>A>	AB		EQ 10MG BASE	N76765	002	May 22,	2006	Oct	CPOT
	AB		10MG	N76765	002	May 22,	2006	May	NEWA
>D>	AB		20MG	N76765	003	May 22,	2006	Oct	CPOT
>A>	AB		EQ 20MG BASE	N76765	003	May 22,	2006	Oct	CPOT
	AB		20MG	N76765	003	May 22,	2006	May	NEWA
		LEXAPRO							
>D>	AB	FOREST LABS	5MG	N21323	001	Aug 14,	2002	Oct	CPOT
>A>	AB		EQ 5MG BASE	N21323	001	Aug 14,	2002	Oct	CPOT
	AB		5MG	N21323	001	Aug 14,	2002	May	CFTG
>D>	AB		10MG	N21323	002	Aug 14,	2002	Oct	CPOT
>A>	AB		EQ 10MG BASE	N21323	002	Aug 14,	2002	Oct	CPOT
	AB		10MG	N21323	002	Aug 14,	2002	May	CFTG
>D>	AB	+	20MG	N21323	003	Aug 14,	2002	Oct	CPOT
>A>	AB	+	EQ 20MG BASE	N21323	003	Aug 14,	2002	Oct	CPOT
	AB	+	20MG	N21323	003	Aug 14,	2002	May	CFTG

ESOMEPRAZOLE MAGNESIUM

>A>		FOR SUSPENSION, DELAYED RELEASE; ORAL							
>A>		NEXIUM							
>A>		ASTRAZENECA	EQ 20MG BASE/PACKET	N21957	001	Oct 20,	2006	Oct	NEWA
>A>	+		EQ 40MG BASE/PACKET	N21957	002	Oct 20,	2006	Oct	NEWA

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

AB		PAR PHARM	1MG	N74826	001	Jul 03,	1997	Apr	CAHN
AB			2MG	N74826	002	Jul 03,	1997	Apr	CAHN

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

AB2		BERLEX	0.025MG/24HR	N20375	004	Mar 05,	1999	Aug	CRLD
AB			0.0375MG/24HR	N20375	005	May 27,	2003	Aug	CRLD
AB	+		0.0375MG/24HR	N20375	005	May 27,	2003	Jul	CFTG
AB2			0.05MG/24HR	N20375	001	Dec 22,	1994	Aug	CRLD
AB			0.06MG/24HR	N20375	006	May 27,	2003	Aug	CRLD
AB	+		0.06MG/24HR	N20375	006	May 27,	2003	Jul	CFTG
AB2			0.075MG/24HR	N20375	003	Mar 23,	1998	Aug	CRLD

ESTRADERM

BX		NOVARTIS	0.05MG/24HR	N19081	002	Sep 10,	1986	Aug	CRLD
	ESTRADIOL								

AB		MYLAN TECHNOLOGIES	0.0375MG/24HR	N75182	004	Jul 20,	2006	Jul	NEWA
AB			0.06MG/24HR	N75182	005	Jul 20,	2006	Jul	NEWA

MENOSTAR

+	BERLEX		0.014MG/24HR	N21674	001	Jun 08,	2004	Jun	CAHN
	VIVELLE-DOT								

BX		NOVARTIS	0.025MG/24HR	N20538	009	May 03,	2002	Aug	CRLD
BX			0.0375MG/24HR	N20538	005	Jan 08,	1999	Aug	CRLD

FILM, EXTENDED RELEASE; TRANSDERMAL

VIVELLE-DOT

AB1	NOVARTIS	0.05MG/24HR	N20538 006 Jan 08, 1999 Aug CRLD
BX		0.075MG/24HR	N20538 007 Jan 08, 1999 Aug CRLD
GEL; TOPICAL			
ESTROGEL			
@ ASCEND 0.06% N21166 001 Feb 09, 2004 Jan CAHN			
GEL, METERED; TOPICAL			
ESTROGEL			
+ ASCEND		0.06%	N21166 002 Feb 09, 2004 Jan CAHN
TABLET; ORAL			
ESTRADIOL			
@ RADIUS PHARMS 0.5MG N40275 001 Dec 29, 1998 Aug CAHN			
@ 1MG N40275 002 Dec 29, 1998 Aug CAHN			
@ 2MG N40275 003 Dec 29, 1998 Aug CAHN			

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ ESPRIT PHARMA	0.25%	N21371 001 Oct 09, 2003 Feb CAHN
-----------------	-------	----------------------------------

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

DURAMED	0.3MG	N21443 001 Dec 20, 2004 Mar CMFD
	0.45MG	N21443 002 Dec 20, 2004 Mar CMFD
	0.625MG	N21443 003 May 10, 2004 Mar CMFD
+	1.25MG	N21443 004 May 10, 2004 Mar CMFD

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRRIN

+ ATON	EQ 50MG BASE/VIAL	N16093 001 Jul CAHN
--------	-------------------	---------------------

ETHACRYNIC ACID

TABLET; ORAL

EDECRRIN

>A>	+ ATON	25MG	N16092 001 Oct CAHN
>A>	@	50MG	N16092 002 Oct CAHN
>D>	+ MERCK	25MG	N16092 001 Oct CAHN
>D>	@	50MG	N16092 002 Oct CAHN

ETHINYLN ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

QUASENSE

AB	WATSON LABS	0.03MG;0.15MG	N77101 001 Sep 06, 2006 Aug NEWA
----	-------------	---------------	----------------------------------

SEASONALE

AB	+ DURAMED	0.03MG;0.15MG	N21544 001 Sep 05, 2003 Aug CFTG
----	-----------	---------------	----------------------------------

SEASONIQUE

+ DURAMED RES	0.03MG,0.01MG;0.15MG,N/A	N21840 001 May 25, 2006 May NEWA
---------------	--------------------------	----------------------------------

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYLN ESTRADIOL

AB2	WATSON LABS	0.02MG;0.1MG	N77681 001 May 31, 2006 May NEWA
-----	-------------	--------------	----------------------------------

ETHINYLY ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21 BALZIVA-21 BARR	0.035MG;0.4MG	N76198 001 Apr 22, 2004 Mar CRLD
TABLET; ORAL-28 OVCON-35		
AB + WARNER CHILCOTT	0.035MG ; 0 . 4MG	N17716 001 Mar CRLD

ETHINYLY ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL LOESTRIN 24 FE + WARNER CHILCOTT	0.02MG;1MG	N21871 001 Feb 17, 2006 Feb NEWA
---	------------	----------------------------------

ETHINYLY ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28 NORGESTIMATE AND ETHINYLY ESTRADIOL AB WATSON LABS	0.035MG,0.035MG,0.035MG;0.18MG,0. 215MG,0.25MG	N76626 001 Aug 17, 2006 Aug NEWA
AB	0.035MG,0.035MG,0.035MG;0.18MG,0. 215MG,0.25MG	N76626 001 Aug 17, 2006 Aug NEWA
AB	0.035MG,0.035MG,0.035MG;0.18MG,0. 215MG,0.25MG	N76626 001 Aug 17, 2006 Aug NEWA
AB	0.035MG;0.25MG	N76627 001 Aug 17, 2006 Aug NEWA

ETODOLAC

CAPSULE; ORAL ETODOLAC @ ENDO PHARMS	200MG	N74842 001 Jul 17, 1997 Feb DISC
@	300MG	N74842 002 Jul 17, 1997 Feb DISC
AB + TARO	300MG	N75078 002 Apr 30, 1998 Mar CRLD
LODINE @ WYETH PHARMS INC	300MG	N18922 003 Jan 31, 1991 Mar DISC
TABLET; ORAL ETODOLAC AB ACTAVIS ELIZABETH	400MG	N74819 001 Feb 28, 1997 Jun CAHN
@ ENDO PHARMS	400MG	N74841 001 Jun 27, 1997 Feb DISC

ETONOGESTREL

IMPLANT; IMPLANTATION IMPLANON + ORGANON USA INC	68MG/IMPLANT	N21529 001 Jul 17, 2006 Jul NEWA
--	--------------	----------------------------------

ETOPOSIDE

INJECTABLE; INJECTION TOPOSAR @ SICOR PHARMS	20MG/ML	N74166 001 Feb 27, 1995 Jun DISC
--	---------	----------------------------------

FAMOTIDINE

TABLET; ORAL FAMOTIDINE AB ACTAVIS ELIZABETH	20MG	N75650 001 Sep 14, 2001 Jun CAHN
	40MG	N75650 002 Sep 14, 2001 Jun CAHN

FENOFIBRATE

CAPSULE; ORAL					
ANTARA (MICRONIZED)					
OSCIENT	43MG	N21695	001	Nov 30, 2004	Aug CAHN
@	87MG	N21695	002	Nov 30, 2004	Aug CAHN
+	130MG	N21695	003	Nov 30, 2004	Aug CAHN
LIPOFEN					
CIPHER	50MG	N21612	001	Jan 11, 2006	Jan NEWA
	100MG	N21612	002	Jan 11, 2006	Jan NEWA
+	150MG	N21612	003	Jan 11, 2006	Jan NEWA
TABLET; ORAL					
FENOFIBRATE					
AB + TEVA	160MG	N76433	002	May 13, 2005	Jan CRLD
TRICOR					
@ ABBOTT	54MG	N21203	001	Sep 04, 2001	Jan DISC
@	160MG	N21203	003	Sep 04, 2001	Jan DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION					
FENOLDOPAM MESYLATE					
AP SANDOZ	EQ 10MG BASE/ML	N77155	001	Feb 15, 2005	Jan CAHN

FENOPROFEN CALCIUM

TABLET; ORAL					
FENOPROFEN CALCIUM					
AB ACTAVIS ELIZABETH	EQ 600MG BASE	N72274	001	May 02, 1988	Jun CAHN
@ CLONMEL HLTHCARE	EQ 600MG BASE	N72326	001	Aug 17, 1988	Jan DISC

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL					
FENTANYL					
AB LAVIPHARM LABS	25UGM/HR	N77051	001	Aug 04, 2006	Jul NEWA
AB	50UGM/HR	N77051	002	Aug 04, 2006	Jul NEWA
AB	75UGM/HR	N77051	003	Aug 04, 2006	Jul NEWA
AB	100UGM/HR	N77051	004	Aug 04, 2006	Jul NEWA

FENTANYL CITRATE

TABLET; BUCCAL					
FENTORA					
CEPHALON	EQ 0.1MG BASE	N21947	001	Sep 25, 2006	Sep NEWA
	EQ 0.2MG BASE	N21947	002	Sep 25, 2006	Sep NEWA
+	EQ 0.4MG BASE	N21947	003	Sep 25, 2006	Sep NEWA
	EQ 0.6MG BASE	N21947	004	Sep 25, 2006	Sep NEWA
	EQ 0.8MG BASE	N21947	005	Sep 25, 2006	Sep NEWA
TROCHE/LOZENGE; ORAL					
FENTANYL					
@ CEPHALON	EQ 0.1MG BASE	N20195	007	Oct 30, 1995	Jul CAHN
@	EQ 0.2MG BASE	N20195	001	Oct 04, 1993	Jul CAHN
@	EQ 0.3MG BASE	N20195	002	Oct 04, 1993	Jul CAHN
@	EQ 0.4MG BASE	N20195	003	Oct 04, 1993	Jul CAHN
TROCHE/LOZENGE; TRANSMUCOSAL					
>A> ACTIQ					
>A> CEPHALON	EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Oct CTNA
>A> +	EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Oct CTNA

TROCHE/LOZENGE; TRANSMUCOSAL

>A>	ACTIQ						
>A>	CEPHALON	EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Oct	CTNA
>A>		EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Oct	CTNA
>A>		EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Oct	CTNA
>A>		EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Oct	CTNA
>D>	ACTIQ (SUGAR-FREE)						
>D>	CEPHALON	EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Oct	CTNA
		EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Mar	CTNA
>D>	+	EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Oct	CTNA
	+	EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Mar	CTNA
>D>		EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Oct	CTNA
		EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Mar	CTNA
>D>		EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Oct	CTNA
		EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Mar	CTNA
>D>		EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Oct	CTNA
		EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Mar	CTNA
>D>		EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Oct	CTNA
		EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Mar	CTNA

FEXOFENADINE HYDROCHLORIDE

>A>	SUSPENSION; ORAL						
>A>	ALLEGRA						
>A>	+ SANOFI AVENTIS US	30MG/5ML	N21963	001	Oct 16, 2006	Oct	NEWA
	TABLET; ORAL						
	FEXOFENADINE HYDROCHLORIDE						
AB	DR REDDYS LABS LTD	30MG	N76502	001	Apr 11, 2006	Mar	NEWA
AB		60MG	N76502	002	Apr 11, 2006	Mar	NEWA
AB		180MG	N76502	003	Apr 11, 2006	Mar	NEWA

FINASTERIDE

	TABLET; ORAL						
	FINASTERIDE						
AB	DR REDDYS LABS INC	1MG	N76436	001	Jul 28, 2006	Jul	NEWA
AB	IVAX PHARMS	5MG	N76340	001	Jun 19, 2006	Jun	NEWA
	PROPECIA						
AB	+ MERCK	1MG	N20788	001	Dec 19, 1997	Jul	CFTG
	PROSCAR						
AB	+ MERCK	5MG	N20180	001	Jun 19, 1992	Jun	CFTG

FLUCONAZOLE

	TABLET; ORAL						
	FLUCONAZOLE						
AB	GLENMARK PHARMA	50MG	N77253	001	Jan 25, 2006	Jan	NEWA
AB		100MG	N77253	002	Jan 25, 2006	Jan	NEWA
AB		150MG	N77253	003	Jan 25, 2006	Jan	NEWA
AB		200MG	N77253	004	Jan 25, 2006	Jan	NEWA

FLUMAZENIL

	INJECTABLE; INJECTION						
	FLUMAZENIL						
AP	SANDOZ	1MG/10ML (0.1MG/ML)	N77071	002	May 03, 2005	Jan	CAHN
AP		0.5MG/5ML (0.1MG/ML)	N77071	001	May 03, 2005	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION
 AEROSPAH HFA
 + FOREST LABS EQ 78UGM BASE/INH N21247 001 Jan 27, 2006 Jan NEWA
 SPRAY, METERED; NASAL
 FLUNISOLIDE
 AB + BAUSCH AND LOMB 0.025MG/SPRAY N74805 001 Feb 20, 2002 Jul CTEC
 AB QPHARMA 0.025MG/SPRAY N77704 001 Aug 03, 2006 Jul NEWA

FLUOCINONIDE

CREAM; TOPICAL
 FLUOCINONIDE
 AB1 ACTAVIS MID ATLANTIC 0.05% N73085 001 Feb 14, 1992 Jun CAHN
 FLUOCINONIDE EMULSIFIED BASE
 AB2 ACTAVIS MID ATLANTIC 0.05% N74204 001 Jun 13, 1995 Jun CAHN
 SOLUTION; TOPICAL
 FLUOCINONIDE
 AT ACTAVIS MID ATLANTIC 0.05% N71535 001 Dec 02, 1988 Jul CAHN

FLUORESCIN SODIUM

INJECTABLE; INTRAVENOUS
 FLUORESCITE
 + ALCON EQ 500MG BASE/5ML (EQ 100MG
 BASE/ML) N21980 001 Mar 28, 2006 May CAHN
 + ALCON RES EQ 500MG BASE/5ML (EQ 100MG
 BASE/ML) N21980 001 Mar 28, 2006 Mar NEWA

FLUOROURACIL

INJECTABLE; INJECTION
 ADRUCIL
 @ SICOR PHARMS 50MG/ML N40023 001 Oct 18, 1991 Jun DISC
 AP + 50MG/ML N40023 001 Oct 18, 1991 Mar CRLD
 @ 50MG/ML N81225 001 Aug 28, 1991 Jun DISC
 FLUOROURACIL
 AP + AM PHARM PARTNERS 50MG/ML N40278 001 Sep 30, 1998 Mar CRLD
 AP + 50MG/ML N40279 001 Sep 30, 1998 Mar CRLD
 AP + 50MG/ML N40291 001 Mar 24, 1999 Mar CRLD
 AP + 50MG/ML N40379 001 Nov 15, 2000 Mar CRLD
 @ BEDFORD 50MG/ML N89508 001 Jan 26, 1988 Apr DISC
 AP + 50MG/ML N89508 001 Jan 26, 1988 Mar CRLD
 AP + SICOR PHARMS 50MG/ML N40333 001 Jan 27, 2000 Mar CRLD
 AP + 50MG/ML N40334 001 Feb 25, 2000 Mar CRLD
 AP + STERIS 50MG/ML N87792 001 Oct 13, 1982 Mar CRLD
 @ WATSON LABS 50MG/ML N87792 001 Oct 13, 1982 Apr DISC

FLUOXETINE HYDROCHLORIDE

SOLUTION; ORAL
 FLUOXETINE
 AA ACTAVIS MID ATLANTIC EQ 20MG BASE/5ML N75690 001 Jan 31, 2002 Jul CAHN
 TABLET; ORAL
 FLUOXETINE HYDROCHLORIDE
 + IVAX PHARMS EQ 40MG BASE N75865 003 Aug 30, 2004 Aug CRLD
 SARAFEM
 WARNER CHILCOTT EQ 10MG BASE N21860 001 May 19, 2006 May NEWA
 EQ 15MG BASE N21860 002 May 19, 2006 May NEWA

TABLET; ORAL

SARAFEM

+ WARNER CHILCOTT EQ 20MG BASE

N21860 003 May 19, 2006 May NEWA

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC	5MG/ML	N74725 001 Sep 16, 1996 Aug CRLD
@ TEVA PHARMS	5MG/ML	N73058 001 Aug 30, 1991 Aug DISC
PROLIXIN		
@ APOTHECON	5MG/ML	N70533 001 Nov 07, 1985 Jul DISC
ELIXIR; ORAL		
FLUPHENAZINE HYDROCHLORIDE		
+ PHARM ASSOC	2.5MG/5ML	N40146 001 Aug 21, 1996 Apr CRLD
@ TEVA PHARMS	2.5MG/5ML	N81310 001 Apr 29, 1993 Apr DISC
PROLIXIN		
@ APOTHECON	2.5MG/5ML	N12145 003 Apr DISC

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

AT BAUSCH AND LOMB 0.03% N74447 001 Jan 04, 1995 Aug CAHN

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

@ SCHERING 125MG N18554 001 Jan 27, 1989 May DISC

FLUTAMIDE

AB PAR PHARM 125MG N75298 001 Sep 18, 2001 Apr CAHN
AB + SANDOZ 125MG N75818 001 Sep 18, 2001 May CRLDFLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

>D> + GLAXOSMITHKLINE	0.044MG/INH	N20548 001 Mar 27, 1996 Oct DISC
>A> @	0.044MG/INH	N20548 001 Mar 27, 1996 Oct DISC
>D> +	0.11MG/INH	N20548 002 Mar 27, 1996 Oct DISC
>A> @	0.11MG/INH	N20548 002 Mar 27, 1996 Oct DISC
>D> +	0.22MG/INH	N20548 003 Mar 27, 1996 Oct DISC
>A> @	0.22MG/INH	N20548 003 Mar 27, 1996 Oct DISC

CREAM; TOPICAL

FLUTICASONE PROPIONATE

AB G AND W LABS 0.05% N77055 001 Jun 30, 2006 Jun NEWA

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB G AND W LABS 0.005% N77168 001 Mar 03, 2006 Feb NEWA

SPRAY, METERED; NASAL

FLONASE

AB + GLAXOSMITHKLINE 0.05MG/SPRAY N20121 001 Oct 19, 1994 Feb CFTG

FLUTICASONE PROPIONATE

AB ROXANE 0.05MG/SPRAY N76504 001 Feb 22, 2006 Feb NEWA

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION								
ADVAIR HFA								
+ GLAXOSMITHKLINE	0.045MG/INH;EQ 0.021MG BASE/INH	N21254	001	Jun 08, 2006	Jun	NEWA		
+	0.115MG/INH;EQ 0.021MG BASE/INH	N21254	002	Jun 08, 2006	Jun	NEWA		
+	0.23MG/INH;EQ 0.021MG BASE/INH	N21254	003	Jun 08, 2006	Jun	NEWA		

FLUVOXAMINE MALEATE

TABLET; ORAL								
FLUVOXAMINE MALEATE								
AB ACTAVIS ELIZABETH	25MG	N75901	001	Dec 28, 2000	Jun	CAHN		
AB	50MG	N75901	002	Dec 28, 2000	Jun	CAHN		
AB	100MG	N75901	003	Dec 28, 2000	Jun	CAHN		
AB CARACO	25MG	N75900	001	Feb 23, 2006	Feb	NEWA		
AB	50MG	N75900	002	Feb 23, 2006	Feb	NEWA		
AB	100MG	N75900	003	Feb 23, 2006	Feb	NEWA		

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS								
FOLLISTIM AQ								
@ ORGANON USA INC	150 IU/0.18ML	N21211	003	Feb 11, 2004	Jul	DISC		
+	300 IU/0.36ML	N21211	001	Mar 23, 2004	Jul	CMFD		
@	300 IU/0.36ML	N21211	001	Mar 23, 2004	Jun	DISC		

FOSCARNET SODIUM

INJECTABLE; INJECTION								
FOSCARNET SODIUM								
AP HOSPIRA	2.4GM/100ML	N77174	001	May 31, 2005	Feb	CAHN		

FOSINOPRIL SODIUM

TABLET; ORAL								
FOSINOPRIL SODIUM								
AB COBALT	10MG	N77531	001	Aug 31, 2006	Aug	NEWA		
AB	20MG	N77531	002	Aug 31, 2006	Aug	NEWA		
AB	40MG	N77531	003	Aug 31, 2006	Aug	NEWA		

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL								
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE								
AB GENPHARM	10MG;12.5MG	N77705	001	Aug 14, 2006	Aug	NEWA		
AB	20MG;12.5MG	N77705	002	Aug 14, 2006	Aug	NEWA		
AB TEVA	10MG;12.5MG	N76945	001	Jul 05, 2006	Jun	NEWA		
AB	20MG;12.5MG	N76945	002	Jul 05, 2006	Jun	NEWA		

FUROSEMIDE

TABLET; ORAL								
FUROSEMIDE								
AB OHM LABS	20MG	N78010	001	Sep 18, 2006	Sep	NEWA		
AB	40MG	N78010	002	Sep 18, 2006	Sep	NEWA		
AB	80MG	N78010	003	Sep 18, 2006	Sep	NEWA		

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	ACTAVIS ELIZABETH	100MG	N75350 001	Sep 12, 2003	Jun	CAHN
AB		300MG	N75350 002	Sep 12, 2003	Jun	CAHN
AB		400MG	N75350 003	Sep 12, 2003	Jun	CAHN
AB	SANDOZ	100MG	N75428 001	Jan 24, 2006	Jan	NEWA
AB		300MG	N75428 002	Jan 24, 2006	Jan	NEWA
AB		400MG	N75428 003	Jan 24, 2006	Jan	NEWA
AB	SUN PHARM INDS LTD	100MG	N77242 001	Aug 24, 2006	Aug	NEWA
AB		300MG	N77242 002	Aug 24, 2006	Aug	NEWA
AB		400MG	N77242 003	Aug 24, 2006	Aug	NEWA

TABLET; ORAL

GABAPENTIN

AB	ACTAVIS ELIZABETH	600MG	N75694 001	Oct 21, 2004	Jun	CAHN
AB		800MG	N75694 002	Oct 21, 2004	Jun	CAHN
AB	APOTEX INC	100MG	N77894 001	Oct 10, 2006	Sep	NEWA
AB		300MG	N77894 002	Oct 10, 2006	Sep	NEWA
AB		400MG	N77894 003	Oct 10, 2006	Sep	NEWA
AB		600MG	N77661 004	Sep 13, 2006	Aug	NEWA
AB		800MG	N77661 005	Sep 13, 2006	Aug	NEWA
AB	GLENMARK PHARMS	600MG	N77662 001	Aug 18, 2006	Aug	NEWA
AB		800MG	N77662 002	Aug 18, 2006	Aug	NEWA
AB	IVAX PHARMS	100MG	N76017 001	Apr 28, 2004	Sep	CFTG
AB		300MG	N76017 002	Apr 28, 2004	Sep	CFTG
AB		400MG	N76017 003	Apr 28, 2004	Sep	CFTG
AB	SANDOZ	600MG	N76120 001	Jan 27, 2006	Jan	NEWA
AB		600MG	N76877 001	Jul 06, 2006	Jun	NEWA
AB		800MG	N76120 002	Jan 27, 2006	Jan	NEWA
AB		800MG	N76877 002	Jul 06, 2006	Jun	NEWA
AB	SUN PHARM INDS LTD	600MG	N77525 001	Aug 24, 2006	Aug	NEWA
AB		800MG	N77525 002	Aug 24, 2006	Aug	NEWA

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937 001	Dec 08, 1999	Jan	CPOT
+		3309MG/10ML (330.9MG/ML)	N20937 002	Dec 08, 1999	Jan	NEWA
+		4963.5MG/15ML (330.9MG/ML)	N20937 003	Dec 08, 1999	Jan	NEWA
+		6618MG/20ML (330.9MG/ML)	N20937 004	Dec 08, 1999	Jan	NEWA
+		16.545GM/50ML (330.9MG/ML)	N20975 001	Dec 08, 1999	Jan	CPOT

OPTIMARK IN PLASTIC CONTAINER

+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20976 001	Dec 08, 1999	Jan	CPOT
+		3309MG/10ML (330.9MG/ML)	N20976 002	Dec 08, 1999	Jan	NEWA
+		4963.5MG/15ML (330.9MG/ML)	N20976 003	Dec 08, 1999	Jan	NEWA
+		6618MG/20ML (330.9MG/ML)	N20976 004	Dec 08, 1999	Jan	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

RAZADYNE ER

+	JANSSEN	EQ 8MG BASE	N21615 001	Apr 01, 2005	May	CMS2
		EQ 16MG BASE	N21615 002	Apr 01, 2005	May	CMS2
		EQ 24MG BASE	N21615 003	Apr 01, 2005	May	CMS2

GANCICLOVIR

CAPSULE; ORAL							
CYTOVENE							
@ ROCHE PALO	250MG			N20460	001	Dec 22, 1994	Jun DISC
@	500MG			N20460	002	Dec 12, 1997	Jun DISC
GANCICLOVIR							
RANBAXY	250MG			N76457	001	Jun 27, 2003	Jun CTEC
+	500MG			N76457	002	Jun 27, 2003	Jun CRLD

GATIFLOXACIN

INJECTABLE; INJECTION							
TEQUIN							
@ BRISTOL MYERS SQUIBB	400MG/40ML(10MG/ML)			N21062	004	Dec 17, 1999	May DISC
TEQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
@ BRISTOL MYERS SQUIBB	200MG/100ML(2MG/ML)			N21062	001	Dec 17, 1999	May DISC
@	400MG/200ML(2MG/ML)			N21062	002	Dec 17, 1999	May DISC
SUSPENSION; ORAL							
TEQUIN							
@ BRISTOL MYERS SQUIBB	200MG/5ML			N21678	001	Aug 27, 2004	Jun DISC
TABLET; ORAL							
TEQUIN							
@ BRISTOL MYERS SQUIBB	200MG			N21061	001	Dec 17, 1999	May DISC
@	400MG			N21061	002	Dec 17, 1999	May DISC

GEMFIBROZIL

TABLET; ORAL							
GEMFIBROZIL							
AB	INVAGEN PHARMS	600MG		N77836	001	Jul 27, 2006	Jul NEWA

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC							
GENTACIDIN							
@ NOVARTIS	EQ 0.3% BASE			N62480	001	Mar 30, 1984	Jun DISC

GLIMEPIRIDE

TABLET; ORAL							
GLIMEPIRIDE							
AB	COBALT	1MG		N77280	001	Feb 03, 2006	Jan NEWA
AB		2MG		N77280	002	Feb 03, 2006	Jan NEWA
AB		4MG		N77280	003	Feb 03, 2006	Jan NEWA
AB	GENPHARM	1MG		N77486	001	Feb 10, 2006	Jan NEWA
AB		2MG		N77486	002	Feb 10, 2006	Jan NEWA
AB		4MG		N77486	003	Feb 10, 2006	Jan NEWA

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL							
DUETACT							
TAKEDA GLOBAL	2MG;30MG			N21925	001	Jul 28, 2006	Jul NEWA
+	4MG;30MG			N21925	002	Jul 28, 2006	Sep CRLD
	4MG;30MG			N21925	002	Jul 28, 2006	Jul NEWA

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	CARACO	5MG	N77820 001 Jul 11, 2006 Jun NEWA
AB		10MG	N77820 002 Jul 11, 2006 Jun NEWA
	@ ENDO PHARMS	5MG	N74378 001 Nov 28, 1994 Feb DISC
	@	10MG	N74378 002 Nov 28, 1994 Feb DISC
TABLET, EXTENDED RELEASE; ORAL			
GLIPIZIDE			
AB	WATSON LABS	2.5MG	N76467 003 Mar 27, 2006 Mar NEWA
GLUCOTROL XL			
AB	PFIZER	2.5MG	N20329 003 Aug 10, 1999 Mar CFTG

GLYBURIDE

TABLET; ORAL
DIABETA

BX	+ SANOFI AVENTIS US	5MG	N17532 003 May 01, 1984 Feb CRLD
----	---------------------	-----	----------------------------------

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	1.25MG;250MG	N76716 001 Jun 28, 2005 Jun CAHN
AB		2.5MG;500MG	N76716 002 Jun 28, 2005 Jun CAHN
AB		5MG;500MG	N76716 003 Jun 28, 2005 Jun CAHN

GLCOPYRROLATE

TABLET; ORAL
GLCOPYRROLATE

AA	KALI LABS	1MG	N40653 001 Aug 31, 2006 Aug NEWA
AA		2MG	N40653 002 Aug 31, 2006 Aug NEWA
	ROBINUL		
AA	+ SCIELE PHARMA INC	1MG	N12827 001 Jun CAHN
	ROBINUL FORTE		
AA	+ SCIELE PHARMA INC	2MG	N12827 002 Jun CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
TENEX

AB	DR REDDYS LABS INC	EQ 1MG BASE	N19032 001 Oct 27, 1986 May CAHN
AB	+	EQ 2MG BASE	N19032 002 Nov 07, 1988 May CAHN
	@	EQ 3MG BASE	N19032 003 Nov 07, 1988 May CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL
HALOBETASOL PROPIONATE

AB	PERRIGO ISRAEL	0.05%	N77123 001 Dec 16, 2004 Apr CAHN
OINTMENT; TOPICAL			
HALOBETASOL PROPIONATE			
AB	ACTAVIS MID ATLANTIC	0.05%	N77109 001 Jun 14, 2005 Jun CAHN
AB	G AND W LABS	0.05%	N77721 001 Sep 07, 2006 Aug NEWA
AB	PERRIGO	0.05%	N76872 001 Dec 16, 2004 Mar CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	SANDOZ	EQ 50MG BASE/ML	N76463 001 Jun 24, 2005 Jan CAHN
AO		EQ 100MG BASE/ML	N76463 002 Jun 24, 2005 Jan CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	SANDOZ	EQ 5MG BASE/ML	N76464 001 Sep 29, 2004 Jan CAHN
SOLUTION; ORAL			
HALOPERIDOL LACTATE			
ACTAVIS MID ATLANTIC EQ 1MG BASE/ML N74536 001 Nov 02, 1995 Jul CAHN			

HALOTHANE

LIQUID; INHALATION

HALOTHANE

@ HOSPIRA	99.99%	N83254 001 Aug DISC
-----------	--------	---------------------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE COMPOUND

AA	ACTAVIS MID ATLANTIC	1.5MG/5ML;5MG/5ML	N88017 001 Jul 05, 1983 Jul CAHN
----	----------------------	-------------------	----------------------------------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

@ SICOR PHARMS	20MG/ML	N40373 001 Feb 23, 2000 Aug DISC
----------------	---------	----------------------------------

TABLET; ORAL

APRESOLINE

@ NOVARTIS	10MG	N08303 004 Feb DISC
@	25MG	N08303 001 Feb DISC
@	50MG	N08303 002 Feb DISC
@	100MG	N08303 005 Feb DISC

HYDRALAZINE HYDROCHLORIDE

AA	+	PLIVA	10MG	N89097 001 Dec 18, 1985 Feb CRLD
AA	+		25MG	N88467 001 May 01, 1984 Feb CRLD
AA	+		50MG	N88468 001 May 01, 1984 Feb CRLD
AA	+		100MG	N89098 001 Dec 18, 1985 Feb CRLD
		@ RADIUS PHARMS	25MG	N86243 001 Aug CAHN
		@	50MG	N86242 002 Aug CAHN
		@ TG UNITED LABS	10MG	N88846 001 Feb 26, 1985 May CAHN
		@	25MG	N88847 001 Feb 26, 1985 May CAHN
		@	50MG	N88848 001 Feb 26, 1985 May CAHN
		@	100MG	N88849 001 Feb 26, 1985 May CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

@ TG UNITED LABS	25MG;15MG;0.1MG	N84897 001 May CAHN
------------------	-----------------	---------------------

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	ACTAVIS ELIZABETH	25MG	N85054 002	Jun	CAHN
AB		50MG	N85208 001	Jun	CAHN
	@ TG UNITED LABS	25MG	N85683 001	May	CAHN
	@	50MG	N83965 001	May	CAHN
AB	WEST WARD	25MG	N84878 002	Jul 12, 2006	Jun NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	ACTAVIS ELIZABETH	12.5MG;10MG	N76230 001	Jul 01, 2002	Jun	CAHN
AB		12.5MG;20MG	N76230 002	Jul 01, 2002	Jun	CAHN
AB		25MG;20MG	N76230 003	Jul 01, 2002	Jun	CAHN
AB	AUROBINDO	12.5MG;10MG	N77606 001	Mar 14, 2006	Feb	NEWA
AB		12.5MG;20MG	N77606 002	Mar 14, 2006	Feb	NEWA
AB		25MG;20MG	N77606 003	Mar 14, 2006	Feb	NEWA
AB	LUPIN	12.5MG;10MG	N77912 001	Sep 27, 2006	Sep	NEWA
AB		12.5MG;20MG	N77912 002	Sep 27, 2006	Sep	NEWA
AB		25MG;20MG	N77912 003	Sep 27, 2006	Sep	NEWA

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

@ MERCK 15MG;250MG

N13402 001 Jun DISC

ALDORIL 25

@ MERCK 25MG;250MG

N13402 002 Jun DISC

ALDORIL D30

@ MERCK 30MG;500MG

N13402 003 Jun DISC

ALDORIL D50

@ MERCK 50MG;500MG

N13402 004 Jun DISC

METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN 15MG;250MG

N70264 001 Jan 23, 1986 Jun CTEC

+ 25MG;250MG

N70265 001 Jan 23, 1986 Jun CRLD

@ PAR PHARM 15MG;250MG

N70616 001 Feb 02, 1987 Jun DISC

@ 25MG;250MG

N70612 001 Feb 02, 1987 Jun DISC

@ 30MG;500MG

N70613 001 Feb 02, 1987 Jun DISC

@ 50MG;500MG

N70614 001 Feb 02, 1987 Jun DISC

@ SANDOZ 15MG;250MG

N70182 001 Jan 15, 1986 Jun DISC

@ 25MG;250MG

N70183 001 Jan 15, 1986 Jun DISC

@ 30MG;500MG

N70543 001 Jan 15, 1986 Jun DISC

@ 50MG;500MG

N70544 001 Jan 15, 1986 Jun DISC

@ WATSON LABS 15MG;250MG

N70958 001 Feb 06, 1989 Jun DISC

@ 25MG;250MG

N70959 001 Jan 19, 1989 Jun DISC

@ 30MG;500MG

N71069 001 Jan 19, 1989 Jun DISC

@ 50MG;500MG

N70960 001 Feb 06, 1989 Jun DISC

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA 12.5MG;EQ 25MG TARTRATE

N21956 001 Aug 28, 2006 Aug NEWA

12.5MG;EQ 50MG TARTRATE

N21956 002 Aug 28, 2006 Aug NEWA

+ 12.5MG;EQ 100MG TARTRATE

N21956 003 Aug 28, 2006 Aug NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	ACTAVIS ELIZABETH	25MG;40MG	N70851 001 May 15, 1986 Jun CAHN
AB		25MG;80MG	N70852 001 May 15, 1986 Jun CAHN

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

@ MERCK 25MG;10MG

N18061 001 Jun DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

NOVARTIS 12.5MG;320MG

N20818 004 Apr 28, 2006 Apr NEWA

25MG;160MG

N20818 003 Jan 17, 2002 Apr CRLD

+ 25MG;320MG

N20818 005 Apr 28, 2006 Apr NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

>D>	+ INTERPHARM	5MG;200MG	N76642 002 Mar 18, 2004 Oct CTEC
>A> AB	+	5MG;200MG	N76642 002 Mar 18, 2004 Oct CTEC
>A> AB	VINTAGE PHARMS	5MG;200MG	N77727 001 Nov 06, 2006 Oct NEWA
>A> AB		7.5MG;200MG	N77723 001 Nov 06, 2006 Oct NEWA
>A>		10MG;200MG	N77723 002 Nov 06, 2006 Oct NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	ACTAVIS MID ATLANTIC	1%	N87795 001 May 03, 1983 Jun CAHN
AT		2.5%	N89682 001 Mar 10, 1988 Jun CAHN

PENECLORT

>D> AT	ALLERGAN HERBERT	1%	N88216 001 Jun 06, 1984 Oct DISC
>A>	@	1%	N88216 001 Jun 06, 1984 Oct DISC

OINTMENT; TOPICAL

HYDROCORTISONE

AT	ACTAVIS MID ATLANTIC	1%	N87796 001 Oct 13, 1982 Jun CAHN
AT			

POWDER; FOR RX COMPOUNDING

HYDRO-RX

+ X GEN PHARMS	100%	N85982 001 Jun CTNA
SOLUTION; TOPICAL		

PENECLORT

>D> AT	ALLERGAN HERBERT	1%	N88214 001 Jun 06, 1984 Oct DISC
>A>	@	1%	N88214 001 Jun 06, 1984 Oct DISC

TABLET; ORAL

CORTEF

@ PHARMACIA AND UPJOHN 10MG

N08697 001 Jun CTEC

HYDROCORTONE

@ MERCK 10MG

N08506 007 Jun DISC

@ 20MG

N08506 011 Jun DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP HOSPIRA EQ 100MG BASE/VIAL N40666 001 Apr 06, 2006 Mar NEWA

HYDROCORTISONE; NEOMYCIN; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT PHARMAFORCE 1%;EQ 3.5MG BASE;10,000 UNITS N65219 001 May 01, 2006 Apr NEWA

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

>A> + ATON 5MG N18771 001 Oct CAHN
>D> + MERCK 5MG N18771 001 Oct CAHNHYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

ATARAX

@ ROERIG 10MG/5ML

N10485 001 Jun DISC

HYDROXYZINE HYDROCHLORIDE

AA + ACTAVIS MID ATLANTIC 10MG/5ML N86880 001 Jul CAHN
AA + ALPHARMA US PHARMS 10MG/5ML N86880 001 Jun CRLD
AA + HI TECH PHARMA 10MG/5ML N40010 001 Oct 28, 1994 Jun CRLD
AA + MORTON GROVE 10MG/5ML N87294 001 Apr 12, 1982 Jun CRLD
AA + VINTAGE PHARMS 10MG/5ML N40391 001 Apr 10, 2002 Jun CRLDHYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

BARR EQ 100MG HCL

N88488 001 Jun 15, 1984 Mar CTEC

VISTARIL

@ PFIZER EQ 100MG HCL

N11459 006 Mar DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

+ ROCHE EQ 3MG BASE/3ML

N21858 001 Jan 06, 2006 Jan NEWA

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

AB ACTAVIS MID ATLANTIC 100MG/5ML N74978 001 Mar 25, 1998 Jul CAHN

TABLET; ORAL

IBU

@ BASF 400MG

N18197 001 Jun DISC

@ 400MG

N70083 001 Feb 22, 1985 Jun DISC

@ 600MG

N70099 001 Mar 29, 1985 Jun DISC

@ 800MG

N70745 001 Jul 23, 1986 Jun DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ FARMACON IL EQ 20MG BASE/2ML (EQ 10MG
BASE/ML)

N21903 001 Apr 13, 2006 Apr NEWA

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB	ACTAVIS ELIZABETH	1.25MG	N74722 001 Jun 17, 1996 Jun CAHN
AB		2.5MG	N74722 002 Jun 17, 1996 Jun CAHN

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE

+ GE HEALTHCARE 1mCi/ML

N19044 001 Dec 24, 1985 Aug CRLD

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+ GE HEALTHCARE 1mCi/ML

N17707 001 Feb 18, 1982 Aug CRLD

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+ MALLINCKRODT 3mCi/ML

N20314 001 Jun 02, 1994 Aug CRLD

INDOMETHACIN

CAPSULE; ORAL

INDOCIN

@ MERCK 25MG N16059 001 Jun DISC

@ 50MG N16059 002 Jun DISC

INDO-LEMMON

@ TEVA 25MG N70266 001 Nov 07, 1985 Jun DISC

@ 50MG N70267 001 Nov 07, 1985 Jun DISC

INDOMETHACIN

@ CLONMEL HLTHCARE 25MG N18851 001 May 18, 1984 Jun DISC

@ 50MG N18851 002 May 18, 1984 Jun DISC

@ IVAX PHARMS 25MG N70719 001 Feb 12, 1986 Jun DISC

@ 50MG N70756 001 Feb 12, 1986 Jun DISC

@ MUTUAL PHARM 25MG N70899 001 Feb 09, 1987 Jun DISC

@ 50MG N70900 001 Feb 09, 1987 Jun DISC

MYLAN 25MG N18858 001 Apr 20, 1984 Jun CTEC

AB	+	50MG	N18858 002 Apr 20, 1984 Jun CRLD
	@ PAR PHARM	25MG	N18829 002 Aug 06, 1984 Jun DISC
	@	50MG	N18829 001 Aug 06, 1984 Jun DISC
	@	50MG	N70651 001 Mar 05, 1986 Jun DISC
	@ PLIVA	25MG	N71148 001 Mar 18, 1987 Jun DISC
	@	50MG	N71149 001 Mar 18, 1987 Jun DISC
	@ RADIUS PHARMS	25MG	N18851 001 May 18, 1984 Aug CAHN
	@	50MG	N18851 002 May 18, 1984 Aug CAHN
	@ SANDOZ	25MG	N70673 001 Apr 29, 1987 Jun DISC
	@	50MG	N70674 001 Apr 29, 1987 Jun DISC
	@ TEVA	25MG	N71342 001 Apr 18, 1988 Jun DISC
	@	50MG	N71343 001 Apr 18, 1988 Jun DISC

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

+ SANDOZ 75MG N74464 001 May 28, 1998 Jun CTEC

INDOMETHACIN

@ INWOOD LABS 75MG N72410 001 Mar 15, 1989 Jun DISC

SUPPOSITORY; RECTAL

INDOMETHACIN

+ G AND W LABS 50MG

N73314 001 Aug 31, 1992 Apr CTNA

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

+ SANOFI AVENTIS US 1000 UNITS/10ML (100 UNITS/ML)
+ 300 UNITS/3ML (100 UNITS/ML)N21629 001 Apr 16, 2004 Mar CMFD
N21629 002 Dec 20, 2005 Mar CMFDINSULIN PURIFIED PORK

INJECTABLE; INJECTION

ILETIN II

@ LILLY 500 UNITS/ML

N18344 002 Jun DISC

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

EXUBERA

PFIZER 1MG/INH
+ 3MG/INHN21868 001 Jan 27, 2006 Jan NEWA
N21868 002 Jan 27, 2006 Jan NEWAIPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

@ BOEHRINGER INGELHEIM 0.018MG/INH

N19085 001 Dec 29, 1986 May DISC

SOLUTION; INHALATION

ATROVENT

@ BOEHRINGER INGELHEIM 0.02%

N20228 001 Sep 29, 1993 May DISC

IPRATROPIUM BROMIDE

AN ACTAVIS MID ATLANTIC 0.02%
AN + DEY 0.02%
@ ROXANE 0.02%N75111 001 Apr 22, 1999 Jul CAHN
N74755 001 Jan 10, 1997 May CRLD
N75867 001 Jul 22, 2002 May DISCISONIAZID

INJECTABLE; INJECTION

ISONIAZID

AP SANDOZ 100MG/ML

N40648 001 Jul 05, 2005 Jan CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

AB DR REDDYS LABS INC 20MG

N19091 001 Dec 30, 1991 May CAHN

ISOSORBIDE MONONITRATE

AB ACTAVIS ELIZABETH 10MG
AB 20MGN75037 002 Oct 30, 1998 Jun CAHN
N75037 001 Oct 30, 1998 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB ACTAVIS ELIZABETH 30MG
AB 60MG
AB WEST WARD 30MGN75306 001 Dec 31, 1998 Jun CAHN
N75306 002 Dec 31, 1998 Jun CAHN
N76813 002 Mar 30, 2006 Mar NEWAISOTRETINOIN

CAPSULE; ORAL

CLARAVIS

AB BARR 30MG

N76135 003 May 11, 2006 May NEWA

CAPSULE; ORAL

SOTRET

AB RANBAXY 30MG N76503 001 Jun 20, 2003 May CTEC

ISRADIPINE

CAPSULE; ORAL

DYNACIRC

@ RELIANT PHARMS 2.5MG

N19546 001 Dec 20, 1990 May DISC

ISRADIPINE

AB + ABRIKA PHARMS 5MG N77317 002 Jan 05, 2006 Jun CRLD
AB 5MG N77317 002 Jan 05, 2006 Apr CTEC
AB AMIDE PHARM 2.5MG N77169 001 Apr 24, 2006 Apr NEWA
AB 5MG N77169 002 Apr 24, 2006 Apr NEWAIVERMECTIN

TABLET; ORAL

STROMECTOL

+ MERCK 3MG
@ 6MGN50742 002 Oct 08, 1998 Jun CRLD
N50742 001 Nov 22, 1996 Jun DISCKETOCONAZOLE

GEL; TOPICAL

XOLEGEL

+ BARRIER THERAP 2%

N21946 001 Jul 28, 2006 Jul NEWA

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AB RADIUS PHARMS 25MG N74014 001 Jan 29, 1993 Jul CAHN
AB 50MG N74014 002 Jan 29, 1993 Jul CAHN
AB 75MG N74014 003 Jan 29, 1993 Jul CAHNKETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP SANDOZ 15MG/ML N76271 001 Oct 06, 2004 Jan CAHN
AP 30MG/ML N76271 002 Oct 06, 2004 Jan CAHNKETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

AT APOTEX EQ 0.025% BASE N77354 001 May 09, 2006 Apr NEWA
>D> AT APOTEX INC EQ 0.025% BASE N77354 001 May 09, 2006 Oct CTEC
>A> EQ 0.025% BASE N77354 001 May 09, 2006 Oct CTEC>A> KUNEcatechins

>A> OINTMENT; TOPICAL

>A> VEREGEN

>A> + MEDIGENE 15%

N21902 001 Oct 31, 2006 Oct NEWA

LACTULOSE

SOLUTION; ORAL

CONSTULOSE

AA + ACTAVIS MID ATLANTIC 10GM/15ML

N70288 001 Aug 15, 1988 Jul CAHN

SOLUTION; ORAL, RECTAL
ENULOSE

AA + ACTAVIS MID ATLANTIC 10GM/15ML N71548 001 Aug 15, 1988 Jul CAHN

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

AB + GLAXOSMITHKLINE	25MG	N20241 005 Dec 27, 1994 Aug CFTG
	100MG	N20241 001 Dec 27, 1994 Aug CFTG
	150MG	N20241 002 Dec 27, 1994 Aug CFTG
	200MG	N20241 003 Dec 27, 1994 Aug CFTG

LAMOTRIGINE

AB TEVA	25MG	N76388 001 Aug 30, 2006 Aug NEWA
	100MG	N76388 002 Aug 30, 2006 Aug NEWA
	150MG	N76388 003 Aug 30, 2006 Aug NEWA
	200MG	N76388 004 Aug 30, 2006 Aug NEWA

TABLET, CHEWABLE; ORAL

LAMICTAL CD

AB GLAXOSMITHKLINE	5MG	N20764 001 Aug 24, 1998 Jun CFTG
AB +	25MG	N20764 002 Aug 24, 1998 Jun CFTG
AB LAMOTRIGINE		
AB TEVA	5MG	N76420 001 Jun 21, 2006 Jun NEWA
	25MG	N76420 002 Jun 21, 2006 Jun NEWA

LANSOPRAZOLE; NAPROXENCAPSULE, DELAYED REL PELLETS, TABLET; ORAL
PREVACID NAPRAPAC 250 (COPACKAGED)

>D>	TAP PHARM	15MG,N/A;N/A,250MG	N21507 002 Nov 14, 2003 Oct DISC
>A>	@	15MG,N/A;N/A,250MG	N21507 002 Nov 14, 2003 Oct DISC
		15MG,N/A;N/A,250MG	N21507 002 Nov 14, 2003 Feb CTNA
	PREVACID NAPRAPAC 375 (COPACKAGED)		
	TAP PHARM	15MG,N/A;N/A,375MG	N21507 003 Nov 14, 2003 Feb CTNA
	PREVACID NAPRAPAC 500 (COPACKAGED)		
+ TAP PHARM		15MG,N/A;N/A,500MG	N21507 004 Nov 14, 2003 Feb CTNA

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE	10MG	N21880 002 Dec 27, 2005 Jul CRLD
	15MG	N21880 003 Jun 29, 2006 Jul NEWA
+	25MG	N21880 004 Jun 29, 2006 Jul NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

+ UCB INC	500MG/5ML (100MG/ML)	N21872 001 Jul 31, 2006 Jul NEWA
-----------	----------------------	----------------------------------

TABLET; ORAL

KEPPRA

UCB INC	750MG	N21035 003 Nov 30, 1999 Mar CRLD
+	1GM	N21035 004 Jan 06, 2006 Mar NEWA

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

@ ALCON	EQ 0.5% BASE	N21114 001 Feb 23, 2000 Feb CAHN
---------	--------------	----------------------------------

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
 LIVOSTIN
 @ NOVARTIS EQ 0.05% BASE N20219 001 Nov 10, 1993 May DISC

LEVONORGESTREL

TABLET; ORAL
 PLAN B
 + DURAMED 0.75MG N21045 002 Aug 24, 2006 Aug NEWA

LEVOTHYROXINE SODIUM**

**Refer to Preface Section 1.7 Levothyroxine Sodium for amplifying information

>A>	CAPSULE; ORAL						
>A>	TIROSINT						
>A>	INST BIOCHIMIQUE	0.025MG	N21924	002	Oct 13, 2006	Oct	NEWA
>A>		0.05MG	N21924	003	Oct 13, 2006	Oct	NEWA
>A>		0.075MG	N21924	004	Oct 13, 2006	Oct	NEWA
>A>		0.1MG	N21924	005	Oct 13, 2006	Oct	NEWA
>A>		0.125MG	N21924	006	Oct 13, 2006	Oct	NEWA
>A>	+	0.15MG	N21924	007	Oct 13, 2006	Oct	NEWA
TABLET; ORAL							
LEVOTHYROXINE SODIUM							
AB2,	GENPHARM	0.025MG	N76752	001	Jun 16, 2005	Sep	CTEC
AB3		0.05MG	N76752	002	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.075MG	N76752	003	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.088MG	N76752	004	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.1MG	N76752	005	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.112MG	N76752	006	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.125MG	N76752	007	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.15MG	N76752	008	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.175MG	N76752	009	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.2MG	N76752	010	Jun 16, 2005	Sep	CTEC
AB2,	AB3	0.3MG	N76752	011	Jun 16, 2005	Sep	CTEC

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION								
XYLOCAINE								
AP	+	ABRAXIS BIOSCIENCE	0.5%	N06488	008	Jul	CAHN	
AP	+		1%	N06488	007	Jul	CAHN	
AP	+		1.5%	N06488	010	Jul	CAHN	
	@		2%	N06488	002	Jul	CAHN	
XYLOCAINE 4% PRESERVATIVE FREE								
AP	+	ABRAXIS BIOSCIENCE	4%	N10417	001	Jul	CAHN	
XYLOCAINE PRESERVATIVE FREE								
AP		ABRAXIS BIOSCIENCE	1%	N16801	005	Jan 19, 1988	Jul	CAHN
AP	+		2%	N16801	001	Jul	CAHN	
AP			4%	N16801	002	Jul	CAHN	
AP	+		10%	N16801	003	Jul	CAHN	

INJECTABLE; INJECTION

XYLOCAINE PRESERVATIVE FREE

AP + ABRAXIS BIOSCIENCE 20% N16801 004 Jul CAHN

INJECTABLE; SPINAL

XYLOCAINE 1.5% W/ DEXTROSE 7.5%

@ ABRAXIS BIOSCIENCE 1.5% N16297 001 Jul CAHN

JELLY; TOPICAL

ANESTACON

AT + POLYMEDICA 2% N80429 001 Jan CDFR

XYLOCAINE

AT + ABRAXIS BIOSCIENCE 2% N08816 001 Jul CAHN

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE VISCOSUS

AT ACTAVIS MID ATLANTIC 2% N86578 001 Jul CAHN

XYLOCAINE VISCOSUS

AT + ABRAXIS BIOSCIENCE 2% N09470 001 Jul CAHN

SOLUTION; TOPICAL

XYLOCAINE 4% PRESERVATIVE FREE

AT + ABRAXIS BIOSCIENCE 4% N10417 002 Jul CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB + ABRAXIS BIOSCIENCE 2.5%;2.5% N19941 001 Dec 30, 1992 Jul CAHN

LIDOCAINE; TETRACAIN

CREAM; TOPICAL

LIDOCAINE AND TETRACAIN

+ ZARS 7%;7% N21717 001 Jun 29, 2006 Jun NEWA

PATCH; TOPICAL

SYNERA

+ ENDO PHARMS 70MG;70MG N21623 001 Jun 23, 2005 Feb CAHN

LINDANE

LOTION; TOPICAL

LINDANE

AT + ACTAVIS MID ATLANTIC 1% N87313 001 Jul CAHN

SHAMPOO; TOPICAL

LINDANE

AT + ACTAVIS MID ATLANTIC 1% N87266 001 Jul CAHN

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

AP X GEN PHARMS EQ 0.01MG BASE/ML N76923 001 Aug 17, 2005 Sep CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB ACTAVIS ELIZABETH 2.5MG N76180 001 Jul 01, 2002 Jun CAHN

AB 5MG N76180 002 Jul 01, 2002 Jun CAHN

AB 10MG N76180 003 Jul 01, 2002 Jun CAHN

AB 20MG N76164 001 Jul 01, 2002 Jun CAHN

AB 30MG N76164 002 Jul 01, 2002 Jun CAHN

AB 40MG N76164 003 Jul 01, 2002 Jun CAHN

TABLET; ORALLISINOPRIL

AB	AUROBINDO	2.5MG	N77622 001	Feb 22, 2006	Feb	NEWA
AB		5MG	N77622 002	Feb 22, 2006	Feb	NEWA
AB		10MG	N77622 003	Feb 22, 2006	Feb	NEWA
AB		20MG	N77622 004	Feb 22, 2006	Feb	NEWA
AB		30MG	N77622 005	Feb 22, 2006	Feb	NEWA
AB		40MG	N77622 006	Feb 22, 2006	Feb	NEWA
	PRINIVIL					
	@ MERCK	2.5MG	N19558 006	Jan 28, 1994	Jun	DISC

LITHIUM CARBONATETABLET; ORALLITHIUM CARBONATE

@ PFIZER	300MG	N16834 001	Aug	DISC	
+ ROXANE	300MG	N18558 001	Jan 29, 1982	Aug	CRLD

TABLET, EXTENDED RELEASE; ORALESCALITH CR

@ GLAXOSMITHKLINE	450MG	N18152 001	Mar 29, 1982	Jul	DISC
-------------------	-------	------------	--------------	-----	------

LITHIUM CARBONATE

@ BARR	450MG	N76366 001	Aug 21, 2003	Jul	DISC
--------	-------	------------	--------------	-----	------

AB + ROXANE	450MG	N76691 001	Jan 05, 2004	Jul	CRLD
-------------	-------	------------	--------------	-----	------

LORAZEPAMTABLET; ORALLORAZEPAM

AB	ACTAVIS ELIZABETH	0.5MG	N71403 001	Apr 21, 1987	Jun	CAHN
AB		1MG	N71404 001	Apr 21, 1987	Jun	CAHN
AB		2MG	N71141 001	Apr 21, 1987	Jun	CAHN
AB	MYLAN	0.5MG	N77657 001	Mar 16, 2006	Mar	NEWA
AB		1MG	N77657 002	Mar 16, 2006	Mar	NEWA
AB		2MG	N77657 003	Mar 16, 2006	Mar	NEWA
AB	VINTAGE PHARMS	0.5MG	N77754 001	May 10, 2006	Apr	NEWA
AB		1MG	N77754 002	May 10, 2006	Apr	NEWA
AB		2MG	N77754 003	May 10, 2006	Apr	NEWA

LOVASTATINTABLET; ORALLOVASTATIN

AB	ACTAVIS ELIZABETH	10MG	N75828 001	Dec 17, 2001	Jun	CAHN
AB		20MG	N75828 002	Dec 17, 2001	Jun	CAHN
AB		40MG	N75828 003	Dec 17, 2001	Jun	CAHN
AB	MUTUAL PHARM	10MG	N77520 001	Apr 14, 2006	Apr	NEWA
AB		20MG	N77520 002	Apr 14, 2006	Apr	NEWA
AB		40MG	N77520 003	Apr 14, 2006	Apr	NEWA
	MEVACOR					
	@ MERCK	10MG	N19643 002	Mar 28, 1991	Aug	DISC

LOVASTATIN; NIACINTABLET, EXTENDED RELEASE; ORALADVICOR

+ KOS LIFE	20MG;750MG	N21249 002	Dec 17, 2001	Feb	CMFD
+	40MG;1GM	N21249 004	Apr 27, 2006	Jul	NEWA

LUBIPROSTONE

CAPSULE; ORAL
AMITIZA
+ SUCAMPO PHARMS 24UGM N21908 001 Jan 31, 2006 Jan NEWA

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION
NORMOCARB HF 25
+ DIALYSIS SUPS 0.21GM/100ML;2.8GM/100ML;9.07GM/100ML N21910 001 Jul 26, 2006 Jul NEWA
NORMOCARB HF 35
+ DIALYSIS SUPS 0.21GM/100ML;3.97GM/100ML;8.3GM/100ML N21910 002 Jul 26, 2006 Jul NEWA

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET, CHEWABLE; ORAL
ZEGERID
SANTARUS 700MG;20MG;600MG N21850 001 Mar 24, 2006 Mar NEWA
+ 700MG;40MG;600MG N21850 002 Mar 24, 2006 Mar NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; SUBCUTANEOUS
DEPO-SUBQ PROVERA 104
+ PHARMACIA AND UPJOHN 104MG/0.65ML N21583 001 Dec 17, 2004 Jan CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE
AB APOTEX 40MG/ML N77404 001 Feb 16, 2006 Jan NEWA

MELOXICAM

TABLET; ORAL
MELOXICAM
AB ACTAVIS TOTOWA 7.5MG N77938 001 Jul 19, 2006 Jul NEWA
AB 15MG N77938 002 Jul 19, 2006 Jul NEWA
AB APOTEX INC 7.5MG N77882 001 Jul 20, 2006 Jul NEWA
AB 15MG N77882 002 Jul 20, 2006 Jul NEWA
AB AUROBINDO PHARMA 7.5MG N78008 001 Oct 02, 2006 Sep NEWA
AB 15MG N78008 002 Oct 02, 2006 Sep NEWA
AB BRECKENRIDGE PHARM 7.5MG N77920 001 Jul 19, 2006 Jul NEWA
AB 15MG N77920 002 Jul 19, 2006 Jul NEWA
AB CARACO 7.5MG N77937 001 Jul 19, 2006 Jul NEWA
AB 15MG N77937 002 Jul 19, 2006 Jul NEWA
AB COREPHARMA 7.5MG N77930 001 Jul 19, 2006 Jul NEWA
AB 15MG N77930 002 Jul 19, 2006 Jul NEWA
AB DR REDDYS LABS INC 7.5MG N77931 001 Jul 25, 2006 Jul NEWA
AB 15MG N77931 002 Jul 25, 2006 Jul NEWA
AB GENPHARM 7.5MG N77934 001 Jul 20, 2006 Jul NEWA
AB 15MG N77934 002 Jul 20, 2006 Jul NEWA
AB GLENMARK PHARMS LTD 7.5MG N77932 001 Jul 19, 2006 Jul NEWA
AB 15MG N77932 002 Jul 19, 2006 Jul NEWA
AB LUPIN PHARMS 7.5MG N77944 001 Jul 19, 2006 Jul NEWA
AB 15MG N77944 002 Jul 19, 2006 Jul NEWA
AB MUTUAL PHARM 7.5MG N77935 001 Jul 19, 2006 Jul NEWA
AB 15MG N77935 002 Jul 19, 2006 Jul NEWA

TABLET; ORAL

MELOXICAM

AB	MYLAN	7.5MG	N77923	001	Jul 19, 2006	Jul	NEWA	
AB		15MG	N77923	002	Jul 19, 2006	Jul	NEWA	
AB	PAR PHARM	7.5MG	N77933	001	Jul 19, 2006	Jul	NEWA	
AB		15MG	N77933	002	Jul 19, 2006	Jul	NEWA	
AB	ROXANE	7.5MG	N77925	001	Jul 19, 2006	Jul	NEWA	
AB		15MG	N77925	002	Jul 19, 2006	Jul	NEWA	
>A>	AB	TARO	7.5MG	N78102	001	Nov 07, 2006	Oct	NEWA
>A>	AB		15MG	N78102	002	Nov 07, 2006	Oct	NEWA
AB	TEVA PHARMS	7.5MG	N77936	001	Jul 19, 2006	Jul	NEWA	
AB		15MG	N77936	002	Jul 19, 2006	Jul	NEWA	
AB	WATSON LABS	7.5MG	N77929	001	Jul 19, 2006	Jul	NEWA	
AB		15MG	N77929	002	Jul 19, 2006	Jul	NEWA	
AB	ZYDUS PHARMS USA	7.5MG	N77921	001	Jul 19, 2006	Jul	NEWA	
AB		15MG	N77921	002	Jul 19, 2006	Jul	NEWA	
	MOBIC							
AB	BOEHRINGER INGELHEIM	7.5MG	N20938	001	Apr 13, 2000	Jul	CFTG	
AB	+	15MG	N20938	002	Aug 23, 2000	Jul	CFTG	

MEPROBAMATETABLET; ORAL

MEPROBAMATE

@	ROXANE	600MG	N84332	001	Jan	DISC	
@	SANDOZ	200MG	N14547	002	Jan	DISC	
@		400MG	N14547	001	Jan	DISC	
@		400MG	N80655	001	Jan	DISC	
@	SCHERER LABS	400MG	N83343	001	Jan	DISC	
@	TABLICAPS	400MG	N83494	001	Jan	DISC	
AA	+	WATSON LABS	200MG	N83304	001	Jan	CRLD
	@	200MG	N85720	001	Jan	DISC	
+		400MG	N83308	001	Jan	CRLD	
	@	400MG	N85721	001	Jan	DISC	
	MILTON						
@	MEDPOINTE PHARM HLC	200MG	N09698	004	Jan	DISC	
@		400MG	N09698	002	Jan	DISC	
	TRANMEP						
@	SOLVAY	400MG	N16249	001	Jan	DISC	

MESALAMINE

ENEMA; RECTAL

ROWASA

AB	+	ALAVEN PHARM	4GM/60ML	N19618	001	Dec 24, 1987	Apr	CAHN
	SUPPOSITORIY; RECTAL							
	CANASA							
@	AXCAN SCANDIPHARM	500MG	N21252	001	Jan 05, 2001	May	DISC	
	ROWASA							
@	ALAVEN PHARM	500MG	N19919	001	Dec 18, 1990	Jul	CAHN	

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

@	MERCK	EQ 10MG BASE/ML	N09509	002	Dec 22, 1987	Jun	DISC
	METARAMINOL BITARTRATE						
+	ABRAXIS PHARM	EQ 10MG BASE/ML	N80722	001		Jun	CRLD

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	500MG	N76033 001	Jan 24, 2002	Jun	CAHN
AB		850MG	N76033 002	Jan 24, 2002	Jun	CAHN
AB		1GM	N76033 003	Jan 24, 2002	Jun	CAHN
AB	AMNEAL PHARM	500MG	N77853 001	Jul 28, 2006	Jul	NEWA
AB		850MG	N77853 002	Jul 28, 2006	Jul	NEWA
AB		1GM	N77853 003	Jul 28, 2006	Jul	NEWA
AB	DR REDDYS LABS INC	500MG	N77787 001	Aug 23, 2006	Aug	NEWA
AB		850MG	N77787 002	Aug 23, 2006	Aug	NEWA
AB		1GM	N77787 003	Aug 23, 2006	Aug	NEWA
AB	INTERPHARM	500MG	N77880 001	Jun 05, 2006	May	NEWA
AB		850MG	N77880 002	Jun 05, 2006	May	NEWA
AB		1GM	N77880 003	Jun 05, 2006	May	NEWA
TABLET, EXTENDED RELEASE; ORAL						
GLUMETZA						
BX	DEPOMED INC	500MG	N21748 001	Jun 03, 2005	Jan	CAHN
BX	+	1GM	N21748 002	Jun 03, 2005	Aug	CRLD
BX		1GM	N21748 002	Jun 03, 2005	Jan	CAHN
METFORMIN HYDROCHLORIDE						
AB	ACTAVIS ELIZABETH	500MG	N76450 001	Oct 01, 2004	Jun	CAHN
AB		750MG	N76878 001	Apr 13, 2005	Jun	CAHN
AB	NOSTRUM	500MG	N76756 001	Jul 26, 2006	Jul	NEWA
AB	SUN PHARM IND (IN)	500MG	N77336 001	Feb 09, 2006	Jan	NEWA
AB		750MG	N77336 002	Feb 09, 2006	Jan	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

+	CEDAR PHARMS	20MG	N40547 004	Feb 18, 2005	May	CRLD
TAPAZOLE						
AB	JONES PHARMA	5MG	N40320 001	Mar 31, 2000	May	CTNA
AB		10MG	N40320 002	Mar 31, 2000	May	CTNA

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE

AP	ABRAXIS PHARM	EQ 50MG BASE/2ML (25MG/ML)	N40263 001	Feb 26, 1999	Jun	CMFD
AP	+	EQ 250MG BASE/10ML (25MG/ML)	N40263 002	Feb 26, 1999	Jul	CRLD
AP		EQ 250MG BASE/10ML (25MG/ML)	N40263 002	Feb 26, 1999	Jun	NEWA

METHOTREXATE PRESERVATIVE FREE

+	BEDFORD	EQ 1GM BASE/VIAL	N40632 001	Aug 12, 2005	Apr	CAIN
+	MAYNE PHARMA USA	EQ 1GM BASE/40ML (25MG/ML)	N11719 012	Apr 13, 2005	Jun	CPOT
+		EQ 1GM BASE/40ML (25 MG/ML)	N11719 012	Apr 13, 2005	Apr	CPOT

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 50MG BASE/2ML (25MG/ML)	N89340 001	Sep 16, 1986	Apr	CPOT
+			EQ 100MG BASE/4ML (25MG/ML)	N89341 001	Sep 16, 1986	Apr	CTEC
+			EQ 200MG BASE/8ML (25MG/ML)	N89342 001	Sep 16, 1986	Apr	CTEC
+			EQ 250MG BASE/10ML (25 MG/ML)	N89343 001	Sep 16, 1986	Apr	CTEC

TABLET; ORAL

METHOTREXATE SODIUM

AB	+	STADA PHARMS	EQ 2.5MG BASE	N08085 002			Aug CAHN
----	---	--------------	---------------	------------	--	--	----------

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

+ SHIRE	10MG/9HR (1.1MG/HR)	N21514 001	Apr 06, 2006	Apr	NEWA
+	15MG/9HR (1.6MG/HR)	N21514 002	Apr 06, 2006	Apr	NEWA
+	20MG/9HR (2.2MG/HR)	N21514 003	Apr 06, 2006	Apr	NEWA
+	30MG/9HR (3.3MG/HR)	N21514 004	Apr 06, 2006	Apr	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

BX UCB INC	40MG	N21259 004	Feb 19, 2006	Feb	NEWA
	50MG	N21259 005	Feb 19, 2006	Feb	NEWA
+	60MG	N21259 006	Feb 19, 2006	Feb	NEWA
RITALIN LA					
BX + NOVARTIS	40MG	N21284 003	Jun 05, 2002	Feb	CTEC
TABLET; ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
AB ACTAVIS ELIZABETH	5MG	N40321 001	Feb 05, 2002	Jun	CAHN
AB	10MG	N40321 002	Feb 05, 2002	Jun	CAHN
AB	20MG	N40321 003	Feb 05, 2002	Jun	CAHN
TABLET, EXTENDED RELEASE; ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
AB ACTAVIS ELIZABETH	20MG	N75450 001	Dec 21, 2001	Jun	CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

>A> AB SICOR PHARMS	40MG/ML	N40620 001	Oct 27, 2006	Oct	NEWA
>A> AB	80MG/ML	N40620 002	Oct 27, 2006	Oct	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE

AA + JVL	EQ 5MG BASE/5ML	N74703 001	Oct 31, 1997	Aug	CRLD
@ VISTAPHARM	EQ 5MG BASE/5ML	N75051 001	Jan 26, 2001	Aug	DISC
METOCLOPRAMIDE HYDROCHLORIDE					
AA ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	N71340 001	Aug 18, 1988	Jul	CAHN
@ ROXANE	EQ 5MG BASE/5ML	N72038 001	Dec 05, 1988	Aug	DISC
@ TEVA	EQ 5MG BASE/5ML	N70819 001	Jul 10, 1987	Aug	DISC
@	EQ 5MG BASE/5ML	N71315 001	Jun 30, 1993	Aug	DISC

TABLET; ORAL

METOCLOPRAMIDE

AB VINTAGE PHARMS	EQ 5MG BASE	N77878 001	Aug 28, 2006	Aug	NEWA
	EQ 10MG BASE	N77878 002	Aug 28, 2006	Aug	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

AB ACTAVIS ELIZABETH	EQ 10MG BASE	N70581 001	Oct 17, 1985	Jun	CAHN
AB MUTUAL PHARM	EQ 5MG BASE	N71536 002	Jan 16, 1997	Apr	CMFD
AB	EQ 10MG BASE	N71536 001	Apr 28, 1993	Apr	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

REGLAN ODT

@ SCHWARZ PHARMA

EQ 5MG BASE

@

EQ 10MG BASE

N21793 001 Jun 10, 2005 May DISC

N21793 002 Jun 10, 2005 May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

AB	SANDOZ	EQ 25MG TARTRATE	N76969 001 Jul 31, 2006 Jul NEWA
	TOPROL-XL		
AB	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004 Feb 05, 2001 Jul CFTG

METRONIDAZOLE

GEL; TOPICAL
METROGEL

AB	+ GALDERMA LABS LP	0.75%	N19737 001 Nov 22, 1988 May CFTG
	METRONIDAZOLE		
AB	ALTANA	0.75%	N77018 001 Jun 06, 2006 May NEWA
AB	QLT USA	0.75%	N77547 001 Jul 13, 2006 Jun NEWA
AB	TARO	0.75%	N77819 001 Jul 18, 2006 Jul NEWA

GEL; VAGINAL
METROGEL-VAGINAL

>D>	BX + 3M	0.75%	N20208 001 Aug 17, 1992 Oct CFTG
>A>	AB +	0.75%	N20208 001 Aug 17, 1992 Oct CFTG
>A>	METRONIDAZOLE		
>A>	QLT USA	0.75%	N77264 001 Oct 31, 2006 Oct NEWA

LOTION; TOPICAL
METROLOTION

AB	+ GALDERMA LABS LP	0.75%	N20901 001 Nov 24, 1998 May CFTG
	METRONIDAZOLE		
AB	ALTANA	0.75%	N77197 001 May 24, 2006 May NEWA

METYROSINE

CAPSULE; ORAL
DEMSER

>A>	+ ATON	250MG	N17871 001 Oct CAHN
>D>	+ MERCK	250MG	N17871 001 Oct CAHN

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE

	ASTELLAS	100MG/VIAL	N21506 003 Jun 27, 2006 Jun NEWA
--	----------	------------	----------------------------------

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ACTAVIS MID ATLANTIC	200MG	N73508 001 Nov 19, 1993 Jun CAHN
	MONISTAT 3		
AB	+ PERSONAL PRODS	200MG	N18888 001 Aug 15, 1984 Aug CAHN

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL
VUSION

+ BARRIER	0.25%;81.35%;15%	N21026 001 Feb 16, 2006 Feb NEWA
-----------	------------------	----------------------------------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

AP	+ HOSPIRA	EQ 5MG BASE/ML	N75293 002 Jun 20, 2000 Mar CRLD
----	-----------	----------------	----------------------------------

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	APOTEX INC	2.5MG	N77746 001 Sep 12, 2006 Aug NEWA
AB		5MG	N77746 002 Sep 12, 2006 Aug NEWA
AB		10MG	N77746 003 Sep 12, 2006 Aug NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>A>	AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	N77190 001 Oct 31, 2006 Oct NEWA
-----	----	------------------	----------------	----------------------------------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	TRIAZ PHARMS	EQ 50MG BASE	N50649 001 May 31, 1990 Feb CAHN
	@	EQ 75MG BASE	N50649 003 Feb 12, 2001 Feb CAHN
AB	+	EQ 100MG BASE	N50649 002 May 31, 1990 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

SOLODYN

MEDICIS

		EQ 45MG BASE	N50808 001 May 08, 2006 May NEWA
		EQ 90MG BASE	N50808 002 May 08, 2006 May NEWA
	+	EQ 135MG BASE	N50808 003 May 08, 2006 May NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB	ACTAVIS ELIZABETH	15MG	N76308 001 Jun 20, 2003 Jun CAHN
AB		30MG	N76308 002 Jun 20, 2003 Jun CAHN
AB		45MG	N76308 003 Jun 20, 2003 Jun CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	45MG	N77376 004 Feb 28, 2006 Feb NEWA
AB	BARR	45MG	N76307 003 Feb 28, 2006 Feb NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE

AP	AM PHARM	EQ 20MG BASE/10ML (2MG/ML)	N77496 001 Apr 11, 2006 Mar NEWA
AP		EQ 25MG BASE/12.5ML (2MG/ML)	N77496 002 Apr 11, 2006 Mar NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N77496 003 Apr 11, 2006 Mar NEWA
AP	BEDFORD	EQ 20MG BASE/10ML (2MG/ML)	N76611 001 Apr 11, 2006 Mar NEWA
AP		EQ 25MG BASE/12.5ML (2MG/ML)	N76611 002 Apr 11, 2006 Mar NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N76611 003 Apr 11, 2006 Mar NEWA
AP	MAYNE PHARMA USA	EQ 20MG BASE/10ML (2MG/ML)	N76871 001 Apr 11, 2006 Mar NEWA
AP		EQ 25MG BASE/12.5ML (2MG/ML)	N76871 002 Apr 11, 2006 Mar NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N76871 003 Apr 11, 2006 Mar NEWA
AP	SICOR PHARMS	EQ 20MG BASE/10ML (2MG/ML)	N77356 001 Apr 11, 2006 Mar NEWA
AP		EQ 25MG BASE/12.5ML (2MG/ML)	N77356 002 Apr 11, 2006 Mar NEWA
AP		EQ 30MG BASE/15ML (2MG/ML)	N77356 003 Apr 11, 2006 Mar NEWA

NOVANTRONE

AP	+	SERONO INC	EQ 20MG BASE/10ML(2MG/ML)	N19297 001 Dec 23, 1987 Mar CFTG
AP	+		EQ 25MG BASE/12.5ML (2MG/ML)	N19297 002 Dec 23, 1987 Mar CFTG
AP	+		EQ 30MG BASE/15ML (2MG/ML)	N19297 003 Dec 23, 1987 Mar CFTG

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON

@ ABBOTT

EQ 2MG BASE/ML

N20098 001 Jan 22, 1992 Sep DISC

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ABBOTT

EQ 50MG BASE/100ML

N20098 003 Jan 22, 1992 Sep DISC

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

AB G AND W LABS 0.1%

N77447 001 May 22, 2006 May NEWA

LOTION; TOPICAL

MOMETASONE FUROATE

AB PERRIGO 0.1%

N77180 001 Apr 06, 2005 Mar CAHN

AB TARO 0.1%

N76788 001 Mar 15, 2006 Feb NEWA

OINTMENT; TOPICAL

MOMETASONE FUROATE

AB G AND W LABS 0.1%

N77401 001 Jun 20, 2006 Jun NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

>A> ALPHARMA US PHARMS 80MG

N20616 006 Oct 27, 2006 Oct NEWA

INJECTABLE; INJECTION

MORPHINE SULFATE

>A> + HOSPIRA 5MG/ML

N19916 002 Oct 27, 2006 Oct NEWA

NABILONE

CAPSULE; ORAL

CESAMET

+ VALEANT

1MG

N18677 001 Dec 26, 1985 May CMFD

NABUMETONE

TABLET; ORAL

NABUMETONE

@ COPLEY PHARM

750MG

N75179 001 Jun 06, 2000 Jun DISC

AB PAR PHARM 500MG

N76009 001 Jan 24, 2003 Apr CAHN

AB 750MG

N76009 002 Jan 24, 2003 Apr CAHN

AB + TEVA 750MG

N75189 002 Sep 24, 2001 Jul CRLD

RELAFEN

@ SMITHKLINE BEECHAM

500MG

N19583 001 Dec 24, 1991 Jul DISC

@

750MG

N19583 002 Dec 24, 1991 Jul DISC

NADOLOL

TABLET; ORAL

CORGARD

AB KING PHARMS 20MG

N18063 005 Oct 28, 1986 Jun CAHN

AB 40MG

N18063 001 Jun CAHN

AB 80MG

N18063 002 Jun CAHN

AB 120MG

N18063 003 Jun CAHN

AB + 160MG

N18063 004 Jun CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP	+	SANDOZ	EQ 1GM BASE/VIAL	N62527 002 Aug 02, 1984 Apr CRLD
AP	+		EQ 1GM BASE/VIAL	N62732 001 Dec 23, 1986 Apr CRLD
AP	+		EQ 2GM BASE/VIAL	N62527 003 Aug 02, 1984 Apr CRLD
AP	+		EQ 2GM BASE/VIAL	N62732 002 Dec 23, 1986 Apr CRLD
AP	+		EQ 10GM BASE/VIAL	N62527 004 Aug 02, 1984 Apr CRLD

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	1%	N19599 001 Feb 29, 1988 Sep CRLD
---	-------------	----	----------------------------------

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+	ALKERMES	380MG/VIAL	N21897 001 Apr 13, 2006 Apr NEWA
---	----------	------------	----------------------------------

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

AB		ACTAVIS ELIZABETH	375MG	N74936 001 Feb 24, 1998 Jun CAHN
AB			500MG	N74936 002 Feb 24, 1998 Jun CAHN

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

@	BRISTOL MYERS SQUIBB	500MG	N60365 001 Jul CPOT	
@	LANNETT	500MG	N60607 001 Jul CPOT	
@	LILLY	500MG	N60385 001 Jul CPOT	
@	ROXANE	500MG	N62173 001 Jul CPOT	
@	SANDOZ	500MG	N61586 001 Jul CPOT	
AB	+	TEVA	500MG	N60304 001 Jul CFTG
AB		X GEN PHARMS	500MG	N65220 001 Jul 28, 2006 Jul NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664 001 Apr 08, 1986 Jul CMFD
AT		X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001 Jan 31, 2006 Jun CTNA
AT			EQ 800MG BASE/20ML;4,000,000 UNITS/20ML	N65108 001 Jan 31, 2006 Jun CTNA

NEOSPORIN AND POLYMYXIN B SULFATE

AT		X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106 001 Jan 31, 2006 Jan NEWA
AT			EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108 001 Jan 31, 2006 Jan NEWA

NEOSPORIN G.U. IRRIGANT

AT	+	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001 Jan CTEC
AT	+		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N60707 002 Jan NEWA

NIACIN

TABLET, EXTENDED RELEASE; ORAL
 NIACIN
 @ BARR 500MG N76378 001 Apr 26, 2005 Sep DISC
 @ 750MG N76378 002 Apr 26, 2005 Sep DISC
 @ 1GM N76250 001 Apr 14, 2005 Sep DISC
 NIASPAN
 + KOS LIFE 500MG N20381 002 Jul 28, 1997 Sep CTEC
 + 750MG N20381 003 Jul 28, 1997 Sep CTEC
 + 1GM N20381 004 Jul 28, 1997 Sep CTEC

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
 NICARDIPINE HYDROCHLORIDE
 AB BARR 20MG N74439 001 Dec 10, 1996 Apr CAHN
 AB 30MG N74439 002 Dec 10, 1996 Apr CAHN
 INJECTABLE; INJECTION
 CARDENE
 + PDL BIOPHARMA INC 2.5MG/ML N19734 001 Jan 30, 1992 Jan CAHN

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
 NICOTINE
 >A> AVEVA 7MG/24HR N74645 001 Oct 20, 1997 Oct CAHN
 >A> 14MG/24HR N74611 001 Oct 20, 1997 Oct CAHN
 >A> 21MG/24HR N74612 001 Oct 20, 1997 Oct CAHN
 >D> SANO 7MG/24HR N74645 001 Oct 20, 1997 Oct CAHN
 >D> 14MG/24HR N74611 001 Oct 20, 1997 Oct CAHN
 >D> 21MG/24HR N74612 001 Oct 20, 1997 Oct CAHN

NIFEDIPINE

CAPSULE; ORAL
 NIFEDIPINE
 AB ACTAVIS ELIZABETH 10MG N72579 001 Jan 08, 1991 Jun CAHN
 AB 20MG N72556 001 Sep 20, 1990 Jun CAHN
 TABLET, EXTENDED RELEASE; ORAL
 AFEDITAB CR
 AB1 WATSON LABS 30MG N75128 001 Mar 10, 2000 Jan CAHN
 AB1 60MG N75659 001 Oct 26, 2001 Jan CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
 SULAR
 + SCIELE PHARMA INC 10MG N20356 001 Feb 02, 1995 Jun CAHN
 + 20MG N20356 002 Feb 02, 1995 Jun CAHN
 + 30MG N20356 003 Feb 02, 1995 Jun CAHN
 + 40MG N20356 004 Feb 02, 1995 Jun CAHN

NITROGLYCERIN

AEROSOL; SUBLINGUAL
 NITROLINGUAL
 @ POHL BOSKAMP 0.4MG/SPRAY N18705 001 Oct 31, 1985 Jun CAHN

SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY

+ POHL BOSKAMP 0.4MG/SPRAY

N18705 002 Jan 10, 1997 Jun CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

AP METRICS PHARM EQ 1MG BASE/ML

N40522 001 Sep 30, 2004 May CAHN

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL
NORTRIPTYLINE HYDROCHLORIDE

AA TARO EQ 10MG BASE/5ML

N77965 001 Jun 20, 2006 Jun NEWA

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT ACTAVIS MID ATLANTIC 100,000 UNITS/GM

N62949 001 Jun 13, 1988 Jun CAHN

@ TARO

100,000 UNITS/GM

N62457 001 Jul 28, 1983 May DISC

AT VINTAGE 100,000 UNITS/GM

N65315 001 May 31, 2006 May NEWA

OINTMENT; TOPICAL

NYSTATIN

AT ACTAVIS MID ATLANTIC 100,000 UNITS/GM

N62840 001 Nov 13, 1987 Jun CAHN

POWDER; ORAL

NILSTAT

@ STADA PHARMS 100%

N50576 001 Dec 22, 1983 Sep CAHN

NYSTATIN

>D> + PADDOCK 100%

N62613 001 Nov 26, 1985 Oct DISC

@

100%

N62613 001 Nov 26, 1985 Oct DISC

POWDER; TOPICAL

NYSTATIN

AT KV PHARM 100,000 UNITS/GM

N65321 001 Aug 18, 2006 Aug NEWA

SUSPENSION; ORAL

NYSTATIN

AA ACTAVIS MID ATLANTIC 100,000 UNITS/ML

N62349 001 Jul 14, 1982 Jul CAHN

AA TARO 100,000 UNITS/ML

N62876 001 Feb 29, 1988 May CMFD

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

AT ACTAVIS MID ATLANTIC 100,000 UNITS/GM;0.1%

N62367 001 May 28, 1985 Jun CAHN

OINTMENT; TOPICAL

MYKACET

AT ACTAVIS MID ATLANTIC 100,000 UNITS/GM;0.1%

N62733 001 Mar 09, 1987 Jun CAHN

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP AM PHARM EQ 0.2MG BASE/ML

N77450 001 Feb 10, 2006 Jan NEWA

AP EQ 1MG BASE/ML

N77450 002 Feb 10, 2006 Jan NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP AM PHARM EQ 0.05MG BASE/ML

N77457 001 Feb 10, 2006 Jan NEWA

AP EQ 0.1MG BASE/ML

N77457 002 Feb 10, 2006 Jan NEWA

AP EQ 0.5MG BASE/ML

N77457 003 Feb 10, 2006 Jan NEWA

OFLOXACIN

SOLUTION/DROPS; OTIC

FLOXIN OTIC

>D>	AT	+	DAIICHI	0.3%	N20799 001 Dec 16, 1997 Oct CTEC
>A>		+		0.3%	N20799 001 Dec 16, 1997 Oct CTEC
TABLET; ORAL					
OFLOXACIN					
AB		DR REDDYS LABS LTD	200MG		N77098 001 Feb 10, 2006 Jan NEWA
AB			300MG		N77098 002 Feb 10, 2006 Jan NEWA
AB			400MG		N77098 003 Feb 10, 2006 Jan NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>D>		+	ALCON	0.2%	N21545 001 Dec 22, 2004 Oct CTNA
>A>			PATADAY		
>A>		+	ALCON	0.2%	N21545 001 Dec 22, 2004 Oct CTNA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID

SANTARUS	20MG;1.1GM	N21849 001 Feb 27, 2006 Feb NEWA
+	40MG;1.1GM	N21849 002 Feb 27, 2006 Feb NEWA

FOR SUSPENSION; ORAL

ZEGERID

SANTARUS	20MG/PACKET;1.68GM/PACKET	N21636 001 Jun 15, 2004 Feb CAIN
+	40MG/PACKET;1.68GM/PACKET	N21706 001 Dec 21, 2004 Feb CAIN

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

AP		AKORN	30MG/ML	N40484 001 May 24, 2006 May NEWA
----	--	-------	---------	----------------------------------

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

@ SANOFI AVENTIS US	50MG/VIAL	N21492 001 Aug 09, 2002 Jun DISC
@	100MG/VIAL	N21492 002 Aug 09, 2002 Jun DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB		ACTAVIS ELIZABETH	600MG	N75843 001 Oct 03, 2001 Jun CAHN
----	--	-------------------	-------	----------------------------------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AB		ACTAVIS ELIZABETH	10MG	N72251 001 Apr 14, 1988 Jun CAHN
AB			15MG	N72252 001 Apr 14, 1988 Jun CAHN
AB			30MG	N72253 001 Apr 14, 1988 Jun CAHN

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DITROPAN XL

>D>	ALZA	5MG	N20897 001 Dec 16, 1998 Oct CFTG
>A>	AB	5MG	N20897 001 Dec 16, 1998 Oct CFTG
>D>		10MG	N20897 002 Dec 16, 1998 Oct CFTG
>A>	AB	10MG	N20897 002 Dec 16, 1998 Oct CFTG
>D>	+	15MG	N20897 003 Jun 22, 1999 Oct CFTG
>A>	AB	15MG	N20897 003 Jun 22, 1999 Oct CFTG
>A>	OXYBUTYNIN CHLORIDE		
>A>	AB	IMPAX PHARMS	15MG N76745 001 Nov 09, 2006 Oct NEWA
>A>	AB	MYLAN	5MG N76702 001 Nov 09, 2006 Oct NEWA
>A>	AB		10MG N76644 001 Nov 09, 2006 Oct NEWA

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

PURDUE PHARMA LP	15MG	N20553 006 Sep 18, 2006 Sep NEWA
	30MG	N20553 007 Sep 18, 2006 Sep NEWA
	60MG	N20553 008 Sep 18, 2006 Sep NEWA

OXYMETHOLONE

TABLET; ORAL
ANADROL-50
+ ALAVEN PHARM 50MG

N16848 001 Apr CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OPANA

ENDO PHARMS	5MG	N21611 001 Jun 22, 2006 Jun NEWA
+	10MG	N21611 002 Jun 22, 2006 Jun NEWA

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

ENDO PHARMS	5MG	N21610 001 Jun 22, 2006 Jun NEWA
	10MG	N21610 002 Jun 22, 2006 Jun NEWA
	20MG	N21610 003 Jun 22, 2006 Jun NEWA
+	40MG	N21610 004 Jun 22, 2006 Jun NEWA

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

+ ABRAXIS BIOSCIENCE 100MG/VIAL

N21660 001 Jan 07, 2005 Apr CAHN

PARICALCITOL

INJECTABLE; INJECTION

ZEMPLAR

+ ABBOTT 0.002MG/ML

N20819 002 Feb 01, 2000 Aug CRLD

PAROXETINE MESYLATE

TABLET; ORAL

PEXEGA

JDS PHARMS	EQ 10MG BASE	N21299 001 Jul 03, 2003 Apr CAHN
	EQ 20MG BASE	N21299 002 Jul 03, 2003 Apr CAHN
	EQ 30MG BASE	N21299 003 Jul 03, 2003 Apr CAHN

TABLET; ORAL

PEXEVA

+ JDS PHARMS

EQ 40MG BASE

N21299 004 Jul 03, 2003 Apr CAHN

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+ OSI EYETECH

EQ 0.3MG ACID/0.09ML

N21756 001 Dec 17, 2004 May CAHN

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

@ ATON

125MG

N19853 002

Aug CAHN

+

250MG

N19853 001

Aug CAHN

@ MERCK

125MG

N19853 002

Jun DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

AA AM ANTIBIOTICS

EQ 125MG BASE/5ML

N61529 001

Jan CAHN

AA

EQ 250MG BASE/5ML

N61529 002

Jan CAHN

TABLET; ORAL

PENICILLIN V POTASSIUM

@ AM ANTIBIOTICS

EQ 250MG BASE

N61528 001

Jan CAHN

@

EQ 500MG BASE

N61528 002

Jan CAHN

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT

+ MAYNE PHARMA USA

10MG/VIAL

N20122 001 Oct 11, 1991 Aug CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB ACTAVIS ELIZABETH

400MG

N74878 001 Jul 09, 1997 Jun CAHN

AB RADIUS PHARMS

400MG

N74877 001 Jul 08, 1997 Jul CAHN

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

AB PAR PHARM

EQ 0.05MG BASE

N76061 001 Nov 27, 2002 Apr CAHN

AB

EQ 0.25MG BASE

N76061 002 Nov 27, 2002 Apr CAHN

AB

EQ 1MG BASE

N76061 003 Nov 27, 2002 Apr CAHN

PERMAX

AB VALEANT

EQ 0.05MG BASE

N19385 001 Dec 30, 1988 Jan CRLD

AB +

EQ 0.25MG BASE

N19385 002 Dec 30, 1988 Jan CRLD

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

AB ACTAVIS MID ATLANTIC 5%

N74806 001 Jan 23, 1998 Jun CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
 CAM-METRAZINE
 @ TG UNITED LABS 35MG N83922 001 May CAHN
 @ 35MG N85318 001 May CAHN
 @ 35MG N85320 001 May CAHN
 @ 35MG N85321 001 May CAHN
 PHENDIMETRAZINE TARTRATE
 @ TG UNITED LABS 35MG N85761 001 May CAHN
 @ 35MG N85941 001 Jun 27, 1983 May CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
 PHENTERMINE HYDROCHLORIDE
 @ TG UNITED LABS 18.75MG N88576 001 May 23, 1984 May CAHN
 @ 30MG N85417 001 May CAHN
 @ 30MG N86732 002 May CAHN
 @ 30MG N87215 001 May CAHN
 @ 37.5MG N87915 001 Dec 22, 1983 May CAHN
 @ 37.5MG N87918 001 Dec 22, 1983 May CAHN
 @ 37.5MG N87930 001 Oct 14, 1983 May CAHN
 @ 37.5MG N88610 001 Jun 04, 1984 May CAHN
 @ 37.5MG N88611 001 Jun 04, 1984 May CAHN
 @ 37.5MG N88625 001 Aug 23, 1984 May CAHN
 TABLET; ORAL
 PHENTERMINE HYDROCHLORIDE
 AA ACTAVIS ELIZABETH 37.5MG N40276 001 Nov 25, 1998 Jun CAHN
 @ TG UNITED LABS 8MG N83923 001 May CAHN
 @ 8MG N85319 001 May CAHN
 @ 37.5MG N87805 001 Dec 06, 1982 May CAHN
 @ 37.5MG N88596 001 Apr 04, 1984 May CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
 PROMETH VC PLAIN
 + ACTAVIS MID ATLANTIC 5MG/5ML;6.25MG/5ML N88761 001 Nov 08, 1984 Jul CAHN
 + ALPHARMA US PHARMS 5MG/5ML;6.25MG/5ML N88761 001 Nov 08, 1984 Jan CTEC
 PROMETHAZINE VC PLAIN
 @ MORTON GROVE 5MG/5ML;6.25MG/5ML N88897 001 Jan 04, 1985 Jan DISC

PHENYTOIN

SUSPENSION; ORAL
 PHENYTOIN
 AB ACTAVIS MID ATLANTIC 125MG/5ML N89892 001 Sep 25, 1992 Jul CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL
 EXTENDED PHENYTOIN SODIUM
 AB TARO 100MG EXTENDED N40684 001 Sep 05, 2006 Aug NEWA
 INJECTABLE; INJECTION
 PHENYTOIN SODIUM
 AP HIKMA FARMACEUTICA 50MG/ML N40573 001 Sep 13, 2006 Aug NEWA

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

>A>	@ ATON	1MG/0.5ML	N12223 002	Oct	CAHN
>A>	@	10MG/ML	N12223 001	Oct	CAHN
>D>	@ MERCK	1MG/0.5ML	N12223 002	Oct	CAHN
	@	1MG/0.5ML	N12223 002	Feb	DISC
>D>	@	10MG/ML	N12223 001	Oct	CAHN
	@	10MG/ML	N12223 001	Feb	DISC
	VITAMIN K1				
BP	+ HOSPIRA	1MG/0.5ML	N87954 001	Jul 25, 1983	Feb CRLD
	+	10MG/ML	N87955 001	Jul 25, 1983	Feb CRLD
	TABLET; ORAL				
	MEPHYTON				
>A>	+ ATON	5MG	N10104 003	Oct	CAHN
>D>	+ MERCK	5MG	N10104 003	Oct	CAHN

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB	IMPAK LABS	5MG	N77248 001	Mar 31, 2006	Mar	NEWA
AB		7.5MG	N77248 002	Mar 31, 2006	Mar	NEWA
	SALAGEN					
AB	+ MGI PHARMA INC	7.5MG	N20237 002	Apr 18, 2003	Mar	CFTG

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

>A>	TAKEDA GLOBAL	EQ 15MG BASE	N21073 001	Jul 15, 1999	Oct	CAHN
>A>		EQ 30MG BASE	N21073 002	Jul 15, 1999	Oct	CAHN
>A>	+	EQ 45MG BASE	N21073 003	Jul 15, 1999	Oct	CAHN
>D>	TAKEDA PHARMS NA	EQ 15MG BASE	N21073 001	Jul 15, 1999	Oct	CAHN
>D>		EQ 30MG BASE	N21073 002	Jul 15, 1999	Oct	CAHN
>D>	+	EQ 45MG BASE	N21073 003	Jul 15, 1999	Oct	CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

AA	COASTAL PHARMS	17GM/SCOOPFUL	N77893 001	May 26, 2006	May	NEWA
AA	KALI LABS	17GM/SCOOPFUL	N77736 001	May 26, 2006	May	NEWA
AA	TEVA PHARMS	17GM/SCOOPFUL	N77445 001	May 04, 2006	Apr	NEWA
AA	YVR THERAP	17GM/SCOOPFUL	N77706 001	Sep 27, 2006	Sep	NEWA

POSACONAZOLE

SUSPENSION; ORAL

NOXAFL

+	SCHERING	40MG/ML	N22003 001	Sep 15, 2006	Sep	NEWA
---	----------	---------	------------	--------------	-----	------

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	+ BAXTER HLTHCARE	14.9MG/ML	N19904 001	Dec 26, 1989	Jun	CTEC
AP	+	746MG/100ML	N19904 005	Dec 17, 1990	Jun	CTEC

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	1.49GM/100ML	N19904 006 Dec 17, 1990 Jun CTEC
AB		TABLET, EXTENDED RELEASE; ORAL KLOR-CON		N19123 001 Apr 17, 1986 Jan CRLD
AB		UPSHER SMITH	8MEQ	
		POTASSIUM CHLORIDE		
AB	+	COPLEY PHARM	8MEQ	N70618 001 Sep 09, 1987 Jan CRLD

POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

>A>	+	BAXTER HLTHCARE	450MG/100ML;150MG/100ML	N17648 005 Nov 26, 2002 Oct NEWA
-----	---	-----------------	-------------------------	----------------------------------

POTASSIUM CITRATETABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB		COREPHARMA	5MEQ	N77440 001 Jun 09, 2006 May NEWA
AB			10MEQ	N77440 002 Jun 09, 2006 May NEWA
		UROCIT-K		
AB		MISSION PHARMA	5MEQ	N19071 001 Aug 30, 1985 May CFTG
AB	+		10MEQ	N19071 002 Aug 31, 1992 May CFTG

PRAVASTATIN SODIUMTABLET; ORAL

PRAVACHOL

AB		BRISTOL MYERS SQUIBB	10MG	N19898 002 Oct 31, 1991 Apr CFTG
AB			20MG	N19898 003 Oct 31, 1991 Apr CFTG
AB			40MG	N19898 004 Mar 22, 1993 Apr CFTG

PRAVASTATIN SODIUM

>A>	AB	APOTEX	10MG	N76341 001 Oct 23, 2006 Oct NEWA
>A>	AB		20MG	N76341 002 Oct 23, 2006 Oct NEWA
>A>	AB		40MG	N76341 003 Oct 23, 2006 Oct NEWA
>A>	AB	COBALT	10MG	N76939 004 Oct 23, 2006 Oct NEWA
>A>	AB		20MG	N76939 003 Oct 23, 2006 Oct NEWA
>A>	AB		40MG	N76939 002 Oct 23, 2006 Oct NEWA
>A>	AB	DR REDDYS LABS INC	10MG	N76714 001 Oct 23, 2006 Oct NEWA
>A>	AB		20MG	N76714 002 Oct 23, 2006 Oct NEWA
>A>	AB		40MG	N76714 003 Oct 23, 2006 Oct NEWA
>A>	AB	GENPHARM	10MG	N77013 001 Oct 23, 2006 Oct NEWA
>A>	AB		20MG	N77013 002 Oct 23, 2006 Oct NEWA
>A>	AB		40MG	N77013 003 Oct 23, 2006 Oct NEWA
>A>	AB	LEK PHARMS DD	10MG	N76397 003 Oct 23, 2006 Oct NEWA
>A>	AB		20MG	N76397 002 Oct 23, 2006 Oct NEWA
>A>	AB		40MG	N76397 001 Oct 23, 2006 Oct NEWA
	AB	TEVA	10MG	N76056 001 Apr 24, 2006 Apr NEWA
	AB		20MG	N76056 002 Apr 24, 2006 Apr NEWA
	AB		40MG	N76056 003 Apr 24, 2006 Apr NEWA
>A>	AB	WATSON LABS	10MG	N77904 001 Oct 23, 2006 Oct NEWA
>A>	AB		20MG	N77904 002 Oct 23, 2006 Oct NEWA
>A>	AB		40MG	N77904 003 Oct 23, 2006 Oct NEWA

PRAZOSIN HYDROCHLORIDECAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ CLONMEL HLTHCARE EQ 1MG BASE

N72705 001 May 16, 1989 Jan DISC

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ CLONMEL HLTHCARE EQ 5MG BASE

N72707 001 May 16, 1989 Jan DISC

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLlient

AB	+	SANOFI AVENTIS US	0.1%	N20279 001 Oct 29, 1993 Sep CFTG
		PREDNICARBATE		
AB		ALTANA	0.1%	N77287 001 Sep 19, 2006 Sep NEWA

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

PREDNISOLONE ACETATE

@ STERIS	25MG/ML	N83398 001	Mar DISC
@	50MG/ML	N83764 001	Mar DISC

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

AB	ALCON	1%	N17469 001	May CTNA
----	-------	----	------------	----------

PREDNISOLONE SODIUM PHOSPHATE

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

>D>		BIOMARIN PHARM	EQ 10MG BASE	N21959 001 Jun 01, 2006 Oct CAHN
			EQ 10MG BASE	N21959 001 Jun 01, 2006 Jun NEWA
>D>			EQ 15MG BASE	N21959 002 Jun 01, 2006 Oct CAHN
			EQ 15MG BASE	N21959 002 Jun 01, 2006 Jun NEWA
>D>	+		EQ 30MG BASE	N21959 003 Jun 01, 2006 Oct CAHN
	+		EQ 30MG BASE	N21959 003 Jun 01, 2006 Jun NEWA
>A>		MEDICIS	EQ 10MG BASE	N21959 001 Jun 01, 2006 Oct CAHN
>A>			EQ 15MG BASE	N21959 002 Jun 01, 2006 Oct CAHN
>A>	+		EQ 30MG BASE	N21959 003 Jun 01, 2006 Oct CAHN

PRIMIDONE

TABLET; ORAL

PRIMIDONE

AB	WEST WARD	50MG	N40667 001 Jul 27, 2006 Jul NEWA
AB		250MG	N40667 002 Jul 27, 2006 Jul NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPATINE

@ GLAXOSMITHKLINE	2.5MG	N11127 003	May DISC
@	5MG	N11127 001	May DISC

PROCHLORPERAZINE EDISYLATE

SYRUP; ORAL

COMPATINE

@ GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N11188 001	May DISC
-------------------	-----------------	------------	----------

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPATINE

@ GLAXOSMITHKLINE	EQ 10MG BASE	N21019 001 Oct 06, 1999 May DISC
-------------------	--------------	----------------------------------

PROGESTERONE

GEL; VAGINAL						
CRINONE						
COLUMBIA LABS	4%					N20701 001 Jul 31, 1997 May CAHN
+	8%					N20701 002 Jul 31, 1997 May CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION						
PROMETHAZINE HYDROCHLORIDE						
>A> AP SANDOZ	25MG/ML					N40593 001 Nov 08, 2006 Oct NEWA
>A> AP	50MG/ML					N40593 002 Nov 08, 2006 Oct NEWA
SUPPOSITORY; RECTAL						
PHENERGAN						
@ WYETH PHARMS INC	12.5MG					N10926 002 Mar DISC
@	25MG					N10926 001 Mar DISC
PROMETHAZINE HYDROCHLORIDE						
AB + G AND W LABS	25MG					N40428 001 Feb 05, 2002 Mar CRLD
>A> AB TARO	12.5MG					N40603 001 Oct 26, 2006 Oct NEWA
>A> AB	25MG					N40603 002 Oct 26, 2006 Oct NEWA
PROMETHEGAN						
+ G AND W LABS	50MG					N87165 001 Aug 14, 1987 Jan CRLD
SYRUP; ORAL						
PROMETH PLAIN						
@ ACTAVIS MID ATLANTIC	6.25MG/5ML					N85953 001 Jul CAHN
PROMETHAZINE HYDROCHLORIDE						
AA VINTAGE	6.25MG/5ML					N40643 001 Apr 26, 2006 Apr NEWA
TABLET; ORAL						
PROMETHAZINE HYDROCHLORIDE						
AB KVK-TECH INC	25MG					N40712 001 Jul 31, 2006 Jul NEWA
AB	50MG					N40713 001 Jul 31, 2006 Jul NEWA
AB VINTAGE PHARMS	12.5MG					N40622 001 Jul 18, 2006 Jul NEWA
AB	25MG					N40622 002 Jul 18, 2006 Jul NEWA
AB	50MG					N40622 003 Jul 18, 2006 Jul NEWA
AB	50MG					N40622 003 Jul 18, 2006 Jun NEWA
AB ZYDUS PHARMS USA	12.5MG					N40596 001 Nov 18, 2005 Jul CTEC

PROPOFOL

INJECTABLE; INJECTION						
DIPRIVAN						
AB + ABRAXIS BIOSCIENCE	10MG/ML					N19627 002 Jun 11, 1996 Jul CAHN
@	10MG/ML					N19627 001 Oct 02, 1989 Jul CAHN
PROPOFOL						
AB HOSPIRA	10MG/ML					N77908 001 Mar 17, 2006 Mar NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL						
DOLENE						
@ RADIUS PHARMS	65MG					N80530 001 Aug CAHN
PROPOXYPHENE HYDROCHLORIDE						
AA PAR PHARM	65MG					N80269 001 Mar CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

AP SANDOZ 1MG/ML N76400 001 Feb 26, 2003 Jan CAHN

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD ACTAVIS ELIZABETH 50MG N80172 001 Jun CAHN
BD + STADA PHARMS 50MG N06188 001 Sep CAHNPYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

REGONOL

AP SANDOZ 5MG/ML N17398 001 Jan CAHN

QUAZEPAM

TABLET; ORAL

DORAL

@ QUESTCOR PHARMS 7.5MG N18708 003 Feb 26, 1987 May CAHN
+ 15MG N18708 001 Dec 27, 1985 May CAHNQUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL

AB LUPIN EQ 5MG BASE N77690 001 Jun 20, 2006 Jun NEWA
AB EQ 10MG BASE N77690 002 Jun 20, 2006 Jun NEWA
AB EQ 20MG BASE N77690 003 Jun 20, 2006 Jun NEWA
AB EQ 40MG BASE N77690 004 Jun 20, 2006 Jun NEWA

QUINAPRIL HYDROCHLORIDE

AB TORPHARM EQ 5MG BASE N76240 001 Jan 26, 2006 Jan NEWA
AB EQ 10MG BASE N76240 002 Jan 26, 2006 Jan NEWA
AB EQ 20MG BASE N76240 003 Jan 26, 2006 Jan NEWA
AB EQ 40MG BASE N76240 004 Jan 26, 2006 Jan NEWAQUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX + MUTUAL PHARM 324MG N89338 001 Feb 11, 1987 Jan CTEC
BX WATSON LABS 324MG N87810 001 Sep 29, 1982 Jan CMFDQUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@ CLONMEL HLTHCARE 200MG N87011 001 Jan DISC
@ LANNETT 200MG N83743 001 Jan DISC
@ MUTUAL PHARM 100MG N81029 001 Apr 14, 1989 Jan DISC
AB 300MG N81031 001 Apr 14, 1989 Jul CMFD
@ PHARM FORM 200MG N83808 001 Jan DISC
@ SANDOZ 200MG N84631 001 Jan DISC
@ 200MG N84914 001 Jan DISC
AB 200MG N88072 002 Jan NEWA
@ 300MG N89839 001 Sep 29, 1988 Jan DISC
AB WATSON LABS 200MG N83288 001 Jul CMFD

TABLET; ORAL

QUINIDINE SULFATE

@ WATSON LABS	200MG	N83288 001	Jan DISC
@	200MG	N85140 002	Jan DISC

QUININE SULFATE

CAPSULE; ORAL

QUININE SULFATE

+ AR HOLDING CO INC	324MG	N21799 001 Aug 12, 2005 Sep CAHN
---------------------	-------	----------------------------------

RANITIDINE

INJECTABLE; INJECTION

RANITIDINE

AP BEDFORD	EQ 25MG BASE/ML	N77458 001 Feb 16, 2006 Feb NEWA
------------	-----------------	----------------------------------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

>A> AB INTERPHARM	EQ 150MG BASE	N77824 001 Oct 13, 2006 Oct NEWA
>A> AB	EQ 300MG BASE	N77824 002 Oct 13, 2006 Oct NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

+ CV THERAP	500MG	N21526 002 Jan 27, 2006 Jan NEWA
-------------	-------	----------------------------------

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

TEVA	EQ 0.5MG BASE	N21641 001 May 16, 2006 May NEWA
+	EQ 1MG BASE	N21641 002 May 16, 2006 May NEWA

RIBAVIRIN

TABLET; ORAL

RIBAVIRIN

AB SANDOZ	200MG	N77743 001 Oct 03, 2006 Sep NEWA
-----------	-------	----------------------------------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

JANSSEN PHARMA	3MG	N21444 004 Dec 23, 2004 Mar CMFD
	4MG	N21444 005 Dec 23, 2004 Mar CMFD

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION

NAROPIN

ABRAXIS BIOSCIENCE	2MG/ML	N20533 001 Sep 24, 1996 Jul CAHN
	5MG/ML	N20533 003 Sep 24, 1996 Jul CAHN
	7.5MG/ML	N20533 004 Sep 24, 1996 Jul CAHN
+	10MG/ML	N20533 005 Sep 24, 1996 Jul CAHN

SALMETEROL XINAFOATE

>D> AEROSOL, METERED; INHALATION SEREVENT		
>D> + GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N20236 001 Feb 04, 1994 Oct DISC

>D> AEROSOL, METERED; INHALATION
 >D> SEREVENT
 >A> @ GLAXOSMITHKLINE EQ 0.021MG BASE/INH N20236 001 Feb 04, 1994 Oct DISC

SAQUINAVIR MESYLATE

>D> CAPSULE; ORAL
 >D> INVIRASE
 >D> + HLR EQ 200MG BASE N20628 001 Dec 06, 1995 Oct DISC
 >A> @ EQ 200MG BASE N20628 001 Dec 06, 1995 Oct DISC

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS
 SECREFLO
 + CHIRHOCLIN 16UGM/VIAL N21136 001 Apr 04, 2002 May CTNA

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL
 EMSAM
 SOMERSET 6MG/24HR N21336 001 Feb 27, 2006 Mar CAIN
 9MG/24HR N21336 002 Feb 27, 2006 Mar CAIN
 + 12MG/24HR N21336 003 Feb 27, 2006 Mar CAIN

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
 SELEGILINE HYDROCHLORIDE
 @ AAIPHARMA LLC 5MG N75145 001 Sep 15, 2003 Sep DISC
 FILM, EXTENDED RELEASE; TRANSDERMAL
 EMSAM
 SOMERSET 6MG/24HR N21336 001 Feb 27, 2006 Feb NEWA
 9MG/24HR N21336 002 Feb 27, 2006 Feb NEWA
 + 12MG/24HR N21336 003 Feb 27, 2006 Feb NEWA
 TABLET, ORALLY DISINTEGRATING; ORAL
 ZELAPAR
 + VALEANT PHARM INTL 1.25MG N21479 001 Jun 14, 2006 Jun NEWA

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
 SELENIUM SULFIDE
 AT ACTAVIS MID ATLANTIC 2.5% N84394 001 Jul CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
 SERTRALINE HYDROCHLORIDE
 AB ROXANE EQ 20MG BASE/ML N76934 001 Jun 30, 2006 Jun NEWA
 ZOLOFT
 AB + PFIZER EQ 20MG BASE/ML N20990 001 Dec 07, 1999 Jun CFTG
 TABLET; ORAL
 SERTRALINE HYDROCHLORIDE
 AB IVAX PHARMS EQ 25MG BASE N75719 003 Jun 30, 2006 Jun NEWA
 AB EQ 50MG BASE N75719 001 Jun 30, 2006 Jun NEWA
 AB EQ 100MG BASE N75719 002 Jun 30, 2006 Jun NEWA
 AB TEVA EQ 25MG BASE N76465 001 Aug 11, 2006 Aug NEWA
 AB EQ 50MG BASE N76465 002 Aug 11, 2006 Aug NEWA
 AB EQ 100MG BASE N76465 003 Aug 11, 2006 Aug NEWA

TABLET; ORAL

ZOLOFT

AB	PFIZER	EQ 25MG BASE	N19839 005 Mar 06, 1996 Jun CFTG
AB		EQ 50MG BASE	N19839 001 Dec 30, 1991 Jun CFTG
AB	+	EQ 100MG BASE	N19839 002 Dec 30, 1991 Jun CFTG

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	IVAX PHARMS	5MG	N76052 001 Jun 23, 2006 Jun NEWA
AB		10MG	N76052 002 Jun 23, 2006 Jun NEWA
AB		20MG	N76052 003 Jun 23, 2006 Jun NEWA
AB		40MG	N76052 004 Jun 23, 2006 Jun NEWA
AB	RANBAXY	80MG	N76285 005 Jun 23, 2006 Jun NEWA
	ZOCOR		
AB	MERCK	5MG	N19766 001 Dec 23, 1991 Jun CFTG
AB		10MG	N19766 002 Dec 23, 1991 Jun CFTG
AB		20MG	N19766 003 Dec 23, 1991 Jun CFTG
AB		40MG	N19766 004 Dec 23, 1991 Jun CFTG
AB	+	80MG	N19766 005 Jul 10, 1998 Jun CFTG

>A> SITAGLIPTIN PHOSPHATE

>A> TABLET; ORAL

JANUVIA

>A>	MERCK CO INC	EQ 25MG BASE	N21995 001 Oct 16, 2006 Oct NEWA
>A>		EQ 50MG BASE	N21995 002 Oct 16, 2006 Oct NEWA
>A>	+	EQ 100MG BASE	N21995 003 Oct 16, 2006 Oct NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	ABRAXIS PHARM	9MG/ML	N88912 001 Jan 10, 1985 Oct CRLD
>A>	AP	+	9MG/ML	N88912 001 Jan 10, 1985 Oct CRLD
	AP	+ B BRAUN	900MG/100ML	N17464 001 May CRLD
	AP	+	900MG/100ML	N19635 002 Mar 09, 1988 May CRLD
	AP	+ BAXTER HLTHCARE	900MG/100ML	N16677 001 May CRLD
	AP	+	900MG/100ML	N20178 001 Dec 07, 1992 May CRLD
>D>	AP	HOSPIRA	9MG/ML	N18803 001 Oct 29, 1982 Oct CRLD
>A>	AP	+	9MG/ML	N18803 001 Oct 29, 1982 Oct CRLD
	AP	+	900MG/100ML	N16366 001 May CRLD
	AP	+	900MG/100ML	N19465 001 Jul 15, 1985 May CRLD
	AP	+	900MG/100ML	N19480 001 Sep 17, 1985 May CRLD
	+	MALLINCKRODT	45MG/50ML (9MG/ML)	N21569 001 Jul 27, 2006 Aug CDFR
			112.5MG/125ML (9MG/ML)	N21569 002 Jul 27, 2006 Aug CDFR
>D>	AP	TARO PHARMS IRELAND	9MG/ML	N77407 001 Aug 11, 2006 Oct CRLD
>A>	AP	+	9MG/ML	N77407 001 Aug 11, 2006 Oct CRLD
	AP		9MG/ML	N77407 001 Aug 11, 2006 Aug NEWA

INJECTABLE; INTRAVASCULAR

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	MALLINCKRODT	45MG/50ML (0.9MG/ML)	N21569 001 Jul 27, 2006 Jul NEWA
		112.5MG/125ML (0.9MG/ML)	N21569 002 Jul 27, 2006 Jul NEWA

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	+	GE HEALTHCARE	100uCi	N17630 001 Sep CRLD
----	---	---------------	--------	---------------------

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	+	SYNCOR PHARMS	100uCi	N18671 001	May 27, 1982	Sep	CRLD
AA	+		200uCi	N18671 002	May 27, 1982	Sep	CRLD
		SOLUTION; ORAL					
		SODIUM IODIDE I 123					
	+	GE HEALTHCARE	2mCi/ML	N17630 002		Sep	CRLD

SODIUM IODIDE, I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

		DRAXIMAGE	100mCi	N21305 004	Nov 18, 2004	Jun	NEWA
--	--	-----------	--------	------------	--------------	-----	------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+	SALIX PHARMS	0.398GM;1.102GM	N21892 001	Mar 16, 2006	Mar	NEWA
---	--------------	-----------------	------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N20280 006	Aug 24, 1995	May	CTEC
		GENOTROPIN PRESERVATIVE FREE					
BX		PHARMACIA AND UPJOHN	1.5MG/VIAL	N20280 004	Aug 24, 1995	May	CTEC
		NUTROPIN DEPOT					
	@	GENENTECH	13.5MG/VIAL	N21075 001	Dec 22, 1999	Jul	DISC
	@		18MG/VIAL	N21075 002	Dec 22, 1999	Jul	DISC
	@		22.5MG/VIAL	N21075 003	Dec 22, 1999	Jul	DISC
		OMNITROPE					
BX		SANDOZ	1.5MG/VIAL	N21426 002	May 30, 2006	May	NEWA
BX			5.8MG/VIAL	N21426 001	May 30, 2006	May	NEWA

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB		ACTAVIS ELIZABETH	25MG	N40353 003	Mar 15, 2006	Jun	CAHN
AB			50MG	N40353 001	Jul 29, 1999	Jun	CAHN
AB			100MG	N40353 002	Jul 29, 1999	Jun	CAHN
AB		PUREPAC PHARM	25MG	N40353 003	Mar 15, 2006	Feb	NEWA
AB		VINTAGE	25MG	N40750 001	Aug 29, 2006	Aug	NEWA
AB			50MG	N40750 002	Aug 29, 2006	Aug	NEWA
AB			100MG	N40750 003	Aug 29, 2006	Aug	NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

AP	+	SANDOZ	20MG/ML	N08453 002		Jan	CAHN
	@		50MG/ML	N08453 003		Jan	CAHN
	@		500MG/VIAL	N08453 001		Jan	CAHN
	@		1GM/VIAL	N08453 004		Jan	CAHN
		SUCCINYLCHOLINE CHLORIDE					
	@	ORGANON USA INC	20MG/ML	N80997 001		Jun	DISC

SULCONAZOLE NITRATE

SOLUTION; TOPICAL
EXELDERM
+ WESTWOOD SQUIBB 1% N18738 001 Aug 30, 1985 Jun CMFD

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM
AT ALCON 30% N89068 001 May 05, 1987 Apr CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
BACTRIM PEDIATRIC
AB MUTUAL PHARM 200MG/5ML;40MG/5ML N17560 002 Apr CMFD
>A> AB SULFAMETHOXAZOLE AND TRIMETHOPRIM
TEVA PHARMS 200MG/5ML;40MG/5ML N77612 001 Nov 13, 2006 Oct NEWA
SULFATRIM
AB ACTAVIS MID ATLANTIC 200MG/5ML;40MG/5ML N18615 002 Jan 07, 1983 Jul CAHN
SULFATRIM PEDIATRIC
AB ACTAVIS MID ATLANTIC 200MG/5ML;40MG/5ML N18615 001 Jan 07, 1983 Jul CAHN

SULFANILAMIDE

CREAM; VAGINAL
AVC
>D> @ PHARMELLE 15% N06530 003 Jan 27, 1987 Oct CMFD
>A> + 15% N06530 003 Jan 27, 1987 Oct CMFD

SULFASALAZINE

TABLET; ORAL
SULFASALAZINE
@ RADIUS PHARMS 500MG N80197 001 Aug CAHN

SULINDAC

TABLET; ORAL
CLINORIL
@ MERCK 150MG N17911 001 Jun DISC
SULINDAC
@ RADIUS PHARMS 150MG N73261 001 Sep 06, 1991 Jul CAHN
@ 200MG N73262 001 Sep 06, 1991 Jul CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
IMITREX
+ GLAXOSMITHKLINE EQ 6MG BASE/0.5ML (12MG/ML) N20080 001 Dec 28, 1992 Feb CDFR
IMITREX STATDOSE
+ GLAXOSMITHKLINE EQ 4MG BASE/0.5ML (8MG/ML) N20080 002 Feb 01, 2006 Feb NEWA
+ EQ 6MG BASE/0.5ML (12MG/ML) N20080 003 Dec 23, 1996 Feb NEWA

SUNITINIB MALATE

CAPSULE; ORAL
SUTENT
CPPI CV EQ 12.5MG BASE N21938 001 Jan 26, 2006 Jul CAHN
EQ 25MG BASE N21938 002 Jan 26, 2006 Jul CAHN
+ EQ 50MG BASE N21938 003 Jan 26, 2006 Jul CAHN

CAPSULE; ORAL

SUTENT

PFIZER	EQ 12.5MG BASE 12.5MG	N21938 001 Jan 26, 2006 Jun CPOT N21938 001 Jan 26, 2006 Jan NEWA
	EQ 25MG BASE 25MG	N21938 002 Jan 26, 2006 Jun CPOT N21938 002 Jan 26, 2006 Jan NEWA
+	EQ 50MG BASE	N21938 003 Jan 26, 2006 Jun CPOT
+	50MG	N21938 003 Jan 26, 2006 Jan NEWA

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

+ SAVIENT PHARMA	EQ 10MG BASE/5ML	N21807 001 Oct 29, 2005 Jun CAHN
+ SAVIENT PHARMS	EQ 10MG BASE/5ML	N21807 001 Oct 29, 2005 Jul CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

@ CIS BIO INTL SA	N/A	N20887 001 Sep 14, 1998 May DISC
	N/A	N20887 001 Sep 14, 1998 Apr CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

@ CIS BIO INTL SA	N/A	N21012 001 Aug 03, 1999 May DISC
+	N/A	N21012 001 Aug 03, 1999 Apr CAHN

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC

+ BRACCO	N/A	N18963 001 Jan 21, 1987 Aug CRLD
----------	-----	----------------------------------

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW 30ML

@ GE HEALTHCARE	N/A	N20372 002 Jul 07, 2005 May DISC
-----------------	-----	----------------------------------

>A>

TELBIVUDINE

>A>

TABLET; ORAL

>A>

TYZEKA

>A>

+ IDENIX	600MG	N22011 001 Oct 25, 2006 Oct NEWA
----------	-------	----------------------------------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB ACTAVIS ELIZABETH	15MG	N71638 001 Aug 07, 1987 Jun CAHN
AB	30MG	N71620 001 Aug 07, 1987 Jun CAHN

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

>A>

SCHERING	140MG	N21029 005 Oct 19, 2006 Oct NEWA
>A>	180MG	N21029 006 Oct 19, 2006 Oct NEWA

>A>

TERBUTALINE SULFATE

INJECTABLE; INJECTION					
BRETHINE					
@ AAIPHARMA LLC	1MG/ML		N18571	001	Aug DISC
TERBUTALINE SULFATE					
AP + BEDFORD	1MG/ML		N76770	001	Apr 23, 2004 Aug CRLD

TERCONAZOLE

CREAM; VAGINAL					
TERAZOL 3					
AB + ORTHO MCNEIL PHARM	0.8%		N19964	001	Feb 21, 1991 Sep CMFD
@	0.8%		N19964	001	Feb 21, 1991 Jul DISC
TERAZOL 7					
AB + ORTHO MCNEIL PHARM	0.4%		N19579	001	Dec 31, 1987 Sep CMFD
@	0.4%		N19579	001	Dec 31, 1987 Jul DISC
TERCONAZOLE					
AB TARO	0.4%		N76043	001	Jan 19, 2005 Sep CRLD
AB +	0.4%		N76043	001	Jan 19, 2005 Jul CRLD
AB	0.8%		N75953	001	Apr 06, 2004 Sep CRLD
BX +	0.8%		N75953	001	Apr 06, 2004 Jul CRLD
SUPPOSITORY; VAGINAL					
TERAZOL 3					
AB + ORTHO MCNEIL PHARM	80MG		N19641	001	May 24, 1988 Mar CFTG
TERCONAZOLE					
AB ALTANA	80MG		N76850	001	Jul 12, 2006 Jun NEWA
AB PERRIGO NEW YORK	80MG		N77149	001	Mar 17, 2006 Mar NEWA

TESTOSTERONE

GEL; TRANSDERMAL					
ANDROGEL					
AB + UNIMED PHARMS	1%		N21015	001	Feb 28, 2000 Jan CTEC
TESTOSTERONE					
AB WATSON LABS	1%		N76737	001	Jan 27, 2006 Jan NEWA

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION					
TESTOSTERONE CYPIONATE					
AO SANDOZ	100MG/ML		N40615	001	Aug 10, 2006 Aug NEWA
AO	200MG/ML		N40615	002	Aug 10, 2006 Aug NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION					
DELATESTRYL					
AO + @ INDEVUS PHARMS	200MG/ML		N09165	001	Jan CAHN
	200MG/ML		N09165	003	Jan CAHN
TESTOSTERONE ETHANATE					
AO PADDOCK	200MG/ML		N40575	001	Jun 14, 2006 May NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL					
ACHROMYCIN V					
@ RADIUS PHARMS	250MG		N50278	003	May CAHN
@	500MG		N50278	001	May CAHN
@ SCIREG INTL INC	250MG		N50278	003	Apr CAHN

CAPSULE; ORAL
 ACHROMYCIN V
 @ SCIREG INTL INC 500MG N50278 001 Apr CAHN
 SUSPENSION; ORAL
 SUMYCIN
 + PAR PHARM 125MG/5ML N60400 001 Aug CAHN

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
 THALLOUS CHLORIDE TL 201
 AP TRACE RADIOCHEMICALS 1mCi/ML N75569 001 Nov 21, 2001 Feb CAHN
 INJECTABLE; INTRAVENOUS
 THALLOUS CHLORIDE TL 201
 >D> + BRISTOL MYERS SQUIBB 2mCi/ML N17806 002 Oct 09, 1998 Oct CFTG
 >A> AP + 2mCi/ML N17806 002 Oct 09, 1998 Oct CFTG
 >A> AP TCI MEDCL 2mCi/ML N77698 001 Nov 09, 2006 Oct NEWA

THEOPHYLLINE

ELIXIR; ORAL
 THEOPHYLLINE
 AA ACTAVIS MID ATLANTIC 80MG/15ML N85863 001 Jul CAHN
 SOLUTION; ORAL
 THEOLAIR
 @ 3M 80MG/15ML N86107 001 Aug DISC
 THEOPHYLLINE
 + ROXANE 80MG/15ML N87449 001 Sep 15, 1983 Aug CRLD
 TABLET, EXTENDED RELEASE; ORAL
 THEOPHYLLINE
 AB NOSTRUM 400MG N40595 001 Apr 21, 2006 Apr NEWA
 AB 600MG N40560 002 Apr 21, 2006 Apr NEWA
 T-PHYL
 @ PURDUE FREDERICK 200MG N88253 001 Aug 17, 1983 Jun DISC
 UNIPHYL
 AB + PURDUE FREDERICK 400MG N87571 001 Sep 01, 1982 Apr CTEC
 AB + 600MG N40086 001 Apr 15, 1996 Apr CTEC

THIABENDAZOLE

SUSPENSION; ORAL
 MINTEZOL
 @ MERCK 500MG/5ML N16097 001 Jun DISC

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
 THIORIDAZINE HYDROCHLORIDE
 AA ACTAVIS MID ATLANTIC 100MG/ML N88229 001 Aug 23, 1983 Jul CAHN

TICARCILLIN DISODIUM

INJECTABLE; INJECTION
 TICAR
 @ GLAXOSMITHKLINE EQ 1GM BASE/VIAL N50497 001 May DISC
 @ EQ 3GM BASE/VIAL N50497 002 May DISC
 @ EQ 20GM BASE/VIAL N50497 004 May DISC
 @ EQ 30GM BASE/VIAL N50497 005 Apr 04, 1984 May DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

AB ACTAVIS ELIZABETH 250MG N75253 001 Aug 20, 1999 Jun CAHN

TIMOLOL MALEATE

TABLET; ORAL

BLOCADREN

@ MERCK 5MG N18017 001 Jun DISC

@ 10MG N18017 002 Jun DISC

@ 20MG N18017 004 Jun DISC

TIMOLOL MALEATE

AB + MYLAN 20MG N72668 001 Jun 08, 1990 Jun CRLD

TINIDAZOLE

TABLET; ORAL

TINDAMAX

MISSION PHARMA 250MG N21618 001 May 17, 2004 Jan CAHN

+ 500MG N21618 002 May 17, 2004 Jan CAHN

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

+ MEDICURE EQ 0.05MG BASE/ML N20913 001 May 14, 1998 Aug CAHN

+ EQ 0.25MG BASE/ML N20912 001 May 14, 1998 Aug CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB ACTAVIS ELIZABETH EQ 2MG BASE N76283 001 Jul 12, 2002 Jun CAHN

AB EQ 4MG BASE N76283 002 Jul 12, 2002 Jun CAHN

TOBRAMYCIN

SOLUTION; INHALATION

TOBI

+ NOVARTIS PHARMS 300MG/5ML N50753 001 Dec 22, 1997 Jul CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN

AP + ABRAXIS PHARM EQ 40MG BASE/ML N65122 002 Nov 29, 2002 Jul CRLD

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

AB ACTAVIS ELIZABETH EQ 400MG BASE N73308 001 Jan 24, 1992 Jun CAHN

TABLET; ORAL

TOLMETIN SODIUM

AB ACTAVIS ELIZABETH EQ 600MG BASE N73527 001 Jun 30, 1992 Jun CAHN

TOPIRAMATE

TABLET; ORAL

TOPAMAX

AB + ORTHO MCNEIL PHARM 25MG N20505 004 Dec 24, 1996 Aug CFTG

TABLET; ORAL

TOPAMAX

AB	ORTHO MCNEIL PHARM	100MG	N20505 001	Dec 24, 1996	Aug	CFTG
AB		200MG	N20505 002	Dec 24, 1996	Aug	CFTG
	TOPIRAMATE					
AB	MYLAN	25MG	N76314 001	Sep 11, 2006	Aug	NEWA
AB		100MG	N76314 002	Sep 11, 2006	Aug	NEWA
AB		200MG	N76314 003	Sep 11, 2006	Aug	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	50MG	N75960 001	Jun 19, 2002	Jun	CAHN
	@ IVAX PHARMS	50MG	N75963 001	Jul 03, 2002	Jan	DISC

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+ GLAXOSMITHKLINE	EQ 10MG BASE	N12342 003	Aug 16, 1985	Jun	CFTG
	TRANLYCYPROMINE SULFATE					
AB	KALI LABS	EQ 10MG BASE	N40640 001	Jun 29, 2006	Jun	NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

+ ALCON	0.004%	N21994 001	Sep 21, 2006	Sep	NEWA
---------	--------	------------	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

@ APOTHECON	50MG	N18207 001		Aug	DISC	
@	100MG	N18207 002		Aug	DISC	
@	150MG	N18207 003	Mar 25, 1985	Aug	DISC	
@	300MG	N18207 004	Nov 07, 1988	Aug	DISC	
	TRAZODONE HYDROCHLORIDE					
AB	ACTAVIS ELIZABETH	50MG	N71636 001	Apr 18, 1988	Jun	CAHN
AB		100MG	N71514 001	Apr 18, 1988	Jun	CAHN
AB	+ BARR	300MG	N71196 003	Apr 26, 1999	Sep	CRLD

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

@ ASTELLAS	4MG	N11161 007		Sep	DISC
	KENACORT				
+ BRISTOL MYERS SQUIBB	4MG	N11283 006		Sep	CRLD

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

ARISTOCORT A

@ ASTELLAS	0.025%	N88818 001	Oct 16, 1984	Sep	DISC	
@	0.1%	N88819 001	Oct 16, 1984	Sep	DISC	
@	0.5%	N88820 001	Oct 16, 1984	Sep	DISC	
	TRIAMCINOLONE ACETONIDE					
AT	ACTAVIS MID ATLANTIC	0.1%	N87798 001	Jun 04, 1982	Jun	CAHN
AT	VINTAGE	0.025%	N40671 001	Jun 09, 2006	May	NEWA

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	VINTAGE	0.1%	N40671 002 Jun 09, 2006 May NEWA
	OINTMENT; TOPICAL		
	TRIAMCINOLONE ACETONIDE		
AT	ACTAVIS MID ATLANTIC	0.1%	N87799 001 Jun 07, 1982 Jun CAHN

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

@ SANDOZ	25MG/ML	N11685 003 Jan CAHN
@	40MG/ML	N12802 001 Jan CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+ SANDOZ	5MG/ML	N16466 001 Jan CAHN
+	20MG/ML	N16466 002 Jan CAHN

TRICHLORMETHIAZIDE

TABLET; ORAL

TRICHLORMETHIAZIDE

@ TG UNITED LABS	4MG	N85568 001 May CAHN
------------------	-----	---------------------

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

>A>	+ ATON	250MG	N19194 001 Nov 08, 1985 Oct CAHN
>D>	+ MERCK	250MG	N19194 001 Nov 08, 1985 Oct CAHN

TRIFLUOPERAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

STELAZINE

@ GLAXOSMITHKLINE	EQ 2MG BASE/ML	N11552 005 May DISC
-------------------	----------------	---------------------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

AB	ODYSSEY PHARMS	EQ 25MG BASE	N16792 001 Jul CFTG
AB		EQ 50MG BASE	N16792 002 Jul CFTG
AB	+	EQ 100MG BASE	N16792 003 Sep 15, 1982 Jul CFTG
	TRIMIPRAMINE MALEATE		
AB	ACTAVIS TOTOWA	EQ 25MG BASE	N77361 001 Aug 02, 2006 Jul NEWA
AB		EQ 50MG BASE	N77361 002 Aug 02, 2006 Jul NEWA
AB		EQ 100MG BASE	N77361 003 Aug 02, 2006 Jul NEWA

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

@ NOVARTIS	50MG	N05914 002 Jan DISC
------------	------	---------------------

TROLEANDOMYCIN

CAPSULE; ORAL

TAO

@ PFIZER	EQ 250MG BASE	N50336 002 Mar DISC
----------	---------------	---------------------

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC RESCULA			
@ R TECH UENO LTD	0.15%	N21214 001	Aug 03, 2000 Jun DISC
+	0.15%	N21214 001	Aug 03, 2000 Feb CAHN

UREA

INJECTABLE; INJECTION UREAPHIL			
@ HOSPIRA	40GM/VIAL	N12154 001	Jun DISC

UROKINASE

INJECTABLE; INJECTION ABBKOKINASE			
@ IMARX THERAP	5,000 IU/VIAL	N21846 003	Apr CAHN
@	9,000 IU/VIAL	N21846 002	Apr CAHN
+	250,000 IU/VIAL	N21846 001	Apr CAHN

URSODIOL

CAPSULE; ORAL URSODIOL			
AB COREPHARMA	300MG	N77895 001	Jul 27, 2006 Jul NEWA

VALPROIC ACID

SOLUTION; ORAL VALPROIC ACID			
>A > AA VINTAGE	250MG/5ML	N77960 001	Oct 13, 2006 Oct NEWA

VALRUBICIN

SOLUTION; INTRAVESICAL VALSTAR PRESERVATIVE FREE			
+ VALERA	40MG/ML	N20892 001	Sep 25, 1998 Jul CAHN

VARENICLINE TARTRATE

TABLET; ORAL CHANTIX			
CPPI CV	EQ 0.5MG BASE	N21928 001	May 10, 2006 Jul CAHN
+	EQ 1MG BASE	N21928 002	May 10, 2006 Jul CAHN
PFIZER	EQ 0.5MG BASE	N21928 001	May 10, 2006 May NEWA
+	EQ 1MG BASE	N21928 002	May 10, 2006 May NEWA
PFIZER INC	EQ 0.5MG BASE	N21928 001	May 10, 2006 Sep CAHN
+	EQ 1MG BASE	N21928 002	May 10, 2006 Sep CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION VECURONIUM BROMIDE			
AP + BEDFORD	20MG/VIAL	N75549 002	Jun 13, 2000 Jan CRLD

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL EFFEXOR			
AB WYETH PHARMS INC	EQ 25MG BASE	N20151 002	Dec 28, 1993 Jul CFTG
AB	EQ 37.5MG BASE	N20151 006	Dec 28, 1993 Jul CFTG
AB +	EQ 50MG BASE	N20151 003	Dec 28, 1993 Jul CFTG

TABLET; ORAL

EFFEXOR

AB	WYETH PHARMS INC	EQ 75MG BASE	N20151 004 Dec 28, 1993 Jul CFTG
AB		EQ 100MG BASE	N20151 005 Dec 28, 1993 Jul CFTG
VENLAFAXINE HYDROCHLORIDE			
AB	TEVA	EQ 25MG BASE	N76690 001 Aug 03, 2006 Jul CTNA
AB		EQ 37.5MG BASE	N76690 002 Aug 03, 2006 Jul NEWA
AB		EQ 50MG BASE	N76690 003 Aug 03, 2006 Jul NEWA
AB		EQ 75MG BASE	N76690 004 Aug 03, 2006 Jul CTNA
AB		EQ 100MG BASE	N76690 005 Aug 03, 2006 Jul NEWA

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	80MG	N71019 001 Sep 24, 1986 Jun CAHN
AB		120MG	N70468 001 Sep 24, 1986 Jun CAHN
	@ RADIUS PHARMS	80MG	N71880 001 Apr 05, 1988 Jul CAHN
	@	120MG	N71881 001 Apr 05, 1988 Jul CAHN

>A> VORINOSTAT

>A> CAPSULE; ORAL

>A> ZOLINZA

>A>	+ MERCK	100MG	N21991 001 Oct 06, 2006 Oct NEWA
-----	---------	-------	----------------------------------

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	PLIVA	1MG	N40616 009 Jul 05, 2006 Jun NEWA
AB		2MG	N40616 001 Jul 05, 2006 Jun NEWA
AB		2.5MG	N40616 002 Jul 05, 2006 Jun NEWA
AB		3MG	N40616 003 Jul 05, 2006 Jun NEWA
AB		4MG	N40616 004 Jul 05, 2006 Jun NEWA
AB		5MG	N40616 005 Jul 05, 2006 Jun NEWA
AB		6MG	N40616 006 Jul 05, 2006 Jun NEWA
AB		7.5MG	N40616 007 Jul 05, 2006 Jun NEWA
AB		10MG	N40616 008 Jul 05, 2006 Jun NEWA
AB	ZYDUS PHARMS USA	1MG	N40663 001 May 30, 2006 May NEWA
AB		2MG	N40663 002 May 30, 2006 May NEWA
AB		2.5MG	N40663 003 May 30, 2006 May NEWA
AB		3MG	N40663 004 May 30, 2006 May NEWA
AB		4MG	N40663 005 May 30, 2006 May NEWA
AB		5MG	N40663 006 May 30, 2006 May NEWA
AB		6MG	N40663 007 May 30, 2006 May NEWA
AB		7.5MG	N40663 008 May 30, 2006 May NEWA
AB		10MG	N40663 009 May 30, 2006 May NEWA

WATER FOR INJECTION, STERILE

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	TARO PHARMS IRELAND	100%	N77393 001 Aug 11, 2006 Aug NEWA
----	---------------------	------	----------------------------------

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

AB	+ GLAXOSMITHKLINE	100MG	N19655 001 Mar 19, 1987 Mar CFTG
----	-------------------	-------	----------------------------------

CAPSULE; ORAL

ZIDOVUDINE

AB AUROBINDO PHARMA LTD 100MG

N78128 001 Mar 27, 2006 Mar NEWA

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL

GEODON

+ PFIZER INC

EQ 10MG BASE/ML

N21483 001 Mar 29, 2006 Mar NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB BANNER PHARMACAPS 25MG

N77813 001 Aug 16, 2006 Aug NEWA

AB 50MG

N77813 002 Aug 16, 2006 Aug NEWA

AB 100MG

N77813 003 Aug 16, 2006 Aug NEWA

AB DR REDDYS LABS LTD 25MG

N77891 001 Sep 29, 2006 Sep NEWA

AB 50MG

N77891 002 Sep 29, 2006 Sep NEWA

AB GLENMARK PHARMS 25MG

N77651 001 Jan 30, 2006 Jan NEWA

AB 50MG

N77651 002 Jan 30, 2006 Jan NEWA

AB 100MG

N77651 003 Jan 30, 2006 Jan NEWA

AB INVAGEN PHARMS 25MG

N77869 001 May 31, 2006 May NEWA

AB 50MG

N77869 002 May 31, 2006 May NEWA

AB 100MG

N77869 003 May 31, 2006 May NEWA

AB SUN PHARM INDS (IN) 25MG

N77634 001 Mar 17, 2006 Mar NEWA

AB 50MG

N77634 002 Mar 17, 2006 Mar NEWA

AB 100MG

N77634 003 Mar 17, 2006 Mar NEWA

AB WATSON LABS 25MG

N77650 001 Apr 20, 2006 Apr NEWA

AB 50MG

N77650 002 Apr 20, 2006 Apr NEWA

AB 100MG

N77650 003 Apr 20, 2006 Apr NEWA

AB WOCKHARDT 25MG

N77636 003 Jul 27, 2006 Jul NEWA

AB 50MG

N77636 002 Jul 27, 2006 Jul NEWA

N77636 001 Oct 16, 2006 Oct NEWA

>A> AB ZYDUS PHARMS USA 25MG

>A> AB 50MG

>A> AB 100MG

N77625 003 Oct 16, 2006 Oct NEWA

OTC DRUG PRODUCT LIST - 26TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 10 - October 2006

2-1

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACETAMINOPHEN

ACTAVIS MID ATLANTIC	120MG	N18337 003	Sep 12, 1983	Jun	CAHN
	325MG	N18337 002		Jun	CAHN
+	650MG	N18337 001		Jun	CAHN
INFANTS' FEVERALL					
ACTAVIS MID ATLANTIC	80MG	N18337 004	Aug 26, 1992	Jun	CAHN
TYLENOL					
@ MCNEIL CONS	120MG	N17756 002		Jun	CAHN
@	650MG	N17756 001		Jun	CAHN
TABLET, EXTENDED RELEASE; ORAL					
TYLENOL (CAPLET)					
+ MCNEIL CONS	650MG	N19872 001	Jun 08, 1994	Jun	CAHN
TYLENOL (GELTAB)					
+ MCNEIL CONS	650MG	N19872 002	Jan 11, 2001	Jun	CAHN

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+ LOREAL USA	2%;2%;10%	N21502 001	Jul 21, 2006	Jul	NEWA
CAPITAL SOLEIL 15					
+ LOREAL USA	2%;3%;10%	N21501 001	Oct 02, 2006	Oct	NEWA

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL

ANTHELIOS 20

+ LOREAL USA	2%;2%;10%;2%	N21471 001	Oct 05, 2006	Oct	NEWA
--------------	--------------	------------	--------------	-----	------

CHLORHEXIDINE GLUCONATE

CLOTH; TOPICAL

CHLORHEXIDINE GLUCONATE

+ SAGE PRODS	2%	N21669 001	Apr 25, 2005	Oct	CTNA
HALO					
+ SAGE PRODS	2%	N21669 001	Apr 25, 2005	Oct	CTNA

+ 2%

N21669 001 Apr 25, 2005 Aug CTNA

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

BECTON DICKINSON 4%

@ KENDALL IL 4%

N72525 001 Oct 24, 1989 Aug CAHN

N19490 001 Mar 27, 1987 Aug DISC

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP WITH TINT

+ MEDI FLEX INC	2%;70% (10.5ML)	N20832 005	Apr 03, 2006	Apr	NEWA
-----------------	-----------------	------------	--------------	-----	------

CLOTTRIMAZOLE

CREAM; VAGINAL

CLOTTRIMAZOLE

ACTAVIS MID ATLANTIC 1%

N74165 001 Jul 16, 1993 Jun CAHN

CROMOLYN SODIUM

SPRAY, METERED; NASAL						
CROMOLYN SODIUM						
ACTAVIS MID ATLANTIC	5.2MG/SPRAY	N74800	001	Jul 26, 2001	Jul	CAHN
ALPHARMA US PHARMS	5.2MG/SPRAY	N74800	001	Jul 26, 2001	Jan	CPOT
+ BAUSCH AND LOMB	5.2MG/SPRAY	N75702	001	Jul 03, 2001	Jan	CRLD
NASALCROM						
@ PHARMACIA UPJOHN	5.2MG/SPRAY	N20463	001	Jan 03, 1997	Jan	DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL						
MUCINEX DM						
ADAMS RESP THERAP	30MG;600MG	N21620	002	Apr 29, 2004	May	CAHN
+ +	60MG;1.2GM	N21620	001	Apr 29, 2004	May	CAHN

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL						
DELSYM						
+ ADAMS RESP THERAP	EQ 30MG HBR/5ML	N18658	001	Oct 08, 1982	Jun	CAHN

FAMOTIDINE

TABLET; ORAL						
FAMOTIDINE						
DR REDDYS LABS LTD	20MG	N77367	001	Sep 25, 2006	Sep	NEWA
PERRIGO	20MG	N77351	001	Sep 25, 2006	Sep	NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL						
HUMABID						
+ ADAMS RESP THERAP	1.2GM	N21282	002	Dec 18, 2002	Aug	CTNA
MUCINEX						
ADAMS RESP THERAP	600MG	N21282	001	Jul 12, 2002	May	CAHN
+ +	1.2GM	N21282	002	Dec 18, 2002	May	CAHN

GUAIFENESIN; PSEUDOEPHENDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL						
MUCINEX D						
ADAMS RESP THERAP	600MG;60MG	N21585	001	Jun 22, 2004	May	CAHN
+ +	1.2GM;120MG	N21585	002	Jun 22, 2004	May	CAHN

IBUPROFEN

SUSPENSION/DROPS; ORAL						
CHILDREN'S MOTRIN						
+ MCNEIL CONS	40MG/ML	N20603	001	Jun 10, 1996	Jun	CAHN
SUSPENSION; ORAL						
CHILDREN'S ELIXSURE						
ALTERNA-TCHP LLC	100MG/5ML	N21604	001	Jan 07, 2004	Jul	CAHN
IBUPROFEN						
ACTAVIS MID ATLANTIC	100MG/5ML	N74916	001	Apr 30, 1999	Jul	CAHN
TABLET, CHEWABLE; ORAL						
CHILDREN'S MOTRIN						
MCNEIL CONS	50MG	N20601	001	Nov 15, 1996	Jun	CAHN
JUNIOR STRENGTH MOTRIN						
+ MCNEIL CONS	100MG	N20601	003	Nov 15, 1996	Jun	CAHN

TABLET; ORAL

JUNIOR STRENGTH MOTRIN
MCNEIL CONS 100MG N20602 001 Jun 10, 1996 Jun CAHN

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL
CHILDREN'S MOTRIN COLD
+ MCNEIL CONS 100MG/5ML;15MG/5ML N21128 001 Aug 01, 2000 Jun CAHN

TABLET; ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE
DR REDDYS LABS LTD 200MG;30MG N77628 001 Aug 14, 2006 Aug NEWA

SINE-AID IB
MCNEIL CONS 200MG;30MG N19899 001 Dec 31, 1992 Jun CAHN

INSULIN PURIFIED PORK

INJECTABLE; INJECTION
REGULAR ILETIN II (PORK)
@ LILLY 100 UNITS/ML N18344 001 Jun DISC

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION
NPH ILETIN I (BEEF-PORK)
@ LILLY 100 UNITS/ML N17936 002 Jun DISC

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION
NPH ILETIN II (PORK)
@ LILLY 100 UNITS/ML N18345 001 Jun DISC

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION
HUMULIN U
@ LILLY 100 UNITS/ML N19571 002 Jun 10, 1987 Jun DISC

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION
LENTE ILETIN II (PORK)
@ LILLY 100 UNITS/ML N18347 001 Jun DISC

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL
DURAPREP
>D> 3M EQ 0.7% IODINE;74% (26ML) N21586 002 Sep 29, 2006 Oct CRLD
>A> + EQ 0.7% IODINE;74% (26ML) N21586 002 Sep 29, 2006 Oct CRLD
+ EQ 0.7% IODINE; 74% (6ML) N21586 001 Sep 29, 2006 Sep NEWA
EQ 0.7% IODINE;74% (26ML) N21586 002 Sep 29, 2006 Sep NEWA

KETOCONAZOLE

SHAMPOO; TOPICAL
NIZORAL A-D
+ MCNEIL CONS 1% N20310 001 Oct 10, 1997 Jun CAHN

KETOPROFEN

TABLET; ORAL
ACTRON
@ BAYER 12.5MG N20499 001 Oct 06, 1995 Feb DISC

TABLET; ORAL

ORUDIS KT
@ WYETH CONS 12.5MG

N20429 001 Oct 06, 1995 Feb DISC

>A> KETOTIFEN FUMARATE

>A> SOLUTION/DROPS; OPHTHALMIC

>A> ZADITOR

>A> + NOVARTIS EQ 0.025% BASE

N21066 002 Oct 19, 2006 Oct NEWA

LEVONORGESTREL

TABLET; ORAL

PLAN B

+ DURAMED 0.75MG

N21045 002 Aug 24, 2006 Aug NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

IMODIUM A-D

+ MCNEIL CONS 1MG/5ML

N19487 001 Mar 01, 1988 Jun CAHN

SUSPENSION; ORAL

IMODIUM A-D

+ MCNEIL 1MG/7.5ML

N19487 002 Jul 08, 2004 Mar CDFR

+ MCNEIL CONS 1MG/7.5ML

N19487 002 Jul 08, 2004 Jun CAHN

TABLET; ORAL

IMODIUM A-D

+ MCNEIL CONS 2MG

N19860 001 Nov 22, 1989 Jun CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM ADVANCED

+ MCNEIL CONS 2MG;125MG

N21140 001 Nov 30, 2000 Jun CAHN

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

RANBAXY 2MG;125MG

N77500 001 Sep 06, 2006 Aug NEWA

LORATADINE

SYRUP; ORAL

LORATADINE

SILARX 1MG/ML

N77421 001 Jun 29, 2006 Jun NEWA

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ SCHERING PLOUGH 5MG

N21891 001 Aug 23, 2006 Aug NEWA

TABLET; ORAL

LORATADINE

APOTEX 10MG

N76471 001 Feb 14, 2006 Jan NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC 2%,200MG

N74926 001 Apr 16, 1999 Jun CAHN

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC 2%,100MG

N74586 001 Jul 17, 1997 Jun CAHN

CREAM; VAGINAL

MICONAZOLE 7

ACTAVIS MID ATLANTIC 2%

N74164 001 Mar 29, 1996 Jun CAHN

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC 100MG

N73507 001 Nov 19, 1993 Jun CAHN

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MEN'S ROGAINE

+ PHARMACIA AND UPJOHN 5%

N21812 001 Jan 20, 2006 Jan NEWA

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC 2%

N74588 001 Apr 05, 1996 Jul CAHN

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC 5%

N75518 001 Nov 17, 2000 Jul CAHN

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

>D>	BANNER PHARMACAPS	EQ 200MG BASE	N21920 001 Feb 17, 2006 Oct CRLD
>A>	+	EQ 200MG BASE	N21920 001 Feb 17, 2006 Oct CRLD
		EQ 200MG BASE	N21920 001 Feb 17, 2006 Sep CMFD
	@	EQ 200MG BASE	N21920 001 Feb 17, 2006 Jul DISC
	+	EQ 200MG BASE	N21920 001 Feb 17, 2006 Feb NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC EQ 220MG BASE;120MG

N77381 001 Sep 27, 2006 Sep NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

GLAXOSMITHKLINE

EQ 2MG BASE

N18612 003 Dec 23, 1998 Mar CRLD

EQ 2MG BASE

N18612 004 Sep 25, 2000 Mar CRLD

EQ 4MG BASE

N20066 004 Sep 25, 2000 Mar CRLD

EQ 4MG BASE

N20066 003 Dec 23, 1998 Mar CRLD

NICORETTE (MINT)

GLAXOSMITHKLINE

EQ 2MG BASE

N18612 003 Dec 23, 1998 Apr CTNA

EQ 4MG BASE

N20066 003 Dec 23, 1998 Apr CTNA

NICOTINE POLACRILEX

PERRIGO

EQ 2MG BASE

N76776 001 Sep 16, 2004 Apr CTNA

EQ 2MG BASE

N76777 001 Sep 16, 2004 Apr CTNA

EQ 4MG BASE

N76778 001 Sep 16, 2004 Apr CTNA

EQ 4MG BASE

N76779 001 Sep 16, 2004 Apr CTNA

>A>

PERRIGO R AND D

EQ 2MG BASE

N78325 001 Oct 30, 2006 Oct NEWA

>A>

WATSON LABS

EQ 2MG BASE

N78326 001 Oct 30, 2006 Oct NEWA

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE

N76569 001 Jul 29, 2004 Apr CTNA

EQ 4MG BASE

N76568 002 Jul 29, 2004 Apr CTNA

N77007 001 Jan 31, 2006 Jan NEWA

TROCHE/LOZENGE; ORAL
NICOTINE POLACRILEX
PERRIGO R AND D EQ 4MG BASE

N77007 002 Jan 31, 2006 Jan NEWA

PERMETHRIN

LOTION; TOPICAL
PERMETHRIN
ACTAVIS MID ATLANTIC 1%

N75014 001 Mar 28, 2000 Jun CAHN

>A> POLYETHYLENE GLYCOL 3350

>A> FOR SOLUTION; ORAL
>A> MIRALAX
>A> + BRAINTREE 17GM/SCOOPFUL

N22015 001 Oct 06, 2006 Oct NEWA

POVIDONE-IODINE

SOLUTION; TOPICAL
E-Z PREP
@ CLINIPAD 10%
SPONGE; TOPICAL
E-Z PREP
@ CLINIPAD 5%
E-Z PREP 220
@ CLINIPAD 5%

N19382 001 Jul 25, 1989 Aug DISC

N19382 002 Jul 25, 1989 Aug DISC

N19382 003 Jul 25, 1989 Aug DISC

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE
WOCKHARDT EQ 75MG BASE

N76760 001 Feb 24, 2006 Feb NEWA

TERBINAFINE

GEL; TOPICAL
LAMISIL AT
+ NOVARTIS 1%

N21958 001 Jul 24, 2006 Jul NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2006

NO OCTOBER 2006 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2006 ADDITIONS

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>							
021652 001	5034394	Dec	18, 2011	DS	DP	D-40	Aug 02, 2007
	5034394*PED	Jun	18, 2012				
	5047407	Nov	17, 2009	DS	DP	U-257	
	5047407*PED	May	17, 2010				
	5089500	Jun	26, 2009			U-257	
	5089500*PED	Dec	26, 2009				
	5905082	May	18, 2016	DS	DP		
	5905082*PED	Nov	18, 2016				
	6294540	May	14, 2018	DS	DP	U-257	
	6294540*PED	Nov	14, 2018				
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>							
021205 001	5034394	Dec	18, 2011	DS	DP		
	5034394*PED	Jun	18, 2012				
<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE - ULTRACET</u>							
021123 001	RE39221	Aug	09, 2011	DS	DP	U-55	
<u>ALBUTEROL SULFATE - PROAIR HFA</u>							
021457 001						I-235	Feb 03, 2009
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>							
020983 001	6131566	Apr	14, 2015	DP	U-716		
	6131566	Apr	14, 2015	DP	U-589		
	6532955	Apr	14, 2015	DP	U-716		
	6532955	Apr	14, 2015	DP	U-590		
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>							
021762 001						NC	Apr 07, 2008
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>							
021287 001	4661491	May	27, 2007			U-706	
<u>ALITRETINOIN - PANRETIN</u>							
020886 001	7056954	Aug	02, 2012	DP			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>							
020364 006	4879303	Mar	25, 2007	DS	DP		
	6162802	Dec	19, 2017	DS	DP	U-185	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>							
020364 007	4879303	Mar	25, 2007	DS	DP		
	6162802	Dec	19, 2017	DS	DP	U-185	
<u>ANIDULAFUNGIN - ERAXIS</u>							
021632 001	5965525	Oct	12, 2016	DS	DP	U-540	
	6384013	Mar	19, 2012	DS			
	6743777	Mar	19, 2012	DP	U-540		
	6960564	Apr	12, 2021	DP	U-540		
<u>APREPITANT - EMEND</u>							
021549 001	5145684	Jan	25, 2011	DP			
	5719147	Jun	29, 2012	DS	DP		
	6096742	Jul	01, 2018	DS	DP	U-745	
	6235735	Jun	29, 2012			U-746	
	6235735	Jun	29, 2012			U-747	
<u>APREPITANT - EMEND</u>							
021549 002	5145684	Jan	25, 2011	DP			
	5719147	Jun	29, 2012	DS	DP		
	6096742	Jul	01, 2018	DS	DP	U-745	
	6235735	Jun	29, 2012			U-747	
	6235735	Jun	29, 2012			U-746	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE			PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>APREPITANT - EMEND</u>								
021549 003	5145684	Jan	25,	2011	DP	I-498	Jun	30, 2009
	5719147	Jun	29,	2012	DS DP	NS	Jun	30, 2009
	6096742	Jul	01,	2018	DS DP	U-745	Mar	26, 2008
	6235735	Jun	29,	2012		U-747		
	6235735	Jun	29,	2012		U-746		
<u>ARFORMOTEROL TARTRATE - BROVANA</u>								
021912 001						>A> NP	Oct	06, 2009
<u>ARIPIPRAZOLE - ABILIFY</u>								
021436 001	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>								
021436 002	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>								
021436 003	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>								
021436 004	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>								
021436 005	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>								
021436 006	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>								
021713 001	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488	Mar 01, 2008
	6977257	Apr	24,	2022	DS DP			
<u>ARIPIPRAZOLE - ABILIFY</u>								
021729 002	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488 I-437 NCE	Mar 01, 2008 Sep 29, 2007 Nov 15, 2007
<u>ARIPIPRAZOLE - ABILIFY</u>								
021729 003	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488 I-437 NCE	Mar 01, 2008 Sep 29, 2007 Nov 15, 2007
<u>ARIPIPRAZOLE - ABILIFY</u>								
021729 004	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488 I-437 NCE	Mar 01, 2008 Sep 29, 2007 Nov 15, 2007
<u>ARIPIPRAZOLE - ABILIFY</u>								
021729 005	>A> 5006528	Oct	20,	2014	DS DP	U-761	I-488 I-437 NCE	Mar 01, 2008 Sep 29, 2007 Nov 15, 2007
<u>ARIPIPRAZOLE - ABILIFY</u>								
021866 001	>A> 5006528	Oct	20,	2014	DS DP	U-763	NDF	Sep 20, 2009
	>A> 7115587	Jul	21,	2024	DS DP	U-764	NCE	Nov 15, 2007
<u>ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE - SEPTOCAINE</u>								
022010 001						NP	Mar	30, 2009
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>								
021881 001						NP	Aug	02, 2009
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>								
021411 001	5658590	Nov	26,	2016		U-494		
	5658590*PED	May	26,	2017		U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>								
021411 002	5658590	Nov	26,	2016		U-494		
	5658590*PED	May	26,	2017		U-494		
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>								
021411 003	5658590	Nov	26,	2016		U-494		
	5658590*PED	May	26,	2017		U-494		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
021411 004	5658590	Nov	26, 2016		U-494	
	5658590*PED	May	26, 2017		U-494	
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
021411 005	5658590	Nov	26, 2016		U-494	
	5658590*PED	May	26, 2017		U-494	
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
021411 006	5658590	Nov	26, 2016		U-494	
	5658590*PED	May	26, 2017		U-494	
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
021411 007	5658590	Nov	26, 2016		U-494	
	5658590*PED	May	26, 2017		U-494	
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
021411 008	5658590	Nov	26, 2016		U-494	
	5658590*PED	May	26, 2017		U-494	
<u>ATROPINE; PRALIDOXIME CHLORIDE - DUODOTE</u>						
021983 001	>A> 5092843	Apr	12, 2010	DP		
<u>AVOBENZONE; ECAMSULE; OCTOCRYLENE - ANTHELIOS SX</u>						
021502 001	4585597	Jun	16, 2007	DS	DP	U-752
	5587150	Dec	24, 2013		DP	U-752
<u>AZELASTINE HYDROCHLORIDE - ASTELIN</u>						
020114 001					D-102	Feb 17, 2009
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
020610 001	4412992*PED	Jan	08, 2007			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
021852 001	4866048	Dec	29, 2007	DS	DP	U-88
	4866048	Dec	29, 2007	DS	DP	U-193
	5763426	Jun	09, 2015	DS	DP	
	6753013	Jan	27, 2020		DP	U-88
	6753013	Jan	27, 2020		DP	U-193
<u>BETAMETHASONE VALERATE - LUXIQ</u>						
020934 001	7078058	Mar	01, 2016	DS	DP	
<u>BETAXOLOL HYDROCHLORIDE - BETOPTIC S</u>						
019845 001	4911920	Mar	27, 2007			
	4911920*PED	Sep	27, 2007			
<u>BIMATOPROST - LUMIGAN</u>						
021275 001	5688819	Aug	19, 2014		U-446	
	6403649	Sep	21, 2012	DS	DP	U-446
<u>BIVALIRUDIN - ANGIOMAX</u>						
020873 001					I-486	Nov 30, 2008
<u>BORTEZOMIB - VELCADE</u>						
021602 001					ODE	Mar 25, 2012
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
021770 001	5424078	Jun	13, 2012	DP		
	5424078*PED	Dec	13, 2012			
	6562873	Jul	10, 2021	DP		
	6562873*PED	Jan	10, 2022			
	6627210	Jul	18, 2021	DP		
	6627210*PED	Jan	18, 2022			
	6641834	Jul	28, 2021	DP		
	6641834*PED	Jan	28, 2022			
	6673337	Jul	26, 2021	DP		
	6673337*PED	Jan	26, 2022			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE			PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRINZOLAMIDE - AZOPT</u>							
020816 001	>A> 5240923	Aug 31, 2010	DS	DP	U-224		
	5240923*PED	Mar 01, 2011					
	>A> 5378703	Apr 01, 2012	DS	DP	U-224		
	5378703*PED	Oct 01, 2012					
	>A> 5461081	Oct 24, 2012		DP	U-225		
	5461081*PED	Apr 24, 2013					
<u>BROMFENAC SODIUM - XIBROM</u>							
021664 001						I-485	Jan 27, 2009
<u>BUDESONIDE - BUDESONIDE</u>							
021949 001						NP	Jul 12, 2009
<u>BUDESONIDE - BUDESONIDE</u>							
021949 002						NP	Jul 12, 2009
<u>BUDESONIDE - PULMICORT RESPULES</u>							
020929 001	6598603*PED	Jun 23, 2019					
	6899099	Dec 23, 2018			U-751		
	6899099*PED	Jun 23, 2019					
<u>BUDESONIDE - PULMICORT RESPULES</u>							
020929 002	6899099	Dec 23, 2018			U-751		
	6899099*PED	Jun 23, 2019					
<u>BUDESONIDE - RHINOCORT</u>							
020746 001	6986904	Apr 29, 2017	DP	DP	U-699		
<u>BUDESONIDE - RHINOCORT</u>							
020746 002	6986904	Apr 29, 2017	DP	DP	U-699		
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT</u>							
021929 001	5674860	Oct 07, 2014	DP	DP	U-754		
	5972919	Dec 17, 2012	DP	DP	U-754		
	6123924	Sep 26, 2017	DP				
	6641800	Sep 26, 2017	DP				
<u>BUDESONIDE; FORMOTEROL FUMARATE - SYMBICORT</u>							
021929 002	5674860	Oct 07, 2014	DP	DP	U-754		
	5972919	Dec 17, 2012	DP	DP	U-754		
	6123924	Sep 26, 2017	DP				
	6641800	Sep 26, 2017	DP				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>							
021515 001						I-497	Jun 12, 2009
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>							
021515 002						I-497	Jun 12, 2009
<u>BUSULFAN - BUSULFEX</u>							
020954 001	>A> 5559148	Sep 30, 2013			U-264		
	>A> 5559148*PED	Mar 30, 2014			U-264		
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>							
021823 001						M-52	Jan 24, 2009
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>							
021485 002	4963590	Nov 27, 2007	DP	DP	U-219		
	5112861	May 12, 2009			U-219		
	5135950	Oct 31, 2010	DS	DP	U-219		
	6500867	Jun 29, 2020	DP	DP	U-219		
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>							
021485 003	4963590	Nov 27, 2007	DP	DP	U-219		
	5112861	May 12, 2009			U-219		
	5135950	Oct 31, 2010	DS	DP	U-219		
	6500867	Jun 29, 2020	DP	DP	U-219		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50								
021485 001	4963590	Nov	27, 2007	DP	U-219			
	5112861	May	12, 2009		U-219			
	5135950	Oct	31, 2010	DS	DP	U-219		
	6500867	Jun	29, 2020		DP	U-219		
CARVEDILOL - COREG								
020297 001	>A> 4503067	Mar	05, 2007		U-3	>A> M-56		
	>A> 4503067*PED	Sep	05, 2007			>A> PED	Aug 28, 2009	Feb 28, 2010
	>A> 5760069	Jun	07, 2015		U-233			
	>A> 5760069*PED	Dec	07, 2015					
	>A> 5902821	Feb	07, 2016		U-313			
	>A> 5902821*PED	Aug	07, 2016					
CARVEDILOL - COREG								
020297 002	>A> 4503067	Mar	05, 2007		U-3	>A> M-56		
	>A> 4503067*PED	Sep	05, 2007			>A> PED	Aug 28, 2009	Feb 28, 2010
	>A> 5760069	Jun	07, 2015		U-233			
	>A> 5760069*PED	Dec	07, 2015					
	>A> 5902821	Feb	07, 2016		U-313			
	>A> 5902821*PED	Aug	07, 2016					
CARVEDILOL - COREG								
020297 003	>A> 4503067	Mar	05, 2007		U-3	>A> M-56		
	>A> 4503067*PED	Sep	05, 2007			>A> PED	Aug 28, 2009	Feb 28, 2010
	>A> 5760069	Jun	07, 2015		U-233			
	>A> 5760069*PED	Dec	07, 2015					
	>A> 5902821	Feb	07, 2016		U-313			
	>A> 5902821*PED	Aug	07, 2016					
CARVEDILOL - COREG								
020297 004	>A> 4503067	Mar	05, 2007		U-3	>A> M-56		
	>A> 4503067*PED	Sep	05, 2007			>A> PED	Aug 28, 2009	Feb 28, 2010
	>A> 5760069	Jun	07, 2015		U-233			
	>A> 5760069*PED	Dec	07, 2015					
	>A> 5902821	Feb	07, 2016		U-313			
	>A> 5902821*PED	Aug	07, 2016					
CARVEDILOL PHOSPHATE - COREG CR								
022012 001						>A> M-56 >A> NDF		
							Aug 28, 2009	Oct 20, 2009
CASPOFUNGIN ACETATE - CANCIDAS								
021227 001	>A> 5514650	Jan	26, 2015	DP	U-607			
CASPOFUNGIN ACETATE - CANCIDAS								
021227 002	>A> 5514650	Jan	26, 2015	DP	U-607			
CEFEDITOREN PIVOXIL - SPECTRACEF								
021222 001	4839350	Apr	14, 2009	DS	DP			
CELECOXIB - CELEBREX								
020998 001	5466823	Nov	30, 2013	DS		I-466 PED		
	5466823*PED	May	30, 2014				Jul 29, 2008	Jan 29, 2009
	5563165	Nov	30, 2013		DP			
	5563165*PED	May	30, 2014					
	5760068	Jun	02, 2015		U-672			
	5760068	Jun	02, 2015		U-299			
	5760068*PED	Dec	02, 2015					
	5972986	Oct	14, 2017		U-299			
	5972986*PED	Apr	14, 2018					

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELEBREX</u>						
020998 002	5466823	Nov 30, 2013	DS		I-466	Jul 29, 2008
	5466823*PED	May 30, 2014			PED	Jan 29, 2009
	5563165	Nov 30, 2013		DP		
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068	Jun 02, 2015			U-299	
	5760068*PED	Dec 02, 2015				
	5972986	Oct 14, 2017			U-299	
	5972986*PED	Apr 14, 2018				
<u>CELECOXIB - CELEBREX</u>						
020998 003	5466823	Nov 30, 2013	DS		I-466	Jul 29, 2008
	5466823*PED	May 30, 2014			PED	Jan 29, 2009
	5563165	Nov 30, 2013		DP		
	5563165*PED	May 30, 2014				
	5760068	Jun 02, 2015			U-672	
	5760068	Jun 02, 2015			U-299	
	5760068*PED	Dec 02, 2015				
	5972986	Oct 14, 2017			U-299	
	5972986*PED	Apr 14, 2018				
<u>CETIRIZINE HYDROCHLORIDE - ZYRTEC</u>						
019835 001	4525358	Jun 25, 2007	DS	DP	U-565	
	4525358*PED	Dec 25, 2007				
<u>CETIRIZINE HYDROCHLORIDE - ZYRTEC</u>						
019835 002	4525358	Jun 25, 2007	DS	DP	U-565	
	4525358*PED	Dec 25, 2007				
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
021150 001	7014867	Jun 10, 2022		DP		
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
021669 001	7066916	Feb 17, 2024			U-737	
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
020832 004	5690958	Sep 30, 2016		DP		
	6536975	Nov 10, 2020		DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>						
020832 003	5538353	Aug 25, 2015		DP		
	5690958	Sep 30, 2016		DP		
	5752363	Apr 22, 2017		DP		
	5772346	Apr 22, 2017		DP		
	D386849	Nov 25, 2011		DP		
	D396911	Aug 11, 2012		DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP SINGLE SWABSTICK</u>						
021555 002	5690958	Sep 30, 2016		DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
020832 002	6991393	Mar 14, 2023		DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
020832 005	5690958	Sep 30, 2016		DP		
	6536975	Nov 10, 2020		DP		
	6729786	Mar 14, 2023		DP		
	6991393	Jan 31, 2024		DP		
<u>CICLESONIDE - OMNARIS</u>						
022004 001					>A> NCE	Oct 20, 2011
<u>CICLOPIROX - LOPROX</u>						
020519 001	7018656	Sep 05, 2018		DP		
	7026337	Apr 02, 2018			U-714	
<u>CIPROFLOXACIN - CIPRO</u>						
019847 002					I-421 PED	Mar 25, 2007 Sep 25, 2007

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CIPROFLOXACIN - CIPRO						
	019847 003				I-421 PED	Mar 25, 2007 Sep 25, 2007
CLOBETASOL PROPIONATE - CLOBEX						
021835 001	5972920	Feb 12, 2018	DP		NDF	Oct 27, 2008
	5990100	Mar 24, 2018	DP	U-742		
CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE						
076274 001					PC	Feb 04, 2007
CLOPIDOGREL BISULFATE - PLAVIX						
020839 001					I-502	Aug 17, 2009
COLESEVELAM HYDROCHLORIDE - WELCHOL						
021176 001	5693675	Dec 02, 2014	DS			
	5917007	Apr 29, 2014	DS		U-323	
	5919832	Jun 10, 2014	DS			
	6066678	Jun 10, 2014	DS		U-323	
	6433026	Jun 10, 2014	DS			
	6784254	Jun 10, 2014	DS	DP		
	7101960	Apr 29, 2014	DS	DP	U-757	
CONIVAPTAN HYDROCHLORIDE - VAPRISOL						
021697 001	5723606	Mar 03, 2015	DS	DP	U-698	
DAPSONE - ACZONE						
021794 001	5863560	Sep 11, 2016	DP			
	6620435	Sep 11, 2016	DP			
DAPTOMYCIN - CUBICIN						
021572 001	6468967	Sep 24, 2019		U-282		
	RE39071	Jun 15, 2016	DS	DP	U-728	
DAPTOMYCIN - CUBICIN						
021572 002	6468967	Sep 24, 2019		U-282	>A> I-505	May 25, 2009
	RE39071	Jun 15, 2016	DS	DP	U-728	
DARUNAVIR ETHANOLATE - PREZISTA						
021976 001	5843946	Dec 01, 2015		DP	U-744	
	6248775	Aug 25, 2012	DS			
	6335460	Aug 25, 2012	DS	DP	U-744	
DASATINIB - SPRYCEL						
021986 001	6596746	Apr 13, 2020	DS	DP	U-748	
DASATINIB - SPRYCEL						
021986 002	6596746	Apr 13, 2020	DS	DP	U-748	
DASATINIB - SPRYCEL						
021986 003	6596746	Apr 13, 2020	DS	DP	U-748	
DECITABINE - DACOGEN						
021790 001					NCE	May 02, 2011
DEFERASIROX - EXJADE						
021882 001	6465504	Jun 24, 2017	DS	DP		
	6596750	Jun 24, 2017	DS		U-735	
DEFERASIROX - EXJADE						
021882 002	6465504	Jun 24, 2017	DS	DP		
	6596750	Jun 24, 2017	DS		U-735	
DEFERASIROX - EXJADE						
021882 003	6465504	Jun 24, 2017	DS	DP		
	6596750	Jun 24, 2017	DS		U-735	
DESFLURANE - SUPRANE						
020118 001	4762856	Feb 02, 2007		U-67		
	4762856*PED	Aug 02, 2007				
	5617906	Apr 08, 2014				
	5617906*PED	Oct 08, 2014	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESLORATADINE - CLARINEX</u>							
021165 001	4659716	Mar	31, 2007	DP	U-725		
	4659716	Mar	31, 2007	DP	U-427		
	4659716*PED	Oct	01, 2007		U-427		
<u>DESLORATADINE - CLARINEX</u>							
021300 001	4659716	Mar	31, 2007	DP	U-725		
	4659716	Mar	31, 2007	DP	U-611		
	4659716*PED	Oct	01, 2007				
<u>DESLORATADINE - CLARINEX</u>							
021312 001	4659716	Mar	31, 2007	DP	U-725		
	4659716	Mar	31, 2007	DP	U-427		
	4659716*PED	Oct	01, 2007		U-427		
	5178878	Jan	12, 2010	DP			
	5607697	Jun	07, 2015	DP			
<u>DESLORATADINE - CLARINEX</u>							
021312 002	4659716	Mar	31, 2007	DP	U-725		
	4659716	Mar	31, 2007	DP	U-427		
	4659716*PED	Oct	01, 2007		DP		
	5178878	Jan	12, 2010	DP			
	5607697	Jun	07, 2015	DP			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>							
021605 001	4659716	Mar	31, 2007	DP	U-726		
	4659716	Mar	31, 2007	DP	U-644		
	4659716*PED	Oct	01, 2007				
	6979463	Mar	28, 2022	DP			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>							
021313 001	4659716	Mar	31, 2007	DP	U-707	NP	Feb 01, 2009
	4659716*PED	Oct	01, 2007			NCE	Dec 21, 2006
	6100274	Jul	07, 2019	DP		NC	Mar 03, 2008
	6100274*PED	Jan	07, 2020			PED	Jun 21, 2007
	6709676	Feb	18, 2021	DP	U-707		
<u>DESMOPRESSIN ACETATE - DDAVP</u>							
019955 001	7022340	Apr	30, 2023	DP			
<u>DESMOPRESSIN ACETATE - DDAVP</u>							
019955 002	7022340	Apr	30, 2023	DP			
<u>DESONIDE - VERDESO</u>							
021978 001	>A> 6730288	Sep	08, 2019	DP		NDF	Sep 19, 2009
	>A> 7029659	Sep	08, 2019	DP			
<u>DEXMEDETOMIDINE - PRECEDEX</u>							
021038 001	4910214	Jul	15, 2013	DS	DP	U-421	
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>							
021802 004						NDF	May 26, 2008
<u>DIAZEPAM - DIASTAT</u>							
020648 001	>A> 5462740	Sep	17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>							
020648 002	>A> 5462740	Sep	17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>							
020648 003	>A> 5462740	Sep	17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>							
020648 004	>A> 5462740	Sep	17, 2013	DP			
<u>DIAZEPAM - DIASTAT</u>							
020648 005	>A> 5462740	Sep	17, 2013	DP			
<u>DIAZEPAM - DIASTAT ACUDIAL</u>							
020648 006	>A> 5462740	Sep	17, 2013	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - DIASTAT ACUDIAL</u>						
020648 007	>A> 5462740	Sep	17, 2013	DP		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
021392 001	7108866	Dec	17, 2019	DP	U-107	
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
021392 002	7108866	Dec	17, 2019	DP	U-107	
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
021392 003	7108866	Dec	17, 2019	DP	U-107	
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
021392 004	7108866	Dec	17, 2019	DP	U-107	
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
021392 005	7108866	Dec	17, 2019	DP	U-107	
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
021392 006	7108866	Dec	17, 2019	DP	U-107	
<u>DOCETAXEL - TAXOTERE</u>						
020449 001	5750561	Jul	03, 2012	DP	I-490	Mar 22, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
021720 001	4895841	Nov	25, 2010	DS	DP	U-713
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
021720 002	4895841	Nov	25, 2010	DS	DP	U-713
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
021676 001	>A> 5569652	Oct	29, 2013	U-758	>A> I-508 NP	Oct 04, 2009 Mar 16, 2009
	>A> 5569652	Oct	29, 2013	U-1		
	5798338	Jul	10, 2015	DP		
	6787531	Aug	31, 2020	DP		
	6933395	Aug	11, 2017	DP		
	6958326	Dec	20, 2021	DP		
	>A> 6987101	Dec	22, 2017	U-758		
	>A> 6987101	Dec	22, 2017	U-1		
	RE37564	Jun	30, 2014	DP		
	RE37838	Jun	30, 2014	DP		
	RE38253	Jun	30, 2014	DP		
<u>EFAVIRENZ - SUSTIVA</u>						
020972 001	5519021	May	21, 2013	DS	DP	
	5663169	Sep	02, 2014		U-257	
	5811423	Aug	07, 2012	DS	DP	U-256
	6238695	Apr	06, 2019		DP	
<u>EFAVIRENZ - SUSTIVA</u>						
020972 002	5519021	May	21, 2013	DS	DP	
	5663169	Sep	02, 2014		U-257	
	5811423	Aug	07, 2012	DS	DP	U-256
	6238695	Apr	06, 2019		DP	
<u>EFAVIRENZ - SUSTIVA</u>						
020972 003	5519021	May	21, 2013	DS	DP	
	5663169	Sep	02, 2014		U-257	
	5811423	Aug	07, 2012	DS	DP	U-256
	6238695	Apr	06, 2019		DP	
<u>EFAVIRENZ - SUSTIVA</u>						
021360 002	5519021	May	21, 2013	DS	DP	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA					
021937 001	5210085	May 11, 2010		U-750	
	5210085*PED	Nov 11, 2010			
	5519021	May 21, 2013	DS DP		
	5663169	Sep 02, 2014		U-750	
	5811423	Aug 07, 2012		U-750	
	5814639	Sep 29, 2015	DS DP		
	5814639*PED	Mar 29, 2016			
	5914331	Sep 29, 2015	DS		
	5914331*PED	Mar 29, 2016			
	5922695	Jul 25, 2017	DS	U-750	
	5935946	Jul 25, 2017	DS DP	U-750	
	5977089	Jul 25, 2017	DS DP	U-750	
	6043230	Jul 25, 2017		U-750	
	6238695	Apr 06, 2019		DP	
	6555133	Apr 06, 2019		U-750	
	6639071	Nov 13, 2021	DS		
	6642245	Nov 04, 2020		U-750	
	6642245*PED	May 04, 2021			
	6703396	Mar 09, 2021	DS DP		
	6703396*PED	Sep 09, 2021			
	6939964	Jan 20, 2018	DS		
EMTRICITABINE - EMTRIVA					
021500 001	5210085	May 11, 2010		NCE	Jul 02, 2008
	5210085*PED	Nov 11, 2010		PED	Jan 02, 2009
	5814639	Sep 29, 2015			
	5814639*PED	Mar 29, 2016			
	5914331	Sep 29, 2015			
	5914331*PED	Mar 29, 2016			
	6642245	Nov 04, 2020		U-541	
	6642245*PED	May 04, 2021			
	6703396	Mar 09, 2021	DS DP		
	6703396*PED	Sep 09, 2021			
EMTRICITABINE - EMTRIVA					
021896 001	5210085	May 11, 2010		U-257	NDF
	5210085*PED	Nov 11, 2010		NCE	Sep 27, 2008
	5814639	Sep 29, 2015	DS DP	PED	Jul 02, 2008
	5814639*PED	Mar 29, 2016		PED	Mar 27, 2009
	5914331	Sep 29, 2015	DS		Jan 02, 2009
	5914331*PED	Mar 29, 2016			
	6642245	Nov 04, 2020		U-257	
	6642245*PED	May 04, 2021			
	6703396	Mar 09, 2021	DS DP		
	6703396*PED	Sep 09, 2021			
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA					
021752 001	5210085	May 11, 2010		U-248	NCE
	5210085	May 11, 2010		U-541	PED
	5210085*PED	Nov 11, 2010			
	5814639	Sep 29, 2015	DS DP		
	5814639*PED	Mar 29, 2016			
	5914331	Sep 29, 2015	DS DP	U-248	
	5914331*PED	Mar 29, 2016			
	6642245	Nov 04, 2020		U-248	
	6642245	Nov 04, 2020		U-541	
	6642245*PED	May 04, 2021			
	6703396	Mar 09, 2021	DS DP		
	6703396*PED	Sep 09, 2021			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTACAPONE - COMTAN</u>							
020796 001	4963590	Nov 27, 2007		DP	U-219		
	5112861	May 12, 2009			U-219		
	5135950	Oct 31, 2010	DS	DP	U-219		
	6599530	Sep 14, 2018		DP	U-219		
<u>EPLERENONE - INSPRA</u>							
021437 001	4559332	Apr 09, 2007	DS	DP	U-537		
<u>EPLERENONE - INSPRA</u>							
021437 002	4559332	Apr 09, 2007	DS	DP	U-537		
<u>EPLERENONE - INSPRA</u>							
021437 003	4559332	Apr 09, 2007	DS	DP	U-537		
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>							
021323 001	>A> RE34712	Sep 14, 2011	DS	DP			
	>A> RE34712*PED	Mar 14, 2012					
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>							
021323 002	>A> RE34712	Sep 14, 2011	DS	DP			
	>A> RE34712*PED	Mar 14, 2012					
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>							
021323 003	>A> RE34712	Sep 14, 2011	DS	DP			
	>A> RE34712*PED	Mar 14, 2012					
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>							
021153 001	>A> 4738974	Apr 19, 2007	DS	DP	U-770	>A> I-504	Oct 11, 2009
	>A> 4738974	Apr 19, 2007	DS	DP	U-635	I-484	Nov 24, 2007
	>A> 4738974	Apr 19, 2007	DS	DP	U-373	NPP	Apr 28, 2009
	4738974*PED	Oct 19, 2007			U-373		
	>A> 4786505	Apr 20, 2007		DP	U-373		
	>A> 4786505	Apr 20, 2007		DP	U-729		
	>A> 4786505	Apr 20, 2007		DP	U-770		
	>A> 4853230	Apr 20, 2007		DP	U-373		
	>A> 4853230	Apr 20, 2007		DP	U-770		
	>A> 4853230	Apr 20, 2007		DP	U-729		
	>A> 4853230	Apr 20, 2007		DP	U-770		
	>A> 5690960	Nov 25, 2014		DP	U-770		
	>A> 5690960	Nov 25, 2014		DP	U-729		
	>A> 5690960	Nov 25, 2014		DP	U-373		
	>A> 5714504	Feb 03, 2015		DP	U-729		
	>A> 5714504	Feb 03, 2015		DP	U-770		
	>A> 5714504	Feb 03, 2015		DP	U-373		
	>A> 5877192	May 27, 2014		DP	U-373		
	>A> 5877192	May 27, 2014		DP	U-770		
	>A> 5877192	May 27, 2014		DP	U-729		
	>A> 5900424	May 04, 2016	DS		U-770		
	>A> 5900424	May 04, 2016	DS		U-729		
	>A> 5900424	May 04, 2016	DS		U-373		
	>A> 6369085	May 25, 2018	DS	DP	U-729		
	>A> 6369085	May 25, 2018	DS	DP	U-770		
	>A> 6428810	Nov 03, 2019		DP	U-469		
	>A> 6428810	Nov 03, 2019		DP	U-770		
	>A> 6428810	Nov 03, 2019		DP	U-729		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE			PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE		
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>										
021153 002	>A> 4738974	Apr	19,	2007	DS	DP	U-635	>A>	I-504	Oct 11, 2009
	>A> 4738974	Apr	19,	2007	DS	DP	U-770		I-484	Nov 24, 2007
	>A> 4738974	Apr	19,	2007	DS	DP	U-373		NPP	Apr 28, 2009
	4738974*PED	Oct	19,	2007			U-373			
	>A> 4786505	Apr	20,	2007		DP	U-373			
	>A> 4786505	Apr	20,	2007		DP	U-770			
	>A> 4786505	Apr	20,	2007		DP	U-729			
	>A> 4853230	Apr	20,	2007		DP	U-373			
	>A> 4853230	Apr	20,	2007		DP	U-729			
	>A> 4853230	Apr	20,	2007		DP	U-770			
	>A> 5690960	Nov	25,	2014		DP	U-770			
	>A> 5690960	Nov	25,	2014		DP	U-729			
	>A> 5690960	Nov	25,	2014		DP	U-373			
	>A> 5714504	Feb	03,	2015		DP	U-729			
	>A> 5714504	Feb	03,	2015		DP	U-770			
	>A> 5714504	Feb	03,	2015		DP	U-373			
	>A> 5877192	May	27,	2014		DP	U-373			
	>A> 5877192	May	27,	2014		DP	U-770			
	>A> 5877192	May	27,	2014		DP	U-729			
	>A> 5900424	May	04,	2016	DS		U-729			
	>A> 5900424	May	04,	2016	DS		U-770			
	>A> 5900424	May	04,	2016	DS		U-373			
	>A> 6369085	May	25,	2018	DS	DP	U-729			
	>A> 6369085	May	25,	2018	DS	DP	U-770			
	>A> 6428810	Nov	03,	2019		DP	U-469			
	>A> 6428810	Nov	03,	2019		DP	U-770			
	>A> 6428810	Nov	03,	2019		DP	U-729			
<u>ESTRADIOL - ESTRADIOL</u>										
075182 004								PC	Feb 06, 2007	
<u>ESTRADIOL - ESTRADIOL</u>										
075182 005								PC	Feb 06, 2007	
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>										
021840 001								NP	May 25, 2009	
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>										
021180 001	5876746	Nov	20,	2015		DP	U-514			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - OVCON-35</u>										
021490 001	6667050	Apr	06,	2019		DP	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>										
021871 001	5552394	Jul	22,	2014			U-1		NP	Feb 17, 2009
<u>ETONOGESTREL - IMPLANON</u>										
021529 001	4957119	Aug	05,	2008		DP			NDF	Jul 17, 2009
	5150718	Sep	29,	2009			U-749			
<u>EXEMESTANE - AROMASIN</u>										
020753 001								I-495	Oct 05, 2008	
<u>EZETIMIBE - ZETIA</u>										
021445 001	7030106	Jan	25,	2022		DP		I-493	May 23, 2009	
	RE37721	Oct	25,	2016	DS	DP	U-473	>A> M-57	Mar 16, 2009	
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>										
021687 001	RE37721	Oct	25,	2016	DS	DP	U-473	>A> M-58	Mar 16, 2009	
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>										
021687 002	RE37721	Oct	25,	2016	DS	DP	U-473	>A> M-58	Mar 16, 2009	
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>										
021687 003	RE37721	Oct	25,	2016	DS	DP	U-473	>A> M-58	Mar 16, 2009	
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>										
021687 004	RE37721	Oct	25,	2016	DS	DP	U-473	>A> M-58	Mar 16, 2009	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMCICLOVIR - FAMVIR</u>					
020363 001			D-103 I-501	Jul 28, 2009 Jul 28, 2009	
<u>FAMCICLOVIR - FAMVIR</u>					
020363 002			D-103 I-501	Jul 28, 2009 Jul 28, 2009	
<u>FAMCICLOVIR - FAMVIR</u>					
020363 003			D-103 I-501	Jul 28, 2009 Jul 28, 2009	
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>					
021695 001	7101574	Aug 20, 2020	DS DP	M-47	Oct 21, 2008
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>					
021695 003	7101574	Aug 20, 2020	DS DP	M-47	Oct 21, 2008
<u>FENOFIBRATE - FENOFIBRATE</u>					
076433 001				PC	May 22, 2006
<u>FENOFIBRATE - FENOFIBRATE</u>					
076433 002				PC	May 22, 2006
<u>FENOFIBRATE - LIPOFEN</u>					
021612 001	5545628	Jan 10, 2015		U-701	
<u>FENOFIBRATE - LIPOFEN</u>					
021612 002	5545628	Jan 10, 2015		U-701	
<u>FENOFIBRATE - LIPOFEN</u>					
021612 003	5545628	Jan 10, 2015		U-701	
<u>FENOFIBRATE - TRICOR</u>					
021656 001	7037529	Jan 09, 2018	DP		
	7041319	Jan 09, 2018	DP		
<u>FENOFIBRATE - TRICOR</u>					
021656 002	7037529	Jan 09, 2018	DP		
	7041319	Jan 09, 2018	DP		
<u>FENTANYL CITRATE - FENTORA</u>					
021947 001	>A> 6200604	Mar 26, 2019	U-767	NDF	Sep 25, 2009
	>A> 6974590	Mar 26, 2019	U-767		
<u>FENTANYL CITRATE - FENTORA</u>					
021947 002	>A> 6200604	Mar 26, 2019	U-767	NDF	Sep 25, 2009
	>A> 6974590	Mar 26, 2019	U-767		
<u>FENTANYL CITRATE - FENTORA</u>					
021947 003	>A> 6200604	Mar 26, 2019	U-767	NDF	Sep 25, 2009
	>A> 6974590	Mar 26, 2019	U-767		
<u>FENTANYL CITRATE - FENTORA</u>					
021947 004	>A> 6200604	Mar 26, 2019	U-767	NDF	Sep 25, 2009
	>A> 6974590	Mar 26, 2019	U-767		
<u>FENTANYL CITRATE - FENTORA</u>					
021947 005	>A> 6200604	Mar 26, 2019	U-767	NDF	Sep 25, 2009
	>A> 6974590	Mar 26, 2019	U-767		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL HYDROCHLORIDE - IONSYS							
021338 001	5232438	Oct	03, 2008	DP	U-736	NDF	May 22, 2009
	5445606	Dec	11, 2011	DP			
	5697896	Dec	16, 2014	DP			
	5843014	Dec	01, 2015	DP			
	6169920	Jan	02, 2018	DP			
	6171294	Jun	05, 2015		U-736		
	6181963	Nov	02, 2019	DP			
	6195582	Jan	28, 2019	DP	U-736		
	6216033	Jun	05, 2015	DP			
	6317629	Jun	02, 2012	DP			
	6425892	Jun	05, 2015		U-736		
	6842640	Jun	02, 2015	DP			
	6881208	Apr	19, 2022		U-736		
	6975902	Apr	01, 2024	DP			
	7018370	Jun	05, 2015		U-736		
	7027859	Sep	26, 2014	DP			
FEXOFENADINE HYDROCHLORIDE - ALLEGRA							
021963 001	>A> 5578610	Nov	26, 2013	DS	DP	U-772	
	>A> 6037353	Mar	14, 2017			U-772	
	>A> 6187791	May	11, 2012			U-772	
	>A> 6399632	May	11, 2012			U-772	
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR							
021704 001	RE39069	May	29, 2018	DP			
FINASTERIDE - FINASTERIDE							
076340 001						PC	Dec 16, 2006
FLUNISOLIDE - AEROSPAN HFA							
021247 001						NP	Jan 27, 2009
FLUOCINOLONE ACETONIDE - RETISERT							
021737 001	6217895	Mar	22, 2019	DP	U-708		
	6548078	Mar	22, 2019	DP	U-708		
FLUOCINONIDE - VANOS							
021758 001						I-487	Mar 02, 2009
FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY							
021235 001	RE39030	May	29, 2017	DP	U-397		
	RE39030	May	29, 2017	DP	U-396		
FLUTICASONE PROPIONATE - FLOVENT HFA							
021433 001	5658549	Sep	19, 2014	DP	U-710	NPP	Feb 28, 2009
	5674472	Oct	07, 2014	DP			
	6251368	Dec	04, 2012	DP			
FLUTICASONE PROPIONATE - FLOVENT HFA							
021433 002	5658549	Sep	19, 2014	DP	U-710	NPP	Feb 28, 2009
	5674472	Oct	07, 2014	DP			
	6251368	Dec	04, 2012	DP			
FLUTICASONE PROPIONATE - FLOVENT HFA							
021433 003	5658549	Sep	19, 2014	DP	U-710	NPP	Feb 28, 2009
	5674472	Oct	07, 2014	DP			
	6251368	Dec	04, 2012	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50							
021077 001	4992474	Feb	12, 2008		U-211		
	4992474*PED	Aug	12, 2008		U-211		
	5126375	Feb	12, 2008				
	5126375*PED	Aug	12, 2008				
	5225445	Feb	12, 2008		U-211		
	5225445*PED	Aug	12, 2008		U-211		
	6536427	Mar	01, 2011	DP			
	6536427*PED	Sep	01, 2011				

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50						
021077 002	4992474	Feb 12, 2008	U-211			
	4992474*PED	Aug 12, 2008	U-211			
	5126375	Feb 12, 2008				
	5126375*PED	Aug 12, 2008				
	5225445	Feb 12, 2008	U-211			
	5225445*PED	Aug 12, 2008	U-211			
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50						
021077 003	4992474	Feb 12, 2008	U-211			
	4992474*PED	Aug 12, 2008	U-211			
	5126375	Feb 12, 2008				
	5126375*PED	Aug 12, 2008				
	5225445	Feb 12, 2008	U-211			
	5225445*PED	Aug 12, 2008	U-211			
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 001	4992474	Feb 12, 2008	DS DP	U-738	NP	Jun 08, 2009
	4992474*PED	Aug 12, 2008				
	5126375	Feb 12, 2008	DS DP			
	5126375*PED	Aug 12, 2008				
	5225445	Feb 12, 2008		U-738		
	5225445*PED	Aug 12, 2008				
	5270305	Sep 07, 2010		U-738		
	5658549	Aug 19, 2014	DP	U-738		
	5674472	Oct 07, 2014	DP			
	6143277	Apr 14, 2015	DP	U-738		
	6251368	Dec 04, 2012	DP			
	6253762	Apr 14, 2015	DP	U-738		
	6315173	Dec 23, 2017	DP			
	6510969	Dec 23, 2017	DP			
	6524555	Apr 14, 2015	DP			
	6546928	Apr 14, 2015	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 002	4992474	Feb 12, 2008	DS DP	U-738	NP	Jun 08, 2009
	4992474*PED	Aug 12, 2008				
	5126375	Feb 12, 2008	DS DP			
	5126375*PED	Aug 12, 2008				
	5225445	Feb 12, 2008		U-738		
	5225445*PED	Aug 12, 2008				
	5270305	Sep 07, 2010		U-738		
	5658549	Aug 19, 2014	DP	U-738		
	5674472	Oct 07, 2014	DP			
	6143277	Apr 14, 2015	DP	U-738		
	6251368	Dec 04, 2012	DP			
	6253762	Apr 14, 2015	DP	U-738		
	6315173	Dec 23, 2017	DP			
	6510969	Dec 23, 2017	DP			
	6524555	Apr 14, 2015	DP			
	6546928	Apr 14, 2015	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
021254 003	4992474	Feb	12, 2008	DS	DP	U-738	NP Jun 08, 2009
	4992474*PED	Aug	12, 2008				
	5126375	Feb	12, 2008	DS	DP		
	5126375*PED	Aug	12, 2008				
	5225445	Feb	12, 2008			U-738	
	5225445*PED	Aug	12, 2008				
	5270305	Sep	07, 2010			U-738	
	5658549	Aug	19, 2014		DP	U-738	
	5674472	Oct	07, 2014		DP		
	6143277	Apr	14, 2015		DP	U-738	
	6251368	Dec	04, 2012		DP		
	6253762	Apr	14, 2015		DP	U-738	
	6315173	Dec	23, 2017		DP		
	6510969	Dec	23, 2017		DP		
	6524555	Apr	14, 2015		DP		
	6546928	Apr	14, 2015		DP		
FLUVASTATIN SODIUM - LESCOL							
020261 001						>A> I-507	Apr 10, 2009
						>A> PED	Oct 10, 2009
FLUVASTATIN SODIUM - LESCOL							
020261 002						>A> I-507	Apr 10, 2009
						>A> PED	Oct 10, 2009
FLUVASTATIN SODIUM - LESCOL XL							
021192 001						>A> I-507	Apr 10, 2009
						>A> PED	Oct 10, 2009
FORMOTEROL FUMARATE - FORADIL							
020831 001	>A> 6887459	Nov	28, 2020			U-762	
FROVATRIPTAN SUCCINATE - FROVA							
021006 001	5464864	Nov	07, 2015			U-436	
FULVESTRANT - FASLODEX							
021344 001	4659516	Dec	11, 2007	DS	DP	U-596	
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 001						NDF	Apr 01, 2008
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 002						NDF	Apr 01, 2008
GALANTAMINE HYDROBROMIDE - RAZADYNE ER							
021615 003						NDF	Apr 01, 2008
GANIRELIX ACETATE - GANIRELIX ACETATE INJECTION							
021057 001	4801577	Feb	05, 2012	DS	DP		
GEMCITABINE HYDROCHLORIDE - GEMZAR							
020509 001						I-499	Jul 14, 2009
GEMCITABINE HYDROCHLORIDE - GEMZAR							
020509 002						I-499	Jul 14, 2009
GEMIFLOXACIN MESYLATE - FACTIVE							
021158 001	5776944	Apr	04, 2017	DS	DP		
GLIMEPIRIDE - AMARYL							
020496 001						M-54 PED	Nov 28, 2008 May 28, 2009
GLIMEPIRIDE - AMARYL							
020496 002						M-54 PED	Nov 28, 2008 May 28, 2009
GLIMEPIRIDE - AMARYL							
020496 003						M-54 PED	Nov 28, 2008 May 28, 2009

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
021925 001	4687777	Jan 17, 2011	DS			
	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
021925 002	4687777	Jan 17, 2011	DS			
	6150383	Jun 19, 2016			U-753	
	6211205	Jun 19, 2016			U-753	
	6303640	Aug 09, 2016			U-753	
	6329404	Jun 19, 2016	DP		U-753	
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
021700 001	5002953	Sep 17, 2011	DS	DP	U-690	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803*PED	Oct 21, 2015				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
021700 002	5002953	Sep 17, 2011	DS	DP	U-690	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803*PED	Oct 21, 2015				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
021700 003	5002953	Sep 17, 2011	DS	DP	U-690	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803*PED	Oct 21, 2015				
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
021859 001					NCE	Dec 02, 2010
<u>HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE - DUTOPROL</u>						
021956 001					NC	Aug 28, 2009
<u>HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE - DUTOPROL</u>						
021956 002					NC	Aug 28, 2009
<u>HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE - DUTOPROL</u>						
021956 003					NC	Aug 28, 2009
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
020818 004					NS	Apr 28, 2009
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
020818 005					NS	Apr 28, 2009
<u>IBANDRONATE SODIUM - BONIVA</u>						
021455 001	4927814	Jul 09, 2007	DS	DP	U-642	
	6143326	Apr 21, 2017			U-642	
<u>IBANDRONATE SODIUM - BONIVA</u>						
021858 001	4927814	Jul 09, 2007	DS	DP	U-700	
	5662918	Sep 02, 2014	DP		NDF	Jan 06, 2009
					NCE	May 16, 2008
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
021903 001					NE	Apr 13, 2009
					ODE	Apr 13, 2013

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
<u>IMATINIB MESYLATE - GLEEVEC</u>								
021335 001	5521184	Jan	04, 2015	DS	DP	I-392	May 20, 2006	
	5521184*PED	Jul	04, 2015			I-376	Dec 20, 2005	
	6894051	May	23, 2019	DS	DP	U-649	NCE	May 10, 2006
	6894051*PED	Nov	23, 2019				ODE	Feb 01, 2009
	6958335	Dec	19, 2021	DS	DP		ODE	May 10, 2008
	6958335*PED	Jun	19, 2022				PED	Aug 01, 2009
							PED	Nov 10, 2008
							PED	Nov 20, 2006
							PED	Nov 10, 2006
							PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>								
021335 002	5521184	Jan	04, 2015			I-392	May 20, 2006	
	5521184*PED	Jul	04, 2015			I-376	Dec 20, 2005	
	6894051	May	23, 2019	DS	DP	U-649	NCE	May 10, 2006
	6894051*PED	Nov	23, 2019				ODE	Feb 01, 2009
	6958335	Dec	19, 2021	DS	DP		ODE	May 10, 2008
	6958335*PED	Jun	19, 2022				PED	Aug 01, 2009
							PED	Nov 10, 2008
							PED	Nov 20, 2006
							PED	Nov 10, 2006
							PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>								
021588 001	5521184	Jan	04, 2015	DS	DP	>A> I-514	Oct 19, 2009	
	5521184*PED	Jul	04, 2015			>A> I-513	Oct 19, 2009	
	6894051	May	23, 2019	DS	DP	U-649	>A> I-512	Oct 19, 2009
	6894051*PED	Nov	23, 2019				>A> I-511	Oct 19, 2009
	6958335	Dec	19, 2021	DS	DP		>A> I-510	Oct 19, 2009
	6958335*PED	Jun	19, 2022				I-392	May 20, 2006
							I-376	Dec 20, 2005
							NCE	May 10, 2006
							ODE	Feb 01, 2009
							ODE	May 10, 2008
							PED	Aug 01, 2009
							PED	Nov 10, 2008
							PED	Nov 20, 2006
							PED	Nov 10, 2006
							PED	Jun 20, 2006
<u>IMATINIB MESYLATE - GLEEVEC</u>								
021588 002	5521184	Jan	04, 2015			>A> I-514	Oct 19, 2009	
	5521184*PED	Jul	04, 2015			>A> I-513	Oct 19, 2009	
	6894051	May	23, 2019	DS	DP	U-649	>A> I-512	Oct 19, 2009
	6894051*PED	Nov	23, 2019				>A> I-511	Oct 19, 2009
	6958335	Dec	19, 2021	DS	DP		>A> I-510	Oct 19, 2009
	6958335*PED	Jun	19, 2022				I-392	May 20, 2006
							I-376	Dec 20, 2005
							NCE	May 10, 2006
							ODE	Feb 01, 2009
							ODE	May 10, 2008
							PED	Aug 01, 2009
							PED	Nov 10, 2008
							PED	Nov 20, 2006
							PED	Nov 10, 2006
							PED	Jun 20, 2006
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>								
021536 001							I-489	Oct 19, 2008
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>								
021081 001	>A> 6100376	Nov	06, 2009	DS	DP	U-771		
	>A> 6100376*PED	May	06, 2010					

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>					
021868 001	5740794	Apr 21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar 07, 2014		U-704	
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019		U-704	
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019		U-704	
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014		U-704	
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>					
021868 002	5740794	Apr 21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar 07, 2014		U-704	
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019		U-704	
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019		U-704	
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014		U-704	
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		
<u>IODINE POVACRYLEX; ISOPROPYL ALCOHOL - DURAPREP</u>					
021586 001				>A> NC	Sep 29, 2009
<u>IODINE POVACRYLEX; ISOPROPYL ALCOHOL - DURAPREP</u>					
021586 002				>A> NC	Sep 29, 2009
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>					
021527 001	6983743	May 26, 2020	DP		
<u>KETOCONAZOLE - XOLEGEL</u>					
021946 001				>A> NDF	Jul 28, 2009
<u>KETOTIFEN FUMARATE - KETOTIFEN FUMARATE</u>					
077354 001				>A> PC	Dec 30, 2006
<u>LAMOTRIGINE - LAMOTRIGINE</u>					
076420 001				>A> PC	Feb 25, 2007
<u>LAMOTRIGINE - LAMOTRIGINE</u>					
076420 002				PC	Dec 25, 2006
<u>LANSOPRAZOLE - PREVACID</u>					
020406 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
020406 002	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021281 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021281 002	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021428 001	6749864	Feb 13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>					
021428 002	6749864	Feb 13, 2007	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>					
021468 003	5968976	Mar 19, 2016	DP	U-613	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 004	5968976	Mar	19, 2016	DP	U-613	
<u>LENALIDOMIDE - REVLIMID</u>						
021880 001	5635517	Jul	24, 2016	DS		
	6045501	Aug	28, 2018		U-694	
>A>	6281230	Jul	24, 2016		U-769	
	6315720	Oct	23, 2020		U-694	
	6555554	Jul	24, 2016	DP		
	6561976	Aug	28, 2018		U-694	
	6561977	Oct	23, 2020		U-694	
	6755784	Oct	23, 2020		U-694	
	6908432	Aug	28, 2018		U-694	
>A>	7119106	Jul	24, 2016	DP		
<u>LENALIDOMIDE - REVLIMID</u>						
021880 002	5635517	Jul	24, 2016	DS		
	6045501	Aug	28, 2018		U-694	
>A>	6281230	Jul	24, 2016		U-769	
	6315720	Oct	23, 2020		U-694	
	6555554	Jul	24, 2016	DP		
	6561976	Aug	28, 2018		U-694	
	6561977	Oct	23, 2020		U-694	
	6755784	Oct	23, 2020		U-694	
	6908432	Aug	28, 2018		U-694	
>A>	7119106	Jul	24, 2016	DP		
<u>LENALIDOMIDE - REVLIMID</u>						
021880 003	5635517	Jul	24, 2016	DS		
	6045501	Aug	28, 2018		U-694	
>A>	6281230	Jul	24, 2016		U-769	
	6315720	Oct	23, 2020		U-694	
	6555554	Jul	24, 2016	DP		
	6561976	Aug	28, 2018		U-694	
	6561977	Oct	23, 2020		U-694	
	6755784	Oct	23, 2020		U-694	
	6908432	Aug	28, 2018		U-694	
>A>	7119106	Jul	24, 2016	DP		
<u>LENALIDOMIDE - REVLIMID</u>						
021880 004	5635517	Jul	24, 2016	DS		
	6045501	Aug	28, 2018		U-694	
>A>	6281230	Jul	24, 2016		U-769	
	6315720	Oct	23, 2020		U-694	
	6555554	Jul	24, 2016	DP		
	6561976	Aug	28, 2018		U-694	
	6561977	Oct	23, 2020		U-694	
	6755784	Oct	23, 2020		U-694	
	6908432	Aug	28, 2018		U-694	
>A>	7119106	Jul	24, 2016	DP		
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
021730 001	5362755	Mar	25, 2013		U-636	
<u>LEVETIRACETAM - KEPPTRA</u>						
021035 001					>A> I-506	Aug 15, 2009
<u>LEVETIRACETAM - KEPPTRA</u>						
021035 002					>A> I-506	Aug 15, 2009
<u>LEVETIRACETAM - KEPPTRA</u>						
021035 003					>A> I-506	Aug 15, 2009
<u>LEVETIRACETAM - KEPPTRA</u>						
021035 004	4943639	Jul	14, 2008	DS		
					>A> I-506	Aug 15, 2009
					NPP	Jun 21, 2008

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE			
<u>LEVETIRACETAM - KEPPRA</u>									
021505 001				>A> I-506		Aug 15, 2009			
<u>LEVETIRACETAM - KEPPRA</u>				NDF		Jul 31, 2009			
021872 001 4943639		Jul 14, 2008	DS						
<u>LEVOBETAXOLOL HYDROCHLORIDE - BETAXON</u>									
021114 001 >A> 4911920		Mar 27, 2007	DS	DP	U-191				
021114 001 >A> 4911920		Mar 27, 2007	DS	DP	U-369				
021114 001 4911920*PED		Sep 27, 2007							
>A> 5540918		Jul 30, 2013			DP				
021114 001 5540918*PED		Jan 30, 2014							
<u>LEVONORGESTREL - PLAN B</u>				NP		Aug 24, 2009			
021045 002									
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 001 7067148		Feb 15, 2022	DP						
021301 001 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 002 7067148		Feb 15, 2022	DP						
021301 002 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 003 7067148		Feb 15, 2022	DP						
021301 003 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 004 7067148		Feb 15, 2022	DP						
021301 004 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 005 7067148		Feb 15, 2022	DP						
021301 005 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 006 7067148		Feb 15, 2022	DP						
021301 006 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 007 7067148		Feb 15, 2022	DP						
021301 007 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 008 7067148		Feb 15, 2022	DP						
021301 008 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 009 7067148		Feb 15, 2022	DP						
021301 009 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 010 7067148		Feb 15, 2022	DP						
021301 010 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 011 7067148		Feb 15, 2022	DP						
021301 011 >A> 7101569		Aug 14, 2022			U-759				
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>									
021301 012 7067148		Feb 15, 2022	DP						
021301 012 >A> 7101569		Aug 14, 2022			U-759				
<u>LIDOCAINE; TETRACAINE - LIDOCAINE AND TETRACAINE</u>									
021717 001 5919479		Jul 28, 2015	DP		NP		Jun 29, 2009		
021717 001 6528086		Sep 28, 2019	DP						
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						NC		Jun 23, 2008	
021623 001									

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>							
021906 001	5541206	Jul	30, 2013	DS	DP	U-688	
	5541206*PED	Jan	30, 2014				
	5635523	Jun	03, 2014			U-688	
	5635523*PED	Dec	03, 2014				
	5648497	Jul	15, 2014	DS	DP		
	5648497*PED	Jan	15, 2015				
	5674882	Oct	07, 2014			U-688	
	5674882*PED	Apr	07, 2015				
	5846987	Dec	29, 2012			U-688	
	5846987*PED	Jun	29, 2013				
	5886036	Dec	29, 2012		DP		
	5886036*PED	Jun	29, 2013				
	6037157	Jun	26, 2016			U-688	
	6037157*PED	Dec	26, 2016				
	6703403	Jun	26, 2016			U-688	
	6703403*PED	Dec	26, 2016				
<u>LOVASTATIN; NIACIN - ADVICOR</u>							
021249 001	>A> 6469035	Mar	15, 2018			U-768	
	7011848	Sep	20, 2013			U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>							
021249 002	>A> 6469035	Mar	15, 2018			U-768	
	7011848	Sep	20, 2013			U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>							
021249 003	>A> 6469035	Mar	15, 2018			U-768	
	7011848	Sep	20, 2013			U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>							
021249 004	>A> 6469035	Mar	15, 2018			U-768	
<u>LUBIPROSTONE - AMITIZA</u>							
021908 001	5284858	Feb	08, 2011	DS	DP	NCE	Jan 31, 2011
	5317032	May	31, 2011	DS	DP		
	6414016	Sep	05, 2020	DS	DP		
	6583174	Oct	16, 2020	DS	DP		
	7064148	Aug	30, 2022	DS	DP		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>							
021850 001	6489346	Jul	16, 2016	DS	DP	U-623	
	6489346	Jul	16, 2016	DS	DP	U-588	
	6645988	Jul	16, 2016	DS	DP	U-623	
	6645988	Jul	16, 2016	DS	DP	U-588	
	6699885	Jul	16, 2016			U-623	
	6699885	Jul	16, 2016			U-588	
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>							
021850 002	6489346	Jul	16, 2016	DS	DP	U-623	
	6489346	Jul	16, 2016	DS	DP	U-588	
	6645988	Jul	16, 2016	DS	DP	U-623	
	6645988	Jul	16, 2016	DS	DP	U-588	
	6699885	Jul	16, 2016			U-623	
	6699885	Jul	16, 2016			U-588	
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>							
021884 001	5200509	Apr	06, 2010	DS			
	5681818	Oct	28, 2014			U-697	
<u>MEGESTROL ACETATE - MEGACE ES</u>							
021778 001	7101576	Apr	22, 2024			U-755	
<u>MELOXICAM - MOBIC</u>							
020938 001						ODE	Aug 11, 2012
						PED	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM - MOBIC</u>					
	020938 002			ODE PED	Aug 11, 2012 Feb 11, 2013
<u>MELOXICAM - MOBIC</u>					
	021530 001			I-469 ODE PED PED	Aug 11, 2008 Aug 11, 2012 Feb 11, 2013 Feb 11, 2009
<u>MEQUINOL; TRETINOIN - SOLAGE</u>					
	020922 001	5194247 Dec 10, 2013	DP	U-294	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 001	5002953	Sep 17, 2011	DS DP	U-690	I-494 May 19, 2009
	5002953	Sep 17, 2011	DS DP	U-734	
	5002953	Sep 17, 2011	DS DP	U-691	
	5002953	Sep 17, 2011	DS DP	U-493	
	5741803	Apr 21, 2015	DS DP	U-734	
	5741803	Apr 21, 2015	DS DP	U-493	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 002	5002953	Sep 17, 2011	DS DP	U-690	I-494 May 19, 2009
	5002953	Sep 17, 2011	DS DP	U-734	
	5002953	Sep 17, 2011	DS DP	U-691	
	5002953	Sep 17, 2011	DS DP	U-493	
	5741803	Apr 21, 2015	DS DP	U-734	
	5741803	Apr 21, 2015	DS DP	U-493	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 003	5002953	Sep 17, 2011	DS DP	U-691	I-494 May 19, 2009
	5002953	Sep 17, 2011	DS DP	U-734	
	5002953	Sep 17, 2011	DS DP	U-690	
	5002953	Sep 17, 2011	DS DP	U-493	
	5741803	Apr 21, 2015	DS DP	U-734	
	5741803	Apr 21, 2015	DS DP	U-493	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 004	5002953	Sep 17, 2011	DS DP	U-691	I-494 May 19, 2009
	5002953	Sep 17, 2011	DS DP	U-734	
	5002953	Sep 17, 2011	DS DP	U-690	
	5002953	Sep 17, 2011	DS DP	U-493	
	5741803	Apr 21, 2015	DS DP	U-734	
	5741803	Apr 21, 2015	DS DP	U-493	
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>					
021410 005	5002953	Sep 17, 2011	DS DP	U-690	I-494 May 19, 2009
	5002953	Sep 17, 2011	DS DP	U-734	
	5002953	Sep 17, 2011	DS DP	U-691	
	5002953	Sep 17, 2011	DS DP	U-493	
	5741803	Apr 21, 2015	DS DP	U-734	
	5741803	Apr 21, 2015	DS DP	U-493	
	5741803*PED	Oct 21, 2015			
<u>METHYLPHENIDATE - DAYTRANA</u>					
021514 001	5958446	Dec 12, 2012	DP		NDF Apr 06, 2009
	6210705	Sep 30, 2018	DP	U-727	
	6348211	Sep 30, 2018	DP	U-727	
<u>METHYLPHENIDATE - DAYTRANA</u>					
021514 002	5958446	Dec 12, 2012	DP		NDF Apr 06, 2009
	6210705	Sep 30, 2018	DP	U-727	
	6348211	Sep 30, 2018	DP	U-727	
<u>METHYLPHENIDATE - DAYTRANA</u>					
021514 003	5958446	Dec 12, 2012	DP		NDF Apr 06, 2009
	6210705	Sep 30, 2018	DP	U-727	
	6348211	Sep 30, 2018	DP	U-727	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE - DAYTRANA					
021514 004	5958446	Dec 12, 2012	DP		
	6210705	Sep 30, 2018	DP	U-727	
	6348211	Sep 30, 2018	DP	U-727	
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD					
021259 001	6344215	Oct 27, 2020	DP		
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD					
021259 002	6344215	Oct 27, 2020	DP		
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD					
021259 003	6344215	Oct 27, 2020	DP		
METHYLPHENIDATE HYDROCHLORIDE - METADATE CD					
021259 004	6344215	Oct 27, 2020	DP		
METOPROLOL SUCCINATE - TOPROL-XL					
019962 001	4927640	May 22, 2007	DP		
	4927640*PED	Nov 22, 2007		D-95	Feb 15, 2008
	4957745	Sep 18, 2007	DP	PED	Aug 15, 2008
	4957745*PED	Mar 18, 2008		U-107	
	5001161	Sep 18, 2007	DP		
	5001161*PED	Mar 18, 2008			
	5081154	Sep 18, 2007	DS		
	5081154*PED	Mar 18, 2008			
METOPROLOL SUCCINATE - TOPROL-XL					
019962 002	4927640	May 22, 2007	DP		
	4927640*PED	Nov 22, 2007		D-95	Feb 15, 2008
	4957745	Sep 18, 2007	DP	PED	Aug 15, 2008
	4957745*PED	Mar 18, 2008		U-107	
	5001161	Sep 18, 2007	DP		
	5001161*PED	Mar 18, 2008			
	5081154	Sep 18, 2007	DS		
	5081154*PED	Mar 18, 2008			
METOPROLOL SUCCINATE - TOPROL-XL					
019962 003	4927640	May 22, 2007	DP		
	4927640*PED	Nov 22, 2007		D-95	Feb 15, 2008
	4957745	Sep 18, 2007	DP	PED	Aug 15, 2008
	4957745*PED	Mar 18, 2008		U-107	
	5001161	Sep 18, 2007	DP		
	5001161*PED	Mar 18, 2008			
	5081154	Sep 18, 2007	DS		
	5081154*PED	Mar 18, 2008			
METOPROLOL SUCCINATE - TOPROL-XL					
019962 004	4927640	May 22, 2007	DP		
	4927640*PED	Nov 22, 2007		D-95	Feb 15, 2008
	4957745	Sep 18, 2007	DP	PED	Aug 15, 2008
	4957745*PED	Mar 18, 2008		U-107	
	5001161	Sep 18, 2007	DP		
	5001161*PED	Mar 18, 2008			
	5081154	Sep 18, 2007	DS		
	5081154*PED	Mar 18, 2008			
METRONIDAZOLE - METROGEL					
021789 001	6881726	Feb 21, 2022	DP	U-743	
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION					
021026 001	4911932	Mar 27, 2007	DP	U-718	
MINOXIDIL - MEN'S ROGAINE					
021812 001	6946120	Apr 20, 2019	DP	U-702	
				NDF	Jan 20, 2009

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MODAFINIL - PROVIGIL</u>						
020717 001	4927855	May	22, 2007	U-255	I-449	Jan 23, 2007
	4927855*PED	Nov	22, 2007		ODE	Dec 24, 2005
	RE37516	Oct	06, 2014	U-255	PED	Jul 23, 2007
	RE37516*PED	Apr	06, 2015		PED	Jun 24, 2006
<u>MODAFINIL - PROVIGIL</u>						
020717 002	4927855	May	22, 2007	U-255	I-449	Jan 23, 2007
	4927855*PED	Nov	22, 2007		ODE	Dec 24, 2005
	RE37516	Oct	06, 2014	U-255	PED	Jul 23, 2007
	RE37516*PED	Apr	06, 2015		PED	Jun 24, 2006
<u>MORPHINE SULFATE - KADIAN</u>						
020616 004	5378474	Mar	23, 2010			
<u>MORPHINE SULFATE - KADIAN</u>						
020616 005	5202128	Apr	13, 2010			
	5378474	Mar	23, 2010			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
021085 001	4990517	Dec	08, 2011	DS	DP	U-298
	6610327	Oct	29, 2019		DP	U-298
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
021277 001	4990517	Dec	08, 2011	DS	DP	U-298
	6548079	Jul	25, 2020		DP	U-298
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
021598 001	4990517	Dec	08, 2011	DS	DP	U-709
	4990517*PED	Jun	08, 2012			
<u>NALTREXONE - VIVITROL</u>						
021897 001	5792477	May	02, 2017	DP		
	5916598	May	02, 2017	DP		
	6110503	May	02, 2017	DP		
	6194006	Dec	30, 2018	DP		
	6264987	May	19, 2020	DP		
	6331317	Nov	12, 2019	DP		
	6379703	Dec	30, 2018	DP		
	6379704	May	19, 2020	DP		
	6395304	Nov	12, 2019	DP		
	6403114	May	02, 2017	DP		
	6495164	May	25, 2020	DP		
	6495166	Nov	12, 2019	DP		
	6534092	May	19, 2020	DP		
	6537586	Nov	12, 2019	DP		
	6596316	Dec	30, 2018	DP		
	6667061	May	25, 2020	DP		
	6713090	Nov	12, 2019	DP		
	6939033	Nov	12, 2019	DP		
<u>NELARABINE - ARRANON</u>						
021877 001	5747472	Feb	20, 2013		U-696	
	5747472	Feb	20, 2013		U-695	
	5747472	Feb	20, 2013		U-689	
	5821236	Feb	20, 2013		U-695	
<u>NIACIN - NIASPAN</u>						
020381 001	7011848	Sep	20, 2013		U-712	
<u>NIACIN - NIASPAN</u>						
020381 002	>A> 6469035	Mar	15, 2018		U-768	
	7011848	Sep	20, 2013		U-712	
<u>NIACIN - NIASPAN</u>						
020381 003	>A> 6469035	Mar	15, 2018		U-768	
	7011848	Sep	20, 2013		U-712	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>					
020381 004	>A> 6469035 7011848	Mar 15, 2018 Sep 20, 2013		U-768 U-712	
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>					
020381 005	7011848	Sep 20, 2013		U-712	
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 001				PC	Aug 21, 2006
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>					
077007 002				PC	Aug 21, 2006
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 001	5753618 5753618*PED	May 19, 2015 Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 002	5753618 5753618*PED	May 19, 2015 Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 003	5753618 5753618*PED	May 19, 2015 Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 004	5753618 5753618*PED	May 19, 2015 Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>					
019667 005	5753618 5753618*PED	May 19, 2015 Nov 19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 001	5538739 5538739*PED 5639480 5639480*PED 5688530 5688530*PED 5922338 5922338*PED 5922682 5922682*PED	Jul 23, 2013 Jan 23, 2014 Jun 17, 2014 Dec 17, 2014 Nov 18, 2014 May 18, 2015 Jul 13, 2016 Jan 13, 2017 Jul 13, 2016 Jan 13, 2017	DP	M-55 ODE PED PED	May 10, 2009 Nov 25, 2005 Nov 10, 2009 May 25, 2006
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 002	5538739 5538739*PED 5639480 5639480*PED 5688530 5688530*PED 5922338 5922338*PED 5922682 5922682*PED	Jul 23, 2013 Jan 23, 2014 Jun 17, 2014 Dec 17, 2014 Nov 18, 2014 May 18, 2015 Jul 13, 2016 Jan 13, 2017 Jul 13, 2016 Jan 13, 2017	DP	M-55 ODE PED PED	May 10, 2009 Nov 25, 2005 Nov 10, 2009 May 25, 2006
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>					
021008 003	5538739 5538739*PED 5639480 5639480*PED 5688530 5688530*PED 5922338 5922338*PED 5922682 5922682*PED	Jul 23, 2013 Jan 23, 2014 Jun 17, 2014 Dec 17, 2014 Nov 18, 2014 May 18, 2015 Jul 13, 2016 Jan 13, 2017 Jul 13, 2016 Jan 13, 2017	DP	M-55 ODE PED PED	May 25, 2009 Nov 25, 2005 Nov 25, 2009 May 25, 2006

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
021545 001	>A> 5116863	Dec	18, 2010	DS	DP	
	>A> 5641805	Jun	06, 2015		U-765	
	>A> 6995186	Nov	12, 2023	DP	U-765	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
021849 001	6489346	Jul	16, 2016	DS	DP	U-588
	6645988	Jul	16, 2016	DS	DP	
	6699885	Jul	16, 2016		U-588	
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
021849 002	6489346	Jul	16, 2016	DS	DP	U-623
	6489346	Jul	16, 2016	DS	DP	U-588
	6645988	Jul	16, 2016	DS	DP	
	6699885	Jul	16, 2016		U-623	
	6699885	Jul	16, 2016		U-588	
<u>OXALIPLATIN - ELOXATIN</u>						
021492 001	5290961	Jan	12, 2013		I-441	Nov 04, 2007
	5290961*PED	Jul	12, 2013		I-425	Jan 09, 2007
	5338874	Apr	07, 2013	DS	NCE	Aug 09, 2007
	5338874*PED	Oct	07, 2013		PED	May 04, 2008
	5420319	Aug	09, 2016	DS	PED	Feb 09, 2008
	5420319*PED	Aug	09, 2016		PED	Jul 09, 2007
<u>OXALIPLATIN - ELOXATIN</u>						
021492 002	5290961	Jan	12, 2013		>A> I-514	Oct 19, 2009
	5290961*PED	Jul	12, 2013		>A> I-513	Oct 19, 2009
	5338874	Apr	07, 2013	DS	>A> I-512	Oct 19, 2009
	5338874*PED	Oct	07, 2013		>A> I-511	Oct 19, 2009
	5420319	Aug	09, 2016	DS	>A> I-510	Oct 19, 2009
	5420319*PED	Aug	09, 2016		I-441	Nov 04, 2007
					I-425	Jan 09, 2007
					NCE	Aug 09, 2007
					PED	May 04, 2008
					PED	Feb 09, 2008
					PED	Jul 09, 2007
<u>OXALIPLATIN - ELOXATIN</u>						
021759 001	5290961	Jan	12, 2013	DS	I-441	Nov 04, 2007
	5290961*PED	Jul	12, 2013		NCE	Aug 09, 2007
	5338874	Apr	07, 2013	DS	PED	May 04, 2008
	5338874*PED	Oct	07, 2013		PED	Feb 09, 2008
	5420319	Aug	08, 2016	DS		
	5420319*PED	Feb	08, 2017			
	5716988	Aug	07, 2015		DP	
	5716988*PED	Feb	07, 2016			
<u>OXALIPLATIN - ELOXATIN</u>						
021759 002	5290961	Jan	12, 2013	DS	I-441	Nov 04, 2007
	5290961*PED	Jul	12, 2013		NCE	Aug 09, 2007
	5338874	Apr	07, 2013	DS	PED	May 04, 2008
	5338874*PED	Oct	07, 2013		PED	Feb 09, 2008
	5420319	Aug	08, 2016	DS		
	5420319*PED	Feb	08, 2017			
	5716988	Aug	07, 2015		DP	
	5716988*PED	Feb	07, 2016			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021014 001	7037525	Feb	12, 2018		U-724	
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021014 002	7037525	Feb	12, 2018		U-724	
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021014 003	7037525	Feb	12, 2018		U-724	
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021285 001	7037525	Feb	12, 2018		U-724	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
020553 001	>A> 5266331	Oct	26, 2007	DP		
	>A> 5549912	Oct	26, 2007	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
020553 002	>A> 5266331	Oct	26, 2007	DP		
	>A> 5549912	Oct	26, 2007	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
020553 003	>A> 5266331	Oct	26, 2007	DP		
	>A> 5549912	Oct	26, 2007	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
020553 004	>A> 5266331	Oct	26, 2007	DP		
	>A> 5549912	Oct	26, 2007	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
020553 005	>A> 5266331	Oct	26, 2007	DP		
	>A> 5549912	Oct	26, 2007	DP		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
020553 006	>A> 5266331	Oct	26, 2007	DP		
	>A> 5508042	Apr	16, 2013		U-443	
	>A> 5549912	Oct	26, 2007	DP		
	>A> 5656295	Oct	26, 2007	DP	U-443	
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
020553 007	>A> 5266331	Oct	26, 2007	DP		
	>A> 5508042	Apr	16, 2013		U-443	
	>A> 5549912	Oct	26, 2007	DP		
	>A> 5656295	Oct	26, 2007	DP	U-443	
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
020553 008	>A> 5266331	Oct	26, 2007	DP		
	>A> 5508042	Apr	16, 2013		U-443	
	>A> 5549912	Oct	26, 2007	DP		
	>A> 5656295	Oct	26, 2007	DP	U-443	
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
021611 001					NDF	Jun 22, 2009
<u>OXYMORPHONE HYDROCHLORIDE - OPANA</u>						
021611 002					NDF	Jun 22, 2009
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
021610 001	5128143	Sep	19, 2008	DP		NDF
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
021610 002	5128143	Sep	19, 2008	DP		NDF
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
021610 003	5128143	Sep	19, 2008	DP		NDF
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
021610 004	5128143	Sep	19, 2008	DP		NDF
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
020031 004	6133289	May	19, 2015		U-358	
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
020031 005	6133289	May	19, 2015		U-358	
<u>POLYETHYLENE GLYCOL 3350 - MIRALAX</u>						
022015 001					>A> NP	Oct 06, 2009
<u>POSACONAZOLE - NOXAFILE</u>						
022003 001	>A> 5661151	Aug	26, 2014	DS	DP	U-760
	>A> 5703079	Dec	30, 2014	DS	DP	U-760
	>A> 6958337	Sep	25, 2020	DS	DP	U-760
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 001	4843086	Jun	27, 2006		U-231	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 002	4843086	Jun	27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 003	4843086	Jun	27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 004	4843086	Jun	27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 005	4843086	Jun	27, 2006		U-231	
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 006	4843086	Jun	27, 2006		U-231	
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>						
076056 001					PC	Oct 21, 2006
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>						
076056 002					PC	Oct 21, 2006
<u>PRAVASTATIN SODIUM - PRAVASTATIN SODIUM</u>						
076056 003					PC	Oct 21, 2006
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
021959 001	>A> 5178878	Jan	12, 2010	DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
021959 002	>A> 5178878	Jan	12, 2010	DP		
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
021959 003	>A> 5178878	Jan	12, 2010	DP		
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 001					>A> I-503	Oct 20, 2009
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 002					>A> I-503	Oct 20, 2009
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 003					>A> I-503	Oct 20, 2009
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 004					>A> I-503	Oct 20, 2009
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 005					>A> I-503	Oct 20, 2009
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 006	4879288	Sep	26, 2011	DS DP	U-550	>A> I-503
<u>QUETIAPINE FUMARATE - SEROQUEL</u>						
020639 007	4879288	Sep	26, 2011	DS DP	U-550	>A> I-503
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
020815 001	RE38968	Jul	28, 2012		U-662	
	RE38968	Jul	28, 2012		U-657	
	RE39049	Jul	28, 2012		U-662	
	RE39049	Jul	28, 2012		U-657	
	RE39050	Mar	02, 2014		U-662	
	RE39050	Mar	02, 2014		U-657	
<u>RAMIPRIL - ALTACE</u>						
019901 001	5061722	Oct	19, 2008			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - RANEXA</u>						
021526 002	4567264	May 18, 2007	DS		NCE	Jan 27, 2011
	6303607	May 27, 2019		U-705		
	6369062	May 27, 2019		DP		
	6479496	May 27, 2019		U-705		
	6503911	May 27, 2019		DP		
	6525057	May 27, 2019		U-705		
	6562826	May 27, 2019		U-705		
	6617328	May 27, 2019		DP		
	6620814	May 27, 2019		U-705		
	6852724	May 27, 2019		U-705		
	6864258	May 27, 2019		U-705		
<u>RASAGILINE MESYLATE - AZILECT</u>						
021641 001	5387612	Feb 07, 2012		U-219	NCE	May 16, 2011
	5453446	Feb 07, 2012		U-219		
	5457133	Feb 07, 2012	DS	DP		
	5532415	Jul 02, 2013	DS			
	5786390	Feb 07, 2012		DP		
	6126968	Sep 18, 2016		DP		
<u>RASAGILINE MESYLATE - AZILECT</u>						
021641 002	5387612	Feb 07, 2012		U-219	NCE	May 16, 2011
	5453446	Feb 07, 2012		U-219		
	5457133	Feb 07, 2012	DS	DP		
	5532415	Jul 02, 2013	DS			
	5786390	Feb 07, 2012		DP		
	6126968	Sep 18, 2016		DP		
<u>RIFAXIMIN - XIFAXAN</u>						
021361 001	7045620	May 22, 2024	DS			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 001					M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 002					M-52	Jan 24, 2009
<u>RISEDRONATE SODIUM - ACTONEL</u>						
020835 003	5583122	Dec 10, 2013	DS	DP	U-756	I-309
	5583122	Dec 10, 2013	DS	DP	U-222	M-52
	6096342	Nov 22, 2011		DP		
<u>RISPERIDONE - RISPERDAL</u>						
020272 001					>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
020272 002					>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
020272 003					>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
020272 004					>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
020272 007					>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
020272 008					>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
020588 001	RE39181	Jul 11, 2014		DP	>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
021444 001					>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
021444 002					>A> I-509	Oct 06, 2009
<u>RISPERIDONE - RISPERDAL</u>						
021444 003					>A> I-509	Oct 06, 2006

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL</u>					>A> I-509	Oct 06, 2006
021444 004						
<u>RISPERIDONE - RISPERDAL</u>					>A> I-509	Oct 06, 2009
021444 005						
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
020823 003 4948807		Aug 14, 2012	DS	U-322		
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
020823 004 4948807		Aug 14, 2012	DS	U-322		
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
020823 005 4948807		Aug 14, 2012	DS	U-322		
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
020823 006 4948807		Aug 14, 2012	DS	U-322		
<u>RIVASTIGMINE TARTRATE - EXELON</u>						
021025 001 4948807		Aug 14, 2012	DS	U-322		
<u>ROCUROMIUM BROMIDE - ZEMURON</u>						
020214 003 4894369		Apr 13, 2008				
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
020236 001 4992474		Feb 12, 2008				
4992474*PED		Aug 12, 2008				
5126375		Feb 12, 2008				
5126375*PED		Aug 12, 2008				
5225445		Feb 12, 2008		U-182		
5225445*PED		Aug 12, 2008				
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
020692 001 4992474		Feb 12, 2008				
4992474*PED		Aug 12, 2008				
5126375		Feb 12, 2008				
5126375*PED		Aug 12, 2008		U-211		
5225445		Feb 12, 2008				
5225445*PED		Aug 12, 2008				
>A> 6536427		Mar 01, 2011	DP			
<u>SELEGILINE - EMSAM</u>						
021336 001 7070808		May 10, 2018	DS	DP	NDF	Feb 27, 2009
RE34579		Aug 18, 2007	DS	DP	U-711	
<u>SELEGILINE - EMSAM</u>						
021336 002 RE34579		Aug 18, 2007	DS	DP	U-711	Feb 27, 2009
<u>SELEGILINE - EMSAM</u>						
021336 003 RE34579		Aug 18, 2007	DS	DP	U-711	Feb 27, 2009
<u>SELEGILINE HYDROCHLORIDE - ZELAPAR</u>						
021479 001 5648093		Jul 15, 2014	DP			
6423342		Mar 01, 2016	DP			
<u>SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE</u>						
075719 001				PC		Feb 06, 2007
<u>SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE</u>						
075719 002				PC		Feb 06, 2007
<u>SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE</u>						
075719 003				PC		Feb 06, 2007
<u>SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE</u>						
076934 001				PC		Feb 03, 2007
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
020990 001 6727283		Oct 11, 2019	DP	U-580		
6727283*PED		Apr 11, 2020				
7067555		Nov 10, 2019	DP			
7067555*PED		May 10, 2020				

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>					
021179 001	7014846	Aug 11, 2013	DP	U-246	
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>					
021179 002	7014846	Aug 11, 2013	DP	U-246	
<u>SIMVASTATIN - SIMVASTATIN</u>					
076052 001				PC	Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>					
076052 002				PC	Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>					
076052 003				PC	Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>					
076052 004				PC	Dec 20, 2006
<u>SIMVASTATIN - SIMVASTATIN</u>					
076285 005				PC	Dec 20, 2006
<u>SIMVASTATIN - ZOCOR</u>					
019766 001	RE36481 ***	Jul 10, 2007		U-300	
	RE36481*PED	Jan 10, 2008		U-300	
	RE36520 ***	May 26, 2009		U-300	
	RE36520*PED	Nov 26, 2009		U-300	
<u>SIMVASTATIN - ZOCOR</u>					
019766 002	RE36481 ***	Jul 10, 2007		U-300	
	RE36481*PED	Jan 10, 2008		U-300	
	RE36520 ***	May 26, 2009		U-300	
	RE36520*PED	Nov 26, 2009		U-300	
<u>SIMVASTATIN - ZOCOR</u>					
019766 003	RE36481 ***	Jul 10, 2007		U-300	
	RE36481*PED	Jan 10, 2008		U-300	
	RE36520 ***	May 26, 2009		U-300	
	RE36520*PED	Nov 26, 2009		U-300	
<u>SIMVASTATIN - ZOCOR</u>					
019766 004	RE36481 ***	Jul 10, 2007		U-300	
	RE36481*PED	Jan 10, 2008		U-300	
	RE36520 ***	May 26, 2009		U-300	
	RE36520*PED	Nov 26, 2009		U-300	
<u>SIMVASTATIN - ZOCOR</u>					
019766 005	RE36481 ***	Jul 10, 2007		U-300	
	RE36481*PED	Jan 10, 2008		U-300	
	RE36520 ***	May 26, 2009		U-300	
	RE36520*PED	Nov 26, 2009		U-300	
<u>SIROLIMUS - RAPAMUNE</u>					
021083 001	5100899	Jul 07, 2013		U-290	
	5100899*PED	Jan 07, 2014			
<u>SIROLIMUS - RAPAMUNE</u>					
021110 001	5100899	Jul 07, 2013		U-290	
	5100899*PED	Jan 07, 2014			
<u>SIROLIMUS - RAPAMUNE</u>					
021110 002	5100899	Jul 07, 2013		U-290	
	5100899*PED	Jan 07, 2014			
<u>SIROLIMUS - RAPAMUNE</u>					
021110 003	5100899	Jul 07, 2013		U-290	
	5100899*PED	Jan 07, 2014			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>					
021995 001				>A> NCE	Oct 16, 2011
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>					
021995 002				>A> NCE	Oct 16, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>					
	021995 003			>A> NCE	Oct 16, 2011
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>					
021892 001	5616346	May 18, 2013	DP U-715	NP	Mar 16, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN</u>					
020280 006	4968299	Jun 28, 2008	DP	I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN</u>					
020280 007	4968299	Jun 28, 2008	DP	I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 001	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 002	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 003	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 004				I-496	Apr 27, 2009
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 005	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 008	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 009	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 010	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 011	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 012	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>					
020280 013	5435076	Apr 16, 2013	DP	I-496	Apr 27, 2009
	5716338	Feb 10, 2015	DP		
<u>SOMATROPIN RECOMBINANT - OMNITROPE</u>					
021426 001				NP	May 30, 2009
<u>SOMATROPIN RECOMBINANT - OMNITROPE</u>					
021426 002				NP	May 30, 2009
<u>SORAFENIB TOSYLATE - NEXAVAR</u>					
021923 001				ODE	Dec 20, 2012
<u>SUMATRIPTAN SUCCINATE - IMITREX STATDOSE</u>					
020080 003	4816470	Dec 28, 2006	U-72		
	4816470*PED	Jun 28, 2007			
	5037845	Aug 06, 2008	U-72		
	5037845*PED	Feb 06, 2009			
<u>SUNITINIB MALATE - SUTENT</u>					
021938 001	6573293	Feb 15, 2021	DS DP U-703	NCE	Jan 26, 2011
<u>SUNITINIB MALATE - SUTENT</u>					
021938 002	6573293	Feb 15, 2021	DS DP U-703	NCE	Jan 26, 2011

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNITINIB MALATE - SUTENT</u>					
021938 003	6573293	Feb 15, 2021	DS DP U-703	NCE	Jan 26, 2011
<u>TACROLIMUS - PROGRAF</u>					
050708 001				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050708 002				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050708 003				ODE	Mar 29, 2013
<u>TACROLIMUS - PROGRAF</u>					
050709 001				ODE	Mar 29, 2013
<u>TELBIVUDINE - TYZEKA</u>					
022011 001				>A> NCE	Oct 25, 2011
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>					
021318 001	6977077	Aug 19, 2019	U-597		
<u>THALIDOMIDE - THALOMID</u>					
020785 001	5629327	Mar 01, 2013	U-731		
	6045501	Aug 28, 2018	U-731		
	6045501	Aug 28, 2018	U-371		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-442		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561976	Aug 28, 2018	U-371		
	6561977	Oct 23, 2020	U-371		
	6561977	Oct 23, 2020	U-731		
	>A> 6755784	Oct 23, 2020	U-731		
	>A> 6755784	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-732		
	6869399	Oct 23, 2020	U-733		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-371		
	6908432	Aug 28, 2018	U-731		
<u>THALIDOMIDE - THALOMID</u>					
020785 002	5629327	Mar 01, 2013	U-731		
	6045501	Aug 28, 2018	U-731		
	6045501	Aug 28, 2018	U-371		
	6235756	Mar 01, 2013	U-731		
	6315720	Oct 23, 2020	U-442		
	6315720	Oct 23, 2020	U-731		
	6561976	Aug 28, 2018	U-731		
	6561976	Aug 28, 2018	U-371		
	6561977	Oct 23, 2020	U-371		
	6561977	Oct 23, 2020	U-731		
	>A> 6755784	Oct 23, 2020	U-731		
	>A> 6755784	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-371		
	6869399	Oct 23, 2020	U-733		
	6869399	Oct 23, 2020	U-732		
	6869399	Oct 23, 2020	U-731		
	6908432	Aug 28, 2018	U-371		
	6908432	Aug 28, 2018	U-731		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
020785 003	5629327	Mar 01, 2013		U-731		
	6045501	Aug 28, 2018		U-731		
	6045501	Aug 28, 2018		U-371		
	6235756	Mar 01, 2013		U-731		
	6315720	Oct 23, 2020		U-442		
	6315720	Oct 23, 2020		U-731		
	6561976	Aug 28, 2018		U-731		
	6561976	Aug 28, 2018		U-371		
	6561977	Oct 23, 2020		U-371		
	6561977	Oct 23, 2020		U-731		
>A>	6755784	Oct 23, 2020		U-731		
>A>	6755784	Oct 23, 2020		U-371		
	6869399	Oct 23, 2020		U-371		
	6869399	Oct 23, 2020		U-732		
	6869399	Oct 23, 2020		U-733		
	6869399	Oct 23, 2020		U-731		
	6908432	Aug 28, 2018		U-371		
	6908432	Aug 28, 2018		U-731		
<u>THYROTROPIN ALFA - THYROGEN</u>						
020898 001					M-53	Jan 23, 2009
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
021395 001	7070800	Jan 22, 2022		DP	U-566	
	RE38912	Oct 11, 2021		DP		
<u>TOPIRAMATE - TOPAMAX</u>						
020505 001	7018983	Oct 13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>						
020505 002	7018983	Oct 13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>						
020505 003	7018983	Oct 13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>						
020505 004	7018983	Oct 13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>						
020505 005	7018983	Oct 13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>						
020505 006	7018983	Oct 13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 001	7018983	Oct 13, 2015			U-723	
	>A> 7125560	Mar 01, 2019			U-766	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
020844 002	7018983	Oct 13, 2015			U-723	
	>A> 7125560	Mar 01, 2019			U-766	
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
020671 001	5004758	May 28, 2010	DS	DP	U-741	
<u>TRAVOPROST - TRAVATAN Z</u>						
021994 001	>A> 5510383	Aug 03, 2013		DP	U-383	
	>A> 5889052	Dec 02, 2014		DP	U-383	
	>A> 6503497	May 06, 2012		DP		
	>A> 6849253	May 06, 2012		DP		
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
021272 001	5153222	Oct 06, 2014			U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>						
021272 002	5153222	Oct 06, 2014			U-455	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL SODIUM - REMODULIN</u>							
021272 003	5153222	Oct 06, 2014		U-455			
<u>TREPROSTINIL SODIUM - REMODULIN</u>							
021272 004	5153222	Oct 06, 2014		U-455			
<u>URSODIOL - URSO FORTE</u>							
020675 002	4859660	Nov 19, 2007		U-740			
<u>VARENICLINE TARTRATE - CHANTIX</u>							
021928 001	6410550	Nov 13, 2018	DS	DP	U-56	NCE	May 10, 2011
	6890927	May 06, 2022	DS	DP	U-56		
<u>VARENICLINE TARTRATE - CHANTIX</u>							
021928 002	6410550	Nov 13, 2018	DS	DP	U-56	NCE	May 10, 2011
	6890927	May 06, 2022	DS	DP	U-56		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>							
076690 001						PC	Jan 30, 2007
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>							
076690 002						PC	Jan 30, 2007
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>							
076690 003						PC	Jan 30, 2007
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>							
076690 004						PC	Jan 30, 2007
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>							
076690 005						PC	Jan 30, 2007
<u>VORINOSTAT - ZOLINZA</u>							
021991 001						>A> NCE	Oct 06, 2011
<u>ZANAMIVIR - RELENZA</u>							
021036 001	5648379	Jul 15, 2014			U-722	I-491	Mar 29, 2009
	5648379	Jul 15, 2014			U-721		
	5648379	Jul 15, 2014			U-274		
	6294572	Dec 15, 2014	DS	DP			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>							
020825 001	4831031	Mar 02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>							
020825 002	4831031	Mar 02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>							
020825 003	4831031	Mar 02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>							
020825 004	4831031	Mar 02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>							
021483 001	4831031	Mar 02, 2012	DS	DP	U-720	I-492	Aug 19, 2007
	5312925	Sep 01, 2012	DS	DP	U-720		
	6150366	May 27, 2019		DP	U-719		
	6245766	Dec 18, 2018			U-601		
<u>ZIPRASIDONE MESYLATE - GEODON</u>							
020919 001	4831031	Mar 02, 2012	DS	DP	U-720		
<u>ZOLEDRONIC ACID - ZOMETA</u>							
021223 001	4939130	Sep 02, 2012	DS	DP	U-53		
<u>ZOLEDRONIC ACID - ZOMETA</u>							
021223 002	4939130	Sep 02, 2012	DS	DP	U-53		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY LIST**

See report footnotes for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
-----------------	--------------	---------------------------	-----------------	------------------------	--------------------------------

Footnotes:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
 DS = Drug Substance claim
 DP = Drug Product claim
 U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at <http://www.fda.gov/cder/orange/patex.htm>
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.
5. *** U.S. Patent Nos. RE 36481 and RE 36520 are being relisted for Zocor (NDA 19-766) pursuant to the decision and related order in Ranbaxy Labs. v. Leavitt, No. 05-1838 (D.D.C. April 30, 2006). The '481 and '520 patents will remain listed in Approved Drug Products with Therapeutic Equivalence Evaluations until any applicable periods of exclusivity pursuant to section 505(j)(5)(B)(iv) of the Federal Food, Drug, and Cosmetic Act have been triggered and run, unless the agency's appeal of the decision to the U.S. Court of Appeals for the District of Columbia is decided in the agency's favor before the exclusivity periods have expired. While the patents remain listed, any new or pending ANDA referencing Zocor must contain patent certifications to these patents. For additional information on this matter, please refer to Docket Nos. 2005P-0008 and 2005P-0046.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/patternsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>